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1Anke J. Laskewitz
General Introduction








Scope of the thesis 
Synthetic glucocorticoids (GCs), such as prednisolone and dexamethasone, are potent 
anti-inflammatory drugs that are widely prescribed for the treatment of chronic inflam-
matory diseases, like rheumatoid arthritis, inflammatory bowel disease and asthma. How-
ever, their use is hampered by the serious adverse effects that accompany chronic GC-
treatment. These side effects include weight gain due to central adiposity, dyslipidemia, 
hypertension, osteoporosis, mood disorders, skin thinning, muscle wasting, acne, glucose 
intolerance and insulin resistance. The endogenous glucocorticoid cortisol plays an es-
sential role in maintaining blood glucose homeostasis. Circulating cortisol levels are under 
tight control of the hypothalamus-pituitary-adrenal gland axis. To accomplish homeosta-
sis, GCs act on many different tissues and the glucocorticoid receptor is ubiquitously ex-
pressed. Therefore, the broad range of side effects when a surplus of GCs is present, as is 
the case in GC treatment, is not too surprising. Many of the side effects mentioned above 
constitute components of the metabolic syndrome (metS), a cluster of metabolically inter-
related risk factors for cardiovascular disease and diabetes mellitus type 2.
Due to the adverse effects there is a need for novel drugs with improved therapeutic 
index, i.e., drugs that reduce inflammation with the same efficacy as classical GCs but 
with less or preferably no adverse effects. In the last two decades, research has focused 
particularly on the mechanism(s) of GC action: this knowledge is essential for efficient 
development of improved drugs. These considerable research efforts have led to the dis-
covery of a novel class of potential therapeutics: selective glucocorticoid receptor modu-
lators (SGRM’s). Unfortunately, these novel GCs are still in the experimental phase and 
have not reached approval for clinical use yet. Moreover, in these studies the focus has 
been mainly on efficacy of the anti-inflammatory effects that were tested predominantly 
in mouse models of inflammation. Yet, also their potential side effects should directly be 
taken into account. Side effects like osteoporosis are relatively easy to monitor in rodents 
by radiographic techniques. Unfortunately, GC-induced metabolic side effects are not as 
clear in mice as in men and are more difficult to address. Therefore, there is a need for 
well-defined and extensively validated animal models to test metabolic side effects of 
GCs; it is well appreciated that separate models will be required for the different side ef-
fects mentioned.
The aim of the work described in this thesis is to define and unravel (molecular) mecha-
nisms that underlie side effects of GCs on glucose and lipid metabolism in appropriate 
mouse models using multiple newly, developed stable isotope methodologies.






Already in the beginning of the 20th century it was appreciated that adrenal extracts in-
fluenced human physiology, which led Reichstein and Mason in 1936 to the purification 
of cortisol, the principal hormone produced by the adrenal gland 1,2. The synthetic form 
of cortisol, e.g., hydrocortisone, was produced in 1946 and soon the use of hydrocorti-
sone was found to suppress symptoms of rheumatoid arthritis 3. Cortisol and hydrocorti-
sone are glucocorticoids (also called corticosteroids) and belong to the family of steroid 
hormones. Other steroid hormones are sex hormones, i.e., estrogen, testosterone and 
progesterone. These are all synthesized from cholesterol and share the steroid-specific 
multiple ring structure. The steroid hormones are hydrophobic in nature and therefore 
are able to diffuse across plasma membranes of cells to reach their intracellular-localized 
receptors 4.
Cortisol is produced in the adrenal gland upon stimulation of the hypothalamus-pituitary-
adrenal gland (HPA)-axis. A stimulus, like stress, causes the release of corticotrophin-re-
leasing hormone (CRH) in the hypothalamus, which travels to the anterior pituitary where 
it triggers the release of adrenocorticotropic hormone (ACTH) into the bloodstream. ACTH 
activates the conversion of cholesterol into cortisol in the adrenal gland. Cortisol itself 
reduces the release of CRH, resulting in a negative feedback circuit 5. The secretion of 
cortisol is under the control of the biological clock and shows a circadian rhythm with the 
highest peak of cortisol secretion early in the morning in humans 6.
The secretion of cortisol by the adrenal gland is only one of the intricate control mecha-
nisms of cortisol availability. Once secreted by the adrenal gland, 90% of cortisol is bound 
to the plasma protein corticosterone binding globulin (CBG) 7, with a small remainder 
bound to albumin 8. After crossing the plasma membrane of cells, free cortisol can bind 
to glucocorticoid receptors (GR) present in many different tissues, where it may exert 
various different functions. In addition, intracellular cortisol availability is regulated by the 
enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD) 9, that converts the inactive 
form of cortisol, cortisone, back into cortisol, thereby locally increasing the cortisol con-
centration. 11β-HSD type 1 acts as a reductase and catalyzes the conversion of cortisone 
into cortisol, while 11β-HSD type 2 acts predominantly as a dehydrogenase, inactivating 
cortisol into cortisone. Whereas the GR is ubiquitously expressed, 11β-HSD is distributed 
in a tissue-specific manner with 11β-HSD-1 mainly present in brain, liver, muscle and adi-
pose tissue and 11β-HSD-2 in kidney and placenta. This specific tissue organization implies 
that 11β-HSD plays an important role in controlling active intracellular GC levels 10. Ro-




dents lack the enzyme 17α-hydroxylase in the adrenal gland, hence the main GC hormone 
in rodents is corticosterone, with 11-dehydroxycorticosterone as its inactive form 11. 
Cortisol is often referred to as a stress hormone, because it is essential for maintaining 
whole body homeostasis in a stressful situation. It does so by fueling the body in a stress-
ful situation by modulation of lipid and glucose metabolism. In addition, cortisol raises 
blood pressure, reduces the immune response, improves memory function and reduces 
sensitivity to pain in order to cope with a stressful situation. These effects are only effec-
tive for a short stress response: prolonged or chronic stress may lead to stress-related 
diseases.
It should be realized that cortisol is not only secreted upon stress but is continuously 
produced in small amounts, implying that, besides its role as a stress hormone, it has 
additional functions. One of these functions relates to control of development: cortisol is 
essential for fetal lung development 13. Moreover, cortisol has many effects on bone and 
muscle maturation in young children. The effects of GCs upon the many different target 
organs and tissues are summarized in figure 2. The role of GCs in control of glucose and 
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The importance of GCs is very clear from two GC-related diseases. In Addison’s disease, 
first described by Thomas Addison in 1855, patients suffer from adrenal insufficiency 
caused by auto-immunity leading to low levels of cortisol 14. Some of the symptoms of 
Addison’s disease are weight loss, low blood pressure and hyperpigmentation 15,16. The 
‘opposite’ of Addison’s disease is Cushing’s syndrome (Cushing 1912), caused by excess 
cortisol secretion by the adrenal gland 17. Cushing’s syndrome can either be caused by 
pituitary or adrenal tumors, but in most cases Cushing’s syndrome is due to administra-
tion of exogenous GCs to treat various inflammatory diseases. Symptoms of Cushing’s 
syndrome are: weight gain with central adiposity, muscle wasting of extremities leading 
to a ‘lemon on a stick’ phenotype, high blood pressure, increased fat pads in the face 
and neck (called moon face and buffalo hump, respectively), hyperglycemia and insulin 
resistance, insomnia and many other symptoms. Many of these symptoms also constitute 
components of the metabolic syndrome 18. 
The glucocorticoid receptor 
GCs exert their functions via activation of the GR, a member of the nuclear receptor super 
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19. Like all nuclear receptors, GR contains multiple functional domains. The N-terminal do-
main contains a transactivation site, whereas the DNA-binding domain lies in the central 
part of the protein. The C-terminus contains the ligand- binding domain and is involved in 
receptor dimerization, nuclear translocation and interaction with heat shock proteins 20.
Two forms of GR have been identified; GRα and GRβ 22 (Fig. 3). GRα constitutes the most 
important receptor in quantitative terms and is widely distributed. Activated GRα is re-
sponsible for induction and repression of target genes, while GRβ is only able to repress 
GRα function. It was long thought that mice only express GRα 20, but a recent paper 
showed that mice do have GRβ as well 23. The role of GRβ, however, is still under discus-
sion: therefore when GR is mentioned in this thesis GRα is meant. 
Mechanism of glucocorticoid action
Already in 1974, a 44 page review on GC action citing more than 350 papers 24 was pub-
lished. Since that review, the expanding availability of cutting-edge technologies has ena-
bled the unraveling of molecular mechanisms of GC action 25. GR is constitutively present 
in the cytoplasm, bound by cofactors such as heath shock proteins (HSPs) 26. When circu-
lating free GCs are taken up by cells, they can bind to cytoplasmic GR (Fig. 4. (1)). Upon 
binding, the HSPs are removed and the GC-GR complex is channeled to the nucleus by im-
portins 22,27 (2). In the nucleus the GC-GR complex can form a homodimer (Bledsoe 2004) 
and act as a transcription factor upon binding to GCs response elements (GRE) present in 
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ferred to as transactivation. However, the GC-GR complex can also bind to other transcrip-
tion factors like NFκB and AP1, both activators of inflammatory processes (4). It is thought 
that most anti-inflammatory effects of GCs are being exerted via this pathway. This re-
sponse is called transrepression 28. Another form of transrepression is direct binding of the 
GC-GR complex to a negative GC response element (nGRE) 29, thereby directly repressing 
gene-transcription. Besides these different roles in the nucleus, the GC-GR complex can 
also interact with other proteins in the cytoplasm, which is thought to be responsible for 
rapid effects of GCs (5) 30. This protein-protein interaction is also referred to as a ‘tethering 
mechanism’ 31,32. 
Synthetic glucocorticoids and side effects 
GCs are well-known for their principal role in control of the immune system. GCs reduce 
inflammation by reducing cytokine expression in both dendritic cells and macrophages. 
GCs can also suppress activity and induce apoptosis of dendritic cells and reduce B-cell 
numbers. T-cells are most important in adaptive immunity. In these cells, GCs can induce 
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exert protection from auto-immunity and graft vs. host response. The role of GCs in the 
immune system is extensively described in reviews 32,33.
Since the discovery of hydrocortisone numerous synthetic GCs have been developed as 
anti-inflammatory and immune suppressive drugs. From the 1960’s onwards GCs have 
been among the most prescribed drugs, particularly prednisolone and dexamethasone. 
While prednisolone is mostly used in chronic inflammatory disorders, e.g., rheumatoid 
arthritis, inflammatory bowel disease and asthma, dexamethasone is predominantly used 
for acute inflammation and in cancer treatment since it has a particularly high affinity for 
GR (Table 1). 
Many differently structured GCs have been developed with different potencies and half 
lives. GCs were particularly enthusiastically prescribed in the late ‘60s and the ‘70s. A 
plethora of adverse effects soon became apparent that still hamper the use of GCs today. 
Since GCs are involved in control of a number of important metabolic processes, there is 
a broad spectrum of side effects that accompanies their application. The adverse effects 
range from minor, predominantly cosmetic effects, like striae and acne, to very severe 
ones, such as diabetes and osteoporosis. Table 2 presents an overview of GC-induced side 
effects. Due to the long history of GC treatment, patients are well aware of these effects, 
sometimes leading to a so-called ‘steroid-phobia’. 
Selective Glucocorticoid Receptor Modulators
From the above mentioned adverse effects it is clear that there is a high medical need for 
new drugs that display the potent anti-inflammatory actions of GCs, without, or with few-
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pharmaceutical industry and academia. To find new drugs there are different approaches. 
In the case of GCs, the ‘easy’ way was followed for many years, by minimally altering 
the structural conformation of known GCs and by trial-and-error functionality testing of 
the new drug. This approach has produced quite good drugs, sometimes translating into 
improved potency and half life compared to the originals, but the side effects were un-
equivocally present. Systemic side effects were overcome by changing the route of ad-
ministration, for instance by topical crèmes in the case of dermatitis and by inhalation in 
asthma. Nevertheless, the ‘perfect’ GC remains to be found. 
After decades of searching new GCs, a more molecular approach is now increasingly being 
applied. As described before, the mechanisms by which GCs exert their function has been 
largely defined by now. Especially the ratio between transrepression vs. transactivation 
activities has gained great attention in the development of new GCs since it is thought 
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sary to reduce inflammation. These insights have led to design of a class of compounds 
called dissociated GCs or selective glucocorticoid receptor modulators (SGRM’s)35,36. These 
compounds, in general, aim to target the transrepressing pathway of the GR, without 
activating the transactivational pathway. A battery of such compounds is currently being 
developed but so far none of these has made it to the clinic 37-39. This could be due to side 
effects occurring in humans, which could not be detected in animal models.
Glucocorticoid-actions on glucose and lipid metabolism 
The name ‘glucocorticoid’ obviously comes from ‘glucose’ relating to its role in control of 
glucose metabolism, ‘cortex’ from the adrenal cortex where it is synthesized, and ‘ster-
oid’ from its steroidal structure. As their name implies, GCs play an important role in the 
control of glucose metabolism, specifically in stress situations. GCs are so-called catabolic 
hormones and their actions ensure rapid energy supply to tissues in order to be able to 
react adequately to a stressful event. Glucose production in the liver is up-regulated by 
induction of gluconeogenesis in order to raise blood glucose levels as a source of energy 
for the brain. Moreover, glucose uptake in muscle and adipose tissue is reduced, while 
lipolysis is increased to release free fatty acids as an energy substrate. In addition, stimu-
lation of protein degradation in muscle leads to mobilization of amino acids to serve as 
additional substrate for gluconeogenesis. Like glucagon, another catabolic hormone, GCs 
oppose the effects of the anabolic hormone insulin.
Hepatic glucose metabolism
As mentioned above, one of the main presumed role of GCs is to stimulate hepatic glucose 
production to provide sufficient glucose for the brain. The liver can be regarded as the 
metabolic center of the body, adapting metabolic pathways to adequately meet altered 
energy needs. In case of energy surplus, the liver is able to store glucose in the form of 
glycogen while in times of energy demand glucose can be produced by liver. The latter can 
Glucose enters the liver and can be converted to glucose-
6-phosphate by glucokinase (GK) (I). Glucose-6-phosphate 
can either be converted back to glucose by glucose-6-phos-
phatase (G6Pase) (II) or to glycogen, by glycogensynthase 
(GS) (IV). Glycogen can be converted back to glucose-
6-phosphate by glycogenphosphorylase (GP) (III). In addi-
tion, glucose-6-phosphatase can be converted to pyruvate 
by a number of enzymes including pyruvate kinase (PK) (VI) 
for use in the TCA cycle or storage. From pyruvate glucose-
6-phosphate can be formed by a number of enzymes includ-









be achieved either by stimulation of gluconeogenesis or by converting glycogen back into 
glucose. For these processes, the enzymes phosphoenolpyruvate carboxykinase (PEPCK) 
and glucose-6-phosphatase (G6Pase), respectively, are essential. 
Hepatic gluconeogenesis is stimulated by GCs, the mechanism is generally thought to be 
due through direct transactivation of Pck1, the gene encoding for PEPCK which is one 
of the enzymes involved in gluconeogenesis. The promoter of Pck1 contains a classical 
GRE 40. However, PEPCK only has a slight control on gluconeogenic flux 41, therefore ad-
ditional mechanisms must be involved. G6pase gene expression is also induced by GC, 
the G6pase was the first gene demonstrated to contain both a GRE and a nGRE. The func-
tion of the latter, however, is still under debate 40. Moreover, GCs can indirectly increase 
hepatic glucose production by antagonizing the suppressive effects of insulin on hepatic 
glucose production. Many studies, both in humans and in rodents, have been performed 
to unravel the molecular mechanisms by which GCs modulate hepatic glucose metabo-
lism. However, all these efforts together have primarily resulted in an enormous amount 
of (partly) contradicting data. Therefore, the events described above provide a generally 
accepted mode by which GCs act on the liver, but the actual mechanism of action still 
remain to be established. Most of the studies showing effects of GCs on hepatic glucose 
metabolism address short-term, direct effects on gene expression, while long-term effects 
of GC treatment on gene expression of Pck1 and G6pase under different nutritional and 
disease conditions are far from clear. Obviously, the fundamental experiments, required 
to obtain these essential pieces of information cannot be performed in humans. 
Peripheral glucose metabolism 
While the liver both produces and clears glucose, the peripheral tissues can only utilize 
or store glucose. The brain, muscle and adipose tissue are the most important tissues 
involved in glucose utilization. 
Muscle tissue can be divided into three main types: skeletal-, cardiac- and smooth muscle. 
While cardiac and smooth muscle cells are essential for survival, skeletal muscle tissue is 
of great importance for mobility. Mobility via skeletal muscle activity is a highly energy de-
manding process, accounting for a major part of glucose consumption. Glucose uptake in 
the muscle is mainly insulin-dependent and is mediated by the glucose transporter GLUT4 
42. Insulin stimulates GLUT4 to go to the cell membrane to take up glucose from the circu-
lation. Upon glucose uptake, glucose can be used as a substrate for energy production by 
conversion into lactate or be stored in the muscle as glycogen. Muscle glycogen can only 
be used by the muscle itself. Sustained GC treatment may induce muscle wasting due to 
decreased protein synthesis and/or increased protein breakdown 43. This phenotype is 




also called steroid myopathy. Muscle protein is broken down under influence of GCs, thus 
mobilizing amino acids to serve as substrate for gluconeogenesis in the liver. In addition, 
high levels of GCs prevent insulin-mediated glucose uptake in muscle, leaving blood glu-
cose as energy for the brain. Energy coming from protein breakdown can be used in the 
muscle itself.
The main source of energy in the body is stored in the adipose tissue as fat. In principle 
GCs have lipolytic effects on adipose tissue, releasing free fatty acids and glycerol 44. The 
fatty acids can be taken up and oxidized in tissues in energy need and via mitochondrial 
β-oxidation yield ATP 45. At the same time the glycerol released by lipolysis can be used 
as a substrate for gluconeogenesis in the liver. The lipolytic pathway is activated by GCs 
mainly by increased protein expression of adipose triglyceride lipase (ATGL) and hormone 
sensitive lipases (HSL) 46,47. In addition, GCs reduce glucose uptake in adipose tissue 48 and 
reduce gene expression of Pck149,50 thereby preventing the glycerolneogenesis. As a con-
sequence, free fatty acids are released and not esterified back into triglycerides. The role 
of GCs on adipose tissue will be discussed more extensively later on.
The brain represents only 2% of the human body weight but accounts for about 25% of 
the bodies glucose utilization 51, because glucose is the main energy substrate for brain 
tissue. In conditions of glucose-shortage, e.g. upon fasting, ketone bodies can also be 
used as a substrate. Brain glucose uptake is largely insulin-independent and the direct role 
of GC is minor and not very extensively studied. In patients with Cushing’s disease, how-
ever, it is thought that reduced glucose uptake by the astrocytes, that surround the blood 
capillaries of the blood brain barrier, leads to astrocyte atrophy and thereby to cognitive 
dysfunction 52. Other brain-related side effects of GCs, such as mood disorders, are more 
likely to be derived from alterations of HPA-axis activity and hippocampus atrophy 53. 
Insulin resistance and diabetes
Insulin is a crucial hormone for adequate regulation of blood glucose homeostasis. It is 
produced in the pancreas by β-cells in the islets of Langerhans. Insulin is actively secreted 
by the pancreas in response to high blood glucose levels to stimulate glucose utilization 
and hence to reduce blood glucose levels 54. Opposite to GCs, insulin is an anabolic hor-
mone, aiming to store energy, since it promotes the uptake of glucose in target tissues 
such as the liver, muscle, where it can either be used or stored as glycogen. In adipose tis-
sue insulin promotes glucose uptake after which glucose is converted into acetyl-CoA and 
via lipogenesis into triglycerides. Insulin resistance is a situation characterized by high cir-
culating plasma glucose levels due to an inability of liver, skeletal muscle and adipose tis-
sue to adequately respond to insulin. Insulin resistance precedes diabetes mellitus type 2, 




in which the inability of insulin-sensitive tissues to respond to insulin cannot be compen-
sated for by increased insulin secretion of the pancreatic β-cells anymore. As mentioned 
previously, insulin resistance is one of the major side effects of GC treatment in humans 
55-57. Yet, compared to the incredible amount of GCs that is daily prescribed around the 
world, the knowledge of adverse events accompanying GC treatment is very limited 58-60. 
GC-induced insulin resistance likely involves several tissues. In the liver and peripheral 
tissues, like muscle and adipose tissue, insulin action appears to be abolished by GCs. 
Moreover, GCs may have a direct effect on the insulin-secreting β-cells of the pancreas. 
These effects, however, are controversial since increased insulin secretion 61 as well as 
decreased insulin secretion 62 upon GC exposure have been reported.
Besides insulin, there are multiple other hormones involved in control of glucose me-
tabolism. Firstly, glucagon produced by the α-cells of the Islets of Langerhans opposes the 
effects of insulin. Secondly, several hormones secreted by the intestine, like glucagon like 
peptide-1 (GLP1) and gastric inhibitory polypeptide (GIP) have been recognized as promi-
nent targets for treatment of diabetes 63. Thirdly, ghrelin, a orexigenic hormone stimulat-
ing appetite that is produced by cells of the stomach wall, modulates insulin secretion and 
sensitivity 64. The adipose tissue has been discovered to secrete hormones as well, with 
leptin, resistin and adiponectin all playing prominent roles in glucose metabolism 65. In ad-
dition to these hormones, other proteins also can affect glucose metabolism. Fibroblast 
growth factor 21 (FGF21), a member of the fibroblast growth factor family, has recently 
been described to function as an endocrine hormone 66. FGF21 is produced during fast-
ing 67,68 and has major effects on glucose uptake in adipocytes 69. Plasminogen activator 
inhibitor-1 (PAI-1), a serine proteinase secreted by endothelial cells, has been shown to 
be associated with diabetes 70.
Lipids and cholesterol metabolism 
Besides insulin resistance, visceral obesity is another major side effect of GC treatment. 
Taking into account that GCs are generally described as being lipolytic, the fact that chron-
ic GCs lead to obesity appears to be contradictory. However, GCs have been found to be 
both lipolytic as well as adipogenic 71 and GC can regulate differentiation, function and 
distribution of adipocytes 72. This shows that the effects of excess GCs on adipose tissue 
are quite complex 44. Central fat depots (visceral, abdominal, facial and fat in the nape 
of the neck) are generally increased upon GC stimulation, while peripheral depots, like 
subcutaneous fat in the legs and arms, become reduced 73. This could result from dif-
ferential effects of GCs on lipolysis, or differentiation of pre-adipocytes and on triglyc-
eride synthesis in various fat depots 74. One reason for this might be the excessive pres-




ence of GRs in visceral fat compared to subcutaneous fat 75. Moreover, the expression of 
11β-hydroxysteroid dehydrogenase type 1 might differ between fat depots 76 and that 
11β-HSD type 1 is more active in visceral (omental) fat depots 77.
Although less frequent than other metabolic derangements, GC treatment is also associ-
ated with dyslipidemia in humans 45,78. Lipoproteins function in the body as transporters 
for lipids and are classified based on their density (Figure 6). 
High dose GC treatment has been associated with increased waist circumference, triglyc-
erides, total and LDL-cholesterol levels 79, all symptoms increasing the risk for cardiovascu-
lar diseases. However, the effects of GCs on HDL-cholesterol are contradictory; in a study 
population of 15.000 Americans, GCs were associated with increased HDL-cholesterol ra-
tio in the >60 years population, implying an improved lipid profile 80. The effects of GCs on 
lipid metabolism might be due to direct effects of GCs to induce VLDL secretion 44,81 and 
lipoprotein lipase (LPL) activity. LPL is essential for the release of fatty acids from triglyc-
erides in VLDL particles, in order to be taken up in the adipose tissue and GCs have been 
shown to increase LPL activity by both transcription as well as posttranslational modifica-
tions 44,82,83.
Cholesterol and GCs also interact on another level, i.e., in the adrenal cortex where steroi-
dogenesis takes place in which cortisol is produced from cholesterol. Scavenger receptor 
B1, is the mediator of HDL-cholesterol uptake in the adrenocortical cells, has been shown 






Lipoproteins are classified based on their density. Chylomicrons are formed in the intestine and carry mainly triglycerides 
to the liver. From the liver very low density lipoproteins (VLDL) transports triglycerides to peripheral tissues and is con-
verted  into intermediate density lipoproteins (IDL) followed by the conversion to low density lipoproteins (LDL) carrying 
mainly cholesterol from the liver to the peripheral tissues. The smallelst high dense lipoprotein (HDL) particle transports 
excess cholesterol from the peripheral cells to the liver.




Animal models for assessment of glucocorticoid actions 
Regarding the complexity of GC actions, specific animal models are essential to elucidate 
the mechanisms of GC-induced metabolic adverse effects. Nevertheless, the animal model 
for GC-induced insulin resistance is currently not available. Several studies on GC-induced 
adverse effects on glucose metabolism have been performed in rats 85-87. An experimental 
model of dexamethasone-induced insulin resistance in rats has first been published by 
Stojanovska et al. 85. This model has been used in many studies. A daily dose of ip. admin-
istered dexamethasone (1 mg/kg/day) for several days up to one week induced (fasting) 
hyperglycemia and hyperinsulinemia 61,86,88. Dexamethasone is mostly used in rats because 
prednisolone has poor bioavailability when given orally in rats. Insulin resistance in dex 
treated rats was studied in more detail by Rafacho et al.61, showing increased AUC in the 
OGTT, while Venkatesan et al.88 showed an apparent reduction in the glucose infusion 
rate during the hyperinsulinemic euglycemic clamp (HIEC). This method was developed to 
study insulin resistance, by infusing insulin to reach high insulin levels in blood (hyperinsu-
linemic), while simultaneously infusing glucose to maintain glucose levels steady (euglyce-
mic) 89 and is regarded as the gold standard to quantitatively assess insulin resistance. The 
glucose infusion rate (GIR) in this method is the measure for insulin sensitivity. The ability 
of dexamethasone to reduce GIR was in rats already apparent after a single injection with 
dexamethasone 90. 
GC-induced insulin resistance has mainly been studied using dexamethasone. Dexameth-
asone is a very potent GC, 7.5 times more potent than prednisolone, and is mainly used 
for treatment of severe acute inflammatory conditions in the clinic. Prednisolone, on the 
other hand, is favoured for chronic treatment in chronic inflammatory diseases, e.g., in-
flammatory bowel disease (IBD) and rheumatoid arthritis (RA), and hence is of most inter-
est in relation to metabolic side effects. 
Although dexamethasone-treatment in rats is an accepted model for GC-induced insulin 
resistance, such a model is not available for mice. Genetically-modified mice provide pow-
erful models for metabolic research and it would be highly desirable to define a mouse 
model for full evaluation of GC-related metabolic consequences. Unfortunately, GR knock-
out mice are not viable which at least demonstrates that GR is essential for development 
13. A transgenic mouse model is available that carries a mutation in the dimerization do-
main of the GR 91. In this model, the GRdim mouse, GR is not able to dimerize, leaving all 
GC-mediated effects restricted to monomeric GR actions. This model is of specific interest 
when studying trans-activating and trans-repressing effect of GCs. 
A limited number of studies on metabolic derangements due to GC treatment involve 
multiple mouse strains 92-96. In a study of Gounarides et al.94, C57BL/6J mice were kept 




on a high-fat diet for 2 months followed by 5 days of dexamethasone treatment. After 
this regimen, mice showed a higher HOMA-IR than control mice, indicating the induction 
of insulin resistance. However, a subsequent oral glucose tolerance test failed to clearly 
confirm the existence of insulin resistance in this particular model. Bernal-Mizrachi et. al. 
96 used low density lipoprotein receptor knockout (LDLR-/-) mice and an extremely high 
dose of dexamethasone for prolonged periods of time (5 months) to show decreased 
glucose tolerance and insulin insensitivity. To our knowledge, studies addressing effects of 
prednisolone on whole body metabolism in conventional wild-type C57BL/6J mice have 
not been reported in the literature. All previous mouse studies have been performed with 
either dexamethasone and/or insulin resistance-prone mouse strains. Moreover, so far 
no ‘gold standard’ HIEC studies have been performed to evaluate GC-induced adverse 
effects on glucose metabolism. Therefore the studies in this thesis focus on the develop-
ment of a mouse model of prednisolone-induced adverse metabolic effects of glucose and 
lipid metabolism. For this, conventional C57BL/6J mice were chosen, because this mouse 
strain is mostly used in metabolic studies and is susceptible to diet-induced obesity. These 
mice were treated with prednisolone, to resemble the long-term treatment in humans 
in which prednisolone-induced metabolic adverse effects occur. To detect metabolic de-
rangements, a variety of novel techniques have been applied. For assessment of insulin 
resistance, the HIEC adapted for mice was combined with stable isotope methodologies 
in order to quantify hepatic glucose metabolism under fasted, hyperinsulinemic euglyce-
mic and hyperglycemic conditions. In addition, a novel stable-isotope technique to assess 
basal glucose kinetics was developed, which is also suited for measurements of glucose 
metabolism in severely ill mice. In addition, we studied the effects of prednisolone in on 
glucose metabolism in an inflamed mouse model. For this, an experimental model for 
arthritis was induced in DBA/1J mice, since this strain is the only mouse strain susceptible 
to collagen induced arthritis. For a more mechanistic insight, we treated GRdim mice with 
prednisolone. This mouse model had a defective dimerization domain in the GR, thereby 
discriminating between monomeric effects and dimeric effects of GR. In this model, pred-
nisolone-induced dyslipidemia was studied.
In short, the work described in this thesis aimed at defining and unraveling of molecular 
mechanism that underlie adverse effects of GCs on glucose and lipid metabolism in ap-
propriate mouse models using multiple newly, developed stable isotope methodologies.





The aim of the research described in this thesis was to define the (molecular) mechanism(s) 
of GC-induced adverse effects on glucose and lipid metabolism in mouse models. For ini-
tial experiments, aimed at evaluating GC-induced side effects on glucose metabolism, we 
monitored fasting blood glucose levels in C57BL/6J mice treated with different doses of 
prednisolone during a four week period. The C57BL/6J mouse is the most extensively 
studied mouse strain in metabolic research and is known to be prone to high-fat diet-
induced insulin resistance. These mice were subjected to an oral glucose tolerance test 
(OGTT) once a week for four weeks. Since there were clear effects on fasting glucose 
levels already after 7 days, but not on outcome of the OGTT, we developed a method to 
determine blood glucose kinetics in the fasted state; Chapter 2 describes this method in 
detail. Blood glucose kinetics was assessed in a fasted, steady state in mice fed a high-fat 
diet. The main advantage of this method is that due to the relatively small blood volumes 
required it is possible to perform the test multiple times in an individual animal, thereby 
enabling monitoring of therapeutic or dietary effects over time.
In Chapter 3 this method was used in a mouse model employed to evaluate GC-induced 
insulin resistance. C57BL/6J mice were treated with prednisolone for 7 days. This treat-
ment regime elevated fasting blood glucose and insulin concentrations, i.e., a situation 
that indicates induction of insulin resistance. However, by the hyperinsulinemic euglyce-
mic clamp (HIEC) technique we showed that these mice actually did not develop a ‘clas-
sical’ insulin resistance. During an HIEC, insulin sensitivity is tested at supraphysiological 
insulin levels. When blood glucose kinetics were evaluated in a fasted state, prednisolone 
treatment clearly increased the endogenous glucose production (EGP) at higher insulin 
levels, suggestive for hepatic insulin resistance. However, we found that the main effect 
op prednisolone treatment on fasting glucose levels was due to an altered fasting re-
sponse. Upon fasting, blood glucose levels drop while ketone bodies and fasting hormone 
fibroblast growth factor 21 (FGF21) increase. In prednisolone-treated mice, FGF21 did in-
crease, but was unable to stimulate ketone body production and to reduce blood glucose 
levels, resulting in increased fasting blood glucose levels. 
In chapter 4 we examined prednisolone-induced insulin resistance in a state of compro-
mised insulin sensitivity induced by feeding C57BL/6J mice a high-fat diet prior to predni-
solone treatment. Like in chow-fed mice, prednisolone treatment increased fasting blood 
glucose levels and plasma insulin levels in high-fat fed mice, resulting in an increased 
HOMA-IR. We measured the hepatic glucose fluxes under basal conditions and hyperinsu-
linemic conditions, again revealing that prednisolone treatment did not aggravate insulin 
resistance in high-fat fed mice, since the GIR of both groups were similar. Nevertheless, 




prednisolone treatment did alter hepatic glucose fluxes in these mice, mainly at the glyco-
gen level, revealing an insulin-independent role for prednisolone on glucose metabolism. 
A spectrum of hormones and adipokines involved in control of glucose metabolism was 
analyzed, which showed that prednisolone treatment led to significantly elevated plasma 
leptin and FGF21 levels, thereby suggesting that prednisolone-induced alterations of glu-
cose metabolism are, at least in part, mediated by other factors than insulin.
In both chapter 3 and 4 we found evidence for insulin-independent effects of predniso-
lone on glucose metabolism, which was only detectable in the fasted state. A new class of 
GCs, called selective glucocorticoids modulators (SGRM), are currently being developed 
with the aim to reduce inflammation in a partial GC-dependent manner with reduced 
potential to induce side effects. In chapter 5 Org-214007, a SGRM, was shown to inhibit 
collagen-induced arthritis in mice even more efficiently than prednisolone did. When Org-
214007 was tested on glucose metabolism by analysis of hepatic glucose fluxes by MIDA, 
it was shown not to induce adverse effects on hepatic glucose fluxes, whereas predniso-
lone clearly reduced the glycogen balance. 
In chapter 5 efficacy and adverse effects were evaluated in different animal models. How-
ever, the disease can modify GC-induced side effects as well, in chapter 6 we therefore 
analysed efficacy and adverse effects in one animal model. For this the blood glucose ki-
netic model described in chapter 2 was performed in collagen induced arthritic mice. The 
resulting model allows the study of effects of (novel) GC compounds on the development 
of arthritis and on glucose kinetics. 
Besides the adverse effects of prednisolone on glucose metabolism, lipid metabolism 
is also unfavorably affected. In chapter 7 development of dyslipidemia was studied in a 
transgenic mouse model, the GRdim mouse. This model was developed to discern the ef-
fects of transactivation by dimeric GR and transrepression of monomeric GR. GRdim mice 
have a mutation in the dimerization part of the GR leading to activation of monomeric GR 
exclusively. Prednisolone treatment in GRdim mice led to an extreme phenotype of dys-
lipidemia, with high plasma triglyceride, cholesterol and phospholipid levels, mainly in 
the very low density lipoprotein (VLDL)-sized fractions. Monomeric GR directly increased 
mRNA expression of hepatic Lpl; future studies should reveal the role of LPL on the devel-
opment of prednisolone-induced dyslipidemia in GRdim mice.
Finally, in chapter 8 the work addressed in this thesis is discussed and future implica-
tions are given. From the various conclusions of the different chapters it is clear that the 
effects of GCs on insulin is only one of many components involved in glucose and lipid 
metabolism and that disturbance of this complex system of multiple organs and opposing 




hormones, will lead to serious metabolic side effects. 
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The etiology of insulin resistance is still an enigma. Mouse models are frequently em-
ployed to solve the underlying pathology. The most commonly used methods to monitor 
insulin resistance are the HOMA-IR, glucose or insulin tolerance tests or the hyperinsulin-
emic euglycemic clamp (HIEC). Unfortunately, these tests disturb steady state glucose me-
tabolism. Here we describe a method in which blood glucose kinetics can be determined 
in fasted mice without noticeably perturbing glucose homeostasis. The method involves 
an intraperitoneal injection of a trace amount of [6,6-2H2]-glucose and can be performed 
repeatedly in individual mice. The validity and performance of this novel method was 
tested in mice fed chow or high-fat diet for a period of 5 weeks. After administering the 
mice with [6,6-2H2]-glucose, decay of the glucose label was followed in small volumes of 
blood collected by tail tip bleeding during a 90 minute period. The total amount of blood 
collected was less than 120 μl. This novel approach confirmed in detail the well-known 
increase in insulin resistance induced by a high-fat diet. The mice showed reduced glucose 
clearance rate, and reduced hepatic and peripheral insulin sensitivity. To compensate for 
this insulin resistance, β-cell function was slightly increased. We conclude that this refine-
ment of existing methods enables detailed interrogation of glucose homeostasis in mice. 
Insulin resistance can be accurately determined while mechanistic insight is obtained 
in underlying pathology. Additionally, this novel approach reduces the number of mice 
needed for longitudinal studies of insulin sensitivity and glucose metabolism.





The metabolic syndrome is one of the most important contemporary disease complexes 
in western societies 1,2. The syndrome is defined as a cluster of interrelated risk factors 
which predict a high incidence of cardiovascular disease and diabetes mellitus type 2. Ac-
cording to the International Diabetes Federation these risk factors include central obesity 
defined by increased waist circumference, hypertension, increased plasma triglyceride 
levels, reduced HDL cholesterol, hyperglycemia and insulin resistance 3. 
To elucidate the effects of multiple factors, such as gender, heredity and environment on 
development of the metabolic syndrome, a number of animal models have been intro-
duced. From these models, mouse models are very important, since they can be geneti-
cally manipulated and hence offer the possibility to study the role of specific genes in the 
development of insulin resistance and/or changes in glucose metabolism independent 
from other circumstances 4-6. In addition, mice have a high reproduction rate and a rela-
tively short lifespan which is essential for studies on parental effects (e.g., in metabolic 
programming) and healthy aging 7. Due to their small size, however, mouse experiments 
are limited by the amount of blood that can be taken, which is restricted to 8 ml/kg/14 
days 8 by most animal ethical committees. In addition, infusion rates during complex sta-
ble isotope infusion protocols have to be adjusted to the high metabolic rate of mice and 
(surgical) handling of mice is complicated and requires specific skills. Therefore, some of 
the published mouse experiments are performed under restrained or even anaesthetized 
conditions which strongly influences rates of glucose turnover, making it difficult to inter-
pret the results 9.
Simple parametric models like the homeostatic model assessment (HOMA-IR) are most 
commonly used to assess the degree of insulin resistance and glucose intolerance. These 
models are solely based on measurements of insulin and glucose concentration and are 
therefore not suited to study the (patho)physiology of inter organ relationships that could 
underlie perturbed insulin sensitivity 10. Moreover, methods need to be developed to al-
low for longitudinal studies in individual mice to evaluate changes in tissue-specific insulin 
sensitivity. For this purpose, the kinetic or steady-state flux experiments are a good ap-
proach. To study insulin resistance in more detail, e.g., tissue-specific insulin sensitivity, a 
number of techniques are available from which the hyperinsulinemic euglycemic clamp 
(HIEC) is regarded as the ‘gold standard’ 11,12. The HIEC can not be used for longitudinal 
studies of tissue-specific insulin sensitivity in individual mice, since the HIEC is invasive and 
can only be performed once in an individual mouse 13. Less invasive techniques are glu-
cose tolerance tests and insulin tolerance test 14, but these tests only evaluate effects on 
whole body glucose metabolism under perturbing conditions and are not tissue-specific.
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Longitudinal studies on changes in insulin sensitivity and glucose tolerance with sequen-
tial testing in individual mice depend on the ability to accurately perform measurements 
in small blood samples. We developed a blood sampling method by taking bloodspots via 
tail tip bleeding on filter paper as starting material for analyses of stable isotopically-la-
beled compounds by gas chromatography-mass spectrometry (GC-MS). Hereby, we were 
able to minimize the volume of blood to be drawn 15 that allowed us to follow the con-
centrations of labeled compounds over time in very small blood volumes. This approach 
can be implemented in other published methods. Galvin and colleagues, for instance, 
estimated glucose kinetics and insulin sensitivity from glucose and insulin data during an 
intravenous glucose tolerance test (IVGTT) 16. This method, however, perturbs the glucose 
and insulin concentrations due to the high amount of glucose given. Pacini et al. intro-
duced a similar method for mice, in which data were analyzed using the minimum model 
technique, according to a two-compartment model 17. During this experiment, mice were 
kept under anesthesia on a heating pad and 7 blood samples were taken of 75µl each. The 
large volume of blood withdrawn in this method perturbs the circulation severely which 
makes interpretation of the data difficult.
We hypothesized that the combination of a trace amount of stable isotopically-labeled 
glucose, combined with collection of small blood samples on filter paper and GC-MS 
analysis, would enable us to obtain the necessary data to calculate glucose kinetics at 
prevailing glucose and insulin concentrations during fasting. In this study, we present a 
method to calculate glucose kinetics and correlate these kinetic data with parameters of 
the HOMA-IR under prevailing glucose and insulin concentrations. To this purpose, a small 
amount of stable isotopically-labeled [6,6-2H]-glucose was administrated intraperitoneally 
to mice fed a standard laboratory chow diet or a high-fat diet for 5 weeks. High-fat diet fed 
mice were included as a well-documented model for insulin resistance. Since basal blood 
glucose and plasma insulin concentrations were not disturbed during the experimental 
protocol, glucose kinetics can be approximated by single-pool first-order kinetic model 20-
22. Furthermore, several parameters describing insulin sensitivity and β-cell function were 
assessed using a HOMA-IR adapted for mice 10. 
Materials and Methods
Animals
Male C57BL/6J mice (25.3 ± 1.4 g), aged 8-12 weeks, were included (n=40). The animals 
were obtained from Harlan Laboratories (Horst, The Netherlands). After arrival, animals 




were allowed to recover for 1 week in groups of 6 animals in plexiglas cages, receiving a 
commercially available lab chow (RMH-B, Arie Blok Diervoeding, Woerden, The Nether-
lands). Mice were subsequently housed individually for 1 week after which the first blood 
glucose kinetics test (day 0) was performed. Next, mice remained on lab chow or received 
a high-fat diet (36% (wt/wt) bovine tallow, i.e., 60% energy from fat) 23 for 5 weeks after 
which the blood glucose kinetics test was repeated. During the whole experiment mice 
were housed under a controlled 12 h light-dark cycle and temperature (21°C) regime. 
The experiments were approved by the Ethical Committee for Animal Experiments of the 
University of Groningen.
Blood glucose kinetics
After 9 hour fast (23:00 h – 8:00 h), at time point 0, mice received a small volume of 2.0 
mg D-[6,6-2H2]glucose in 0.20 ml by intraperitoneal injection (~450 µmol kg
-1 BW). Blood 
glucose concentrations were determined and blood spots obtained by tail tip bleeding 
were collected on filter paper just before (time point 0) and at 10, 20, 30, 40, 50 60, 75 
and 90 minutes after glucose administration. At the end of the test, a blood sample of 
~30 µl was taken for insulin measurements. This represents a total volume of ~120 μl of 
blood which is less than 7% of the total blood volume. Blood samples were centrifuged 
immediately and plasma was stored at -20°C until analysis. Blood spots were air-dried and 
stored at room temperature until analysis. In an additional group of mice (n=12) the effect 
of the experimental procedure on insulin levels was measured. To study the influence of 
the administrated glucose on insulin levels, in a separate experiment, blood glucose levels 
were measured and blood samples of ~30 µl were taken for insulin measurements before 
and at 15, 30 and 90 minutes after D-[6,6-2H2]glucose injection.
Metabolite concentrations
Blood glucose concentrations were determined with a handheld OneTouch Ultra Blood 
Glucose Meter (LifeScan Benelux, Beerse, Belgium). Plasma insulin concentrations were 
determined using enzyme-linked immunosorbent assay adapted for measurements in 10 
µl plasma (Ultrasensitive Mouse Insulin kit, Mercodia, Uppsala, Sweden). HOMA-IR was 
calculated by a formula adapted to Mathews et al. 10. For mice, reference values were 
calculated using average fasting glucose (6.4 mM) and plasma insulin (2.2 mU.l-1) concen-
trations from the control group at the start of the experiment (Table 1, eq.9 to eq. 15).
Derivatization and GC-MS measurements of glucose
Fractional distributions of D-[6,6-2H2]glucose in bloodspot were measured according to 
Van Dijk et al. 15. In short, glucose was extracted from bloodspots by punching out a disk 
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(6.5 mm in diameter), transferred to a reaction vial and wetted with 50 µl water for 10 min 
followed by the addition of 500 µl ethanol after which the mixture was incubated over-
night at room temperature. Subsequently, the solution was centrifuged in a centrifuge for 
5 min after which 400 µl supernatant was removed and transferred to a Teflon-capped 
reaction vial and dried at 60°C under a stream of nitrogen. Glucose was converted to its 
pentaacetate derivative by adding 300 µl pyridine/acetic anhydride (1:2) to the residue, 
incubating it overnight at room temperature, followed by drying at 60°C under a stream 
of nitrogen. The residue was dissolved in 200 µl ethylacetate and transferred into injection 
vials for analysis. All samples were analyzed by gas chromatography mass spectrometry 
(Agilent 9575C inert MSD; Agilent Technologies, Amstelveen, The Netherlands). Deriva-
tives were separated on AT-1701 30 m x 0.25 mm ID (0.25 µm film thickness) capillary 
column (Alltech, Breda, The Netherlands). The separation for glucose pentaacetate was 
as follows: the oven temperature started at 150°C for 0.5 min, increased to 280°C at a 
rate of 80°C min-1, and remained at 280°C for 4.4 min. Mass spectrometric analyses were 
performed by positive chemical ionization with ammonia. Ions monitored, m/z 408-414 
(m0 - m6), were corrected for the fractional distribution due to natural abundance of 
13C by 
multiple linear regression as described by Lee et al. 24 to obtain the excess fractional distri-
bution of mass isotopomers (M0 - M6) due to the dilution of administered labelled glucose, 
i.e., M2 represents the fractional contribution of D-[6,6-
2H2]glucose in blood glucose. This 
fractional contribution was used in the calculations of blood glucose kinetics.
Calculation of blood glucose kinetics
Whole body glucose turnover and clearance were calculated by kinetic analysis from the 
wash-out of injected D-[6,6-2H2]-glucose from the circulation. Formulas used for calcula-
tions of the kinetic parameters are given in Table 1. Since there is no dynamic insulin 
action under these conditions, we used a single-pool first-order kinetic model for basal 
glucose kinetics as described previously 22,25,26. This was confirmed by comparison of the 
results on glucose turnover and metabolic clearance rates obtained from a two-compart-
ment model with those obtained from a single compartment model, which resulted in 
similar turnover and clearance rates. To fit the model, the average time course was con-
structed for each of the studied groups using SAAMII. The values obtained were used as 
Bayesian values in the fitting of the model to the data points for individual mice. Next, 
averages of the parameter values of the individual mice were calculated for each of the 
studied groups and compared to the initial parameter values extracted from the average 
time-course. The estimates of parameters for each individual mouse were accepted when 
no significant difference remained between both sets of values. Otherwise, the procedure 
was repeated with adjusted Bayesian values. 





Deming regression was used for comparisons of different methods. Data were plotted as 
median values in a Tukey box-plot, showing 2x SD with its outliers. Two group compari-
sons were done by the Wilcoxon signed-rank test or Mann-Whitney U test for related and 
unrelated groups, respectively. Differences were considered statistically significant when 
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To investigate the effect of this experimental protocol on glucose metabolism, a small 
amount (2.0 mg per mouse) of D-[6,6-2H2]-glucose was injected intraperitoneally into 9 
hours-fasted mice (n=40) and the effect on glucose concentration was measured (Fig. 1A). 
Due to handling of the animals, blood glucose concentrations increased from 4.6 mM 
at t=0 min to 6.6 mM at t=30 min (Fig. 1A). Subsequently, blood glucose concentration 
declined slightly to 5.9 mM at t=90 min. The wash-out of stable isotopically-labeled glu-
cose from the circulation was determined by analyzing the isotopic enrichment of glu-
cose eluted from bloodspots collected consecutively on filter paper obtained by tail tip 
bleeding (Fig 1B). The concentration of [6,6-2H2]-glucose tracer in blood was calculated 
according to eq. 1 (Table 1). The influence of tracer injection on insulin levels was tested 
in a second group of mice (n=12) that also received D-[6,6-2H2]-glucose intraperitoneally. 
Since insulin measurement requires a relatively large amount of blood, glucose and insu-
lin levels were measured at four time points during a separate experiment to avoid large 
blood volume to be drawn from each individual animal (Fig. 1C-D). Figure 1C shows the 
blood glucose curve during this experiment, which was very similar to the curve shown 
in figure 1A. There was no change in plasma insulin levels (p=0.4) during the experiment 
(Fig. 1D), which confirms that the amount of glucose tracer injected, did not trigger insulin 
secretion. This indicates that the insulin level measured at the end of the experiment is 







 1 Formulas for the calculated parameters for the single-pool first order glucose kinetics
Relevant equations in blood glucose kinetics and HOMA-IR are shown. Mt represents the fractional contribution of the 




0 represent the extrapolated 
concentrations of tracer at time point 0 in the elimination and absorption curve, respectively. kel and kab represent rate 
constants of elimination and absorption, respectively, which were calculated using SAAM II software (Version 1.2.1 Com-
partmental, SAAM Institute, University of Washington). D represents the dose of tracer in µmol-1.kg-1 given to the mice at 
time point 0. BG is the mean blood glucose level during the experiment and PI the plasma insulin level at time point 90 min.
 %S represents whole body insulin sensitivity, however, blood glucose kinetics in combination with plasma insulin levels 
were used to distinguish between hepatic (%H) and peripheral (%P) insulin sensitivity. %H was calculated as a constant 
divided by the product of blood glucose and plasma insulin. 
The clearance of the administrated glucose tracer (MCR) was assumed to be independent from endogenous glucose pro-
duction the relation to plasma insulin levels (PI) was used to estimate peripheral insulin sensitivity (%P), which was cal-
culated as the ratio of MCR and PI of individual mice divided by the median of these ratios of the control group. Note; for 
these calculations a linear relationship between PI and MCR was assumed. Because kinetics of glucose tracer were identical 
to the kinetics of glucose tracee (3) the calculations were also valid for blood glucose metabolism. 
To deduce the line of representing 100% β-cell function (%B) in the control group as shown in Fig. 3A we used an empirical 
approach. It was assumed that this line intersects the median data point of the control group, i.e. 6.4 mM and 2.2 mU.l-1 
for blood glucose and plasma insulin, respectively. Additionally, it was assumed that median β -cell function of the group 
equals 100%. The optimal result was obtained for this line is described by eq. 12. From this equation it can be deduced 
that %B for the individual mice can be calculated by eq. 13. It has been shown that in normal situations changes in %S are 
adjusted by inverse effects in %B so that the relation between %B and %S can be described by a hyperbolic function (eq. 
14). Eq. 15 gives the adjusted HOMA-IR for mice for this study, in which fasting BG is blood glucose in mM and fasting ins 
is fasting insulin in mU.l-1.




A high-fat diet increases HOMA-IR and reduces insulin sensitivity 
Next the performance of the blood glucose kinetics test was investigated in a group of 
mice fed either a chow or a high-fat diet for 5 weeks. Both groups had similar median 
values of fasting blood glucose levels on day 0 of the experiment (Fig. 2A). Fasting blood 
glucose levels increased significantly when mice received a high-fat diet for 35 days, i.e., 
from a median of 6.5 mM to 11.9 mM, while it remained almost unchanged in the chow-
fed group. Plasma insulin levels showed a very similar course (Fig. 2B): plasma insulin lev-
els only increased in mice fed a high-fat diet for 35 days, i.e., from 2.3 mU.l-1 to 10.3 mU.l-1. 
The values measured in mice at day 0 of the experiment (i.e. 6.4 mM for glucose and 2.2 
mU.l-1 for insulin) were used to calculate the basal values of the HOMA-IR, which allowed 
for adjustment of the HOMA-IR for mice. High-fat feeding of mice resulted in a significant-
ly increased HOMA-IR (Fig. 2C). Additionally, the insulin sensitivity (%S) and β-cell function 
(%B) were calculated, according to eq. 9 and eq. 13 from Table 1, respectively, for which 
the values of day 0 represents 100% insulin sensitivity (%S) and 100% β-cell function (%B). 
After 35 days %S was slightly but significantly reduced in the chow-fed group (Fig. 2D), i.e., 
from 97% to 79%. In contrast, the high-fat fed group had a very strong reduction of 88% in 
%S. In contrast, β-cell function (%B) was increased in the high-fat fed group (Fig. 2E), i.e., 
median 91% to 177%, implying compensation for reduced insulin sensitivity by increasing 
β-cell activity. Subsequently, the relationship was studied between β-cell function and 
insulin sensitivity in mice (Fig. 2F-G). In figure 2G the relationship between %B and %S is 
shown. Like in humans, the relationship can be described by a hyperbolic function in mice 
Glucose and insulin levels during experiment 
Blood concentrations of glucose, tracer D-[6,6-2H]glucose and insulin after a in-
traperitoneal bolus of D-[6,6-2H]glucose from two separate experiments. Two 
parallel experiments were carried out; the first experiment focused on actual 
blood glucose kinetics, while the second experiment focused on analysis of insu-
lin concentrations during the experiment. 
A, Concentrations of glucose in blood B, Concentration of [6,6-2H]glucose in 
blood. C, Blood glucose concentrations during second experiment. D, Plasma in-
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as well. The disposition index (%DI), a measure for the ability of β-cells to compensate for 
reduced insulin sensitivity, was calculated according to eq. 14 (Table 1). It was clear that 
%DI at the end of the experiment in chow fed animals was very comparable to that cal-
culated for the start of the experiment (Fig. 2F). In contrast, the %DI of high-fat fed mice 
was greatly reduced at the end of the experiment when compared to the value of %DI 
observed at the start of the experiment. 
A high-fat diet reduces metabolic clearance rate and apparent volume of distribution 
of glucose in mice 
Glucose kinetics was studied in chow-fed and high-fat fed mice at the start and end of 
Implications of a high-fat diet on HOMA-IR 
A, Blood glucose concentrations. B, Plasma 
insulin concentrations. C, HOMA-IR. D, Insulin 
sensitivity. E, β-cell function. F, Disposition in-
dex. G, Relationship between β-cell function 
(%B) and insulin sensitivity (%S). Open circles: 
40 individual mice at day 0; closed circles: 20 
mice that continued chow diet for 35 days; 
closed squares: 20 mice receiving a high-fat diet 
for 35 days. White bars: data from day 0; Grey 
bars: data from day 35. The data are present-
ed as median with ranges in a Tukey-box plot 
with outliers represented as black dots. *, p < 

















the experiment (Fig. 3A-H). Chow-fed mice slightly gained bodyweight over time, from 
25.3 ± 1.1 g at the start of the experiment to 28.0 ± 1.7 g at day 35. Mice fed a high-fat 
diet showed a more pronounced increase in bodyweight, i.e., from 25.2 ± 1.1 g to 31.0 ± 
2.3 g. The increase in bodyweight of the mice over time in combination with an identical 
amount of administered tracer resulted in a significantly lower dose of tracer per kg body-
weight on day 35 compared to day 0 for both groups (Fig. 3A). 
Metabolic clearance of glucose (MCR), i.e., the volume of blood completely cleared from 
glucose in by peripheral tissue, i.e., muscle, brain and adipose tissue, is an important pa-
Multiple parameters calculated by 
tracer kinetics
From the tracer kinetics the follow-
ing parameters were calculated by the 
equations described in table 1 from 
which median and ranges are depict-
ed in a Tukey-box plot, with outliers 
represented as black dots. A, The ad-
ministrated dose [D], B, bioavailability 
[F], C, area under the curve [AUC], D, 
clearance of the tracer [MCR], E, elimi-
nation rate [kel], F, apparent volume of 
distribution [V], G, turnover rate [Ra] 
(HGP) and H, pool size [A] from mice on 
a chow diet or high-fat diet are shown 
with white bars representing day 0 and 
grey bars after 35 days of diet. *, p < 
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rameter in blood glucose kinetics. Equation 5 from Table 1 shows that MCR depends on 
the dose of D-[6,6-2H2]glucose administrated, the bioavailability of D-[6,6-
2H2]glucose (F) 
(eq. 3) and the area under the concentration curve of D-[6,6-2H2]glucose (AUC) (eq. 4). 
The bioavailability of the tracer, i.e., the fraction of administered tracer that enters the 
sampled pool, was significantly lower on day 35 compared to day 0 in both the chow and 
high-fat diet group (Fig. 3B). After 35 days of high-fat feeding the AUC was considerably 
higher as compared to a 35-day chow diet (Fig. 3C) which resulted in significant differ-
ences in AUC between both groups on day 35. The calculated MCR of the tracer (Fig. 3D) 
was similar in both groups on day 0 and did not change in the chow-fed group over time, 
but was reduced in the high-fat fed mice MCR, i.e., from 0.022 l.kg-1.min-1 to 0.014 l.kg-1.
min-1, resulting in a significant difference in MCR after 5 weeks between both groups. 
According to eq. 6 from Table 1, the apparent volume in which glucose is distributed (V) 
depends on the MCR of glucose and the elimination rate kel (Fig. 3E). After 35 days of chow 
diet median kel was significantly changed from 0.026 min
-1 to 0.033 min-1, yet, kel remained 
unchanged in the high-fat fed group over the same period of time. The apparent volume 
of distribution (Fig. 3F) was slightly decreased after 35 days in the chow-fed group, i.e., 
from median 0.83 l.kg-1 to 0.64 l.kg-1. However, in the high-fat fed group, V was more re-
duced, i.e., from 0.87 l.kg-1 to 0.50 l.kg-1.
Other relevant parameters in blood glucose kinetics, i.e., turnover rate (Ra) and pool size 
(A) were calculated according to eq. 7 and eq. (Table 1), respectively (Fig. 3G-H). The pool 
size was slightly reduced in chow-fed mice after 35 days, while there were no differences 
in mice fed a high-fat diet. Although Ra was slightly increased on day 35 in both groups, 
no significant difference was observed between either group or time point. Since the mice 
were fasted prior to the study of glucose kinetics, the turnover rate of glucose can be 
regarded as the endogenous glucose production rate, which implicated that high-fat diet 
feeding did not alter hepatic glucose production. 
HOMA-IR and glucose kinetics
Matsuda et al. 18 and Færch et al. 19 presented arguments to merge certain kinetic param-
eter of whole body glucose metabolism with the HOMA-IR such that changes in tissue-
specific insulin sensitivity can be evaluated. In their discussion the authors related insulin 
levels to the endogenous glucose production to evaluate hepatic insulin sensitivity (%H, 
eq. 10, Table 1). In fasted mice the turnover of glucose (Ra) in the circulation reflects this 
production. We assumed that peripheral insulin sensitivity (%P, eq. 11, Table 1) could be 
reflected by the relation between MCR and insulin concentration. Since both turnover and 
MCR can be derived from the data of the wash-out of a tracer amount of stable isotopic 




labeled glucose after injection, %H and %P were calculated for individual mice both at the 
start and the end of the experiment. After 35 days, %H was decreased slightly in the chow-
fed group, while the reduction of %H in the high-fat fed group was 5-fold, i.e., from 101% 
to 22% (Fig. 4A). In addition, the high-fat fed group showed an almost 7-fold reduction in 
%P, i.e., from a median of 110% to 16% after 35 days of high-fat feeding (Fig. 4B), implying 
that a high-fat diet reduces both peripheral and hepatic insulin sensitivity.
Discussion
In this paper, we present a novel approach to assess interorgan relationships determining 
insulin and glucose action in small laboratory animals. The approach is a combination of 
the application of HOMA-IR to assess insulin resistance and analysis of a glucose tracer 
wash-out by a single-pool, first-order kinetic model to assess whole body glucose metabo-
lism. The merging of both methods makes evaluation of tissue-specific insulin sensitivity 
possible during fasting at prevailing insulin an glucose concentration in a fasted steady-
state condition. By collecting bloodspots on filter paper by tail tip bleeding, this approach 
allows for sequential application in individual mice in order to document time-dependent 
changes in insulin action and whole body glucose metabolism in small laboratory animals,
The approach starts with an intraperitoneal injection of 2 mg D-[6,6-2H2]glucose per an-
imal. Subsequently, blood glucose is measured and bloodspots are taken at nine time 
points (~10 µl per time point). At the final time point a larger sample (~30 µl blood) is 
taken to measure insulin levels. In total, about 120 μl of blood is taken per animal during 
the experiment. This very small volume of blood drawn is an important refinement in mice 
studies, compared to, for instance, Pacini et al. 17 who collected as much as 525 µl during 
a comparable experiment. In addition, our novel procedure can be repeated (within lim-
its of time) in the same animal and therefore reduces the number of animals needed to 
study effects of different dietary protocols and pharmacological treatments. The validity 
Implications of a high-fat diet on insu-
lin related glucose kinetics
A, Hepatic insulin sensitivity (%H). 
B, Peripheral insulin sensitivity (%P). 
White bars: day 0; grey bars: day 3. The 
data are presented in a Tukey-box plot, 
with outliers represented as black dots. 
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of the single-compartment first-order kinetic model used to calculate glucose kinetics was 
compared with results calculated from the generally used two-compartment model. No 
differences were observed between both models (data not shown), which confirmed our 
hypothesis that the single-compartment first-order kinetic model is valid under fasted in-
sulin and glucose concentrations. Since Matthews et al. 10 presented their model to asses 
insulin action for humans, the model parameters they derived are only applicable for hu-
mans. In mice a new set of parameters needed to be established. To do so, we assumed 
that all data measured and calculated at the start of the experiment in young, wild-type, 
chow fed mice reflects 100% insulin sensitivity and β-cell function. Subsequently, model 
parameters for insulin sensitivity and β-cell function could be calculated 27,28. To calculate 
hepatic insulin sensitivity (%H) we used the product of endogenous glucose production 
and plasma insulin level as presented by Matsuda et al. 18, which was discussed by Færch 
et al. 19, and for peripheral insulin sensitivity (%P) the ratio of clearance rate and plasma 
insulin level was used. Note that the values given in this study adapting the HOMA-IR for 
use in mice is only applicable for mice of this particular mouse strain, in which glucose and 
insulin concentration are measured using the same methods.
We investigated the performance of our approach in a large group of young C57BL/6J 
mice at the start and after a period of 5 weeks in which they received either a high-fat diet 
or continued their habitual chow diet. It is well-known that feeding mice a high-fat diet 
induces insulin resistance 29. An important observation was that in young mice on a chow 
diet (day 0) fasting insulin concentrations vary highly in combination with almost identical 
blood glucose concentrations, indicating that insulin plays a minor role in regulation of 
glucose homeostasis under fasting conditions. Thus other hormones, like glucagon might 
be more important in regulation of glucose homeostasis during fasting. The broad range 
in fasted insulin concentrations resulted in large ranges in the calculated overall and tissue 
specific insulin sensitivities, i.e., %S, %H, and %P. High-fat feeding significantly increased 
both fasting insulin and glucose levels, resulting in an increased HOMA-IR, a decreased 
disposition index (%DI) and a reduction in all three insulin sensitivity indices, i.e., overall 
insulin sensitivity (%S), hepatic insulin sensitivity (%H) and peripheral insulin sensitivity 
(%P). In contrast, the animals that continued the chow diet over the same period showed 
hardly any changes in fasting glucose and insulin levels, resulting in no changes in %S and 
%P and only a minor reduction in %H.
In addition, using HIEC, we have previously shown that feeding mice the same high-fat 
diet as used in the present paper resulted in peripheral insulin resistance accompanied by 
a reduced disposal of glucose by 40% 30, which was also seen in this study (see values for 
MCR in Fig. 2D). It should be realized, however, when comparing HIEC and the combined 
HOMA-glucose kinetic models that during HIEC supraphysiological concentrations of in-




sulin were applied, while for the HOMA-glucose kinetic model the measurements were 
done under prevailing concentrations of insulin. The Ra remained unchanged over time 
in both groups. The calculated turnover rate (which during fasting equals HGP) and meta-
bolic clearance rate (MCR) were in the same order of magnitude as calculated by Mass 
Isotopomer Distribution Analysis as previously published 31-33, and thus show the validity 
of the presented kinetic analysis of the wash-out of stable isotopic labeled glucose after 
injection of a tracer amount.
The median apparent volume of distribution of 0.67 l.kg-1 calculated on day 0 was higher 
than the extracellular fluid volume (0.22 l.kg-1) often used in non-steady-state calculations 
34,35 implicating that intracellular fluid volume is involved in the distribution of the admin-
istrated glucose. High-fat feeding reduced this volume to 0.46 l.kg-1, most likely the result 
of a reduction in involved intracellular volume. The effect of high-fat feeding on the ap-
parent distribution volume of glucose has not been reported before, although it is known 
that high-fat feeding reduces GLUT4 concentration and translocation form intracellular 
stores to the plasma membrane 36-38. Furthermore, high-fat feeding impairs central insulin 
stimulation of blood flow 39, adding to the already perturbed glucose disposal in periph-
eral tissue and therefore in a reduced volume of distribution.
In conclusion, we describe a refined approach to evaluate blood glucose metabolism with 
a minimum level of inconvenience for the mice, which can be used in longitudinal studies 
in individual mice. This represents an opportunity for a major reduction in the number 
of animals necessary for these metabolic studies. It combines known protocols for cal-
culation of insulin sensitivity and blood glucose kinetics under basal situations and can 
be repeated over time. In our view, the single pool kinetic analysis of intraperitoneally 
injected D-[6,6-2H2]-glucose offers a valuable alternative to estimate whole body glucose 
metabolism without perturbing its metabolism.
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Chronic glucocorticoid use for treatment of inflammatory diseases is accompanied by se-
vere side effects in humans, e.g., hyperglycemia and insulin resistance. The present stud-
ies were conducted to characterize consequences of chronic treatment with the synthetic 
glucocorticoid prednisolone on insulin sensitivity and blood glucose kinetics in mice. Pred-
nisolone treatment increased fasting blood glucose and plasma insulin concentrations, 
but this apparent reduced insulin sensitivity could not be confirmed in hyperinsulinemic 
euglycemic clamp studies. Therefore, a novel method to study whole-body glucose ki-
netics was used. This revealed that prednisolone-treated mice had an increased hepatic 
glucose production (HGP). The increased HGP was accompanied by elevated plasma insu-
lin concentrations, indicating reduced insulin sensitivity of hepatic glucose metabolism in 
prednisolone-treated mice. Compared to vehicle-treatment, prednisolone-treated mice 
had lower blood glucose concentrations, higher plasma free fatty acids and higher plasma 
FGF21 concentration in the fed condition, mimicking a fasting situation. Next, the effects 
of 24-h fasting on energy metabolism were studied. Compared to controls, fasted prednis-
olone-treated mice had higher blood glucose concentrations and a hampered induction 
of plasma β-hydroxybutyrate concentrations. In conclusion, these results indicate that 
chronic prednisolone treatment reduces insulin sensitivity of hepatic glucose production, 
induces a fasting-like phenotype in fed mice and perturbs the fed-to-fasting transition. 





The human steroid hormone cortisol and its rodent variant corticosterone are endoge-
nous glucocorticoids that control a plethora of processes such as bone formation, blood 
pressure, stress response, blood glucose homeostasis, and the immune response 1. When 
a glucocorticoid binds to the glucocorticoid receptor (GR), the formed complex can bind to 
glucocorticoid response elements (GREs) located in promoter regions of GR-target genes 
2, hence activating or repressing gene transcription. In addition, the activated GR can also 
bind to cytosolic proteins, e.g., nuclear factor-kappa B and activator protein-1, to perform 
immune suppressive roles via protein-protein interactions 3. 
Synthetic glucocorticoids such as prednisolone and dexamethasone are widely used as 
anti-inflammatory and immunosuppressive drugs in the treatment of (chronic) inflamma-
tory diseases. Side effects of synthetic glucocorticoids are widespread and include hyper-
tension, hypertriglyceridemia, central obesity, and insulin resistance 4. These side effects 
are all components of the metabolic syndrome, a cluster of metabolically interrelated 
risk factors for diabetes mellitus and cardiovascular diseases in which insulin resistance is 
thought to be of key relevance 5. Insulin resistance, for instance, is a very common meta-
bolic disturbance found in rheumatic patients treated chronically with glucocorticoids 3,6. 
Interestingly, insulin resistance has also been reported to occur in a disorder characterized 
by elevated cortisol levels, Cushing’s syndrome 7. 
Studies in humans have provided evidence for increased hepatic gluconeogenesis (GNG) 
and reduced peripheral glucose uptake upon glucocorticoid treatment 8-12. Stimulation 
of GNG might be the result of increased activity of phosphoenolpyruvate carboxykinase 
(PCK1), a direct GR-target 13. 
Although most studies suggest a role of hepatic PCK1 and disturbed GNG in the develop-
ment of glucocorticoid-induced insulin resistance, the exact mechanism of action remains 
unclear. Animal models might help to unravel these mechanisms. Indirect and direct evi-
dence is available that glucocorticoids affect insulin sensitivity and GNG in animal studies. 
However, most animal studies were conducted with rats 14-16 or special mouse strains, e.g., 
low density lipoprotein receptor knockout (Ldlr-/-) mice 17, or diet induced obese mice 18, 
and/or involved the extreme chronic use of high dose of dexamethasone for very long pe-
riods 17,19. In these studies, whole body insulin resistance has been assessed on the basis 
of fasting glucose and insulin levels or by performing oral glucose tolerance tests (OGTTs) 
and insulin tolerance tests (ITTs). These tests, however, do not distinguish between hepat-
ic and peripheral insulin sensitivity, i.e., the ability of insulin to suppress hepatic glucose 
production and stimulate peripheral glucose uptake, respectively. 
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The studies presented in this paper were performed to obtain more insight in the mecha-
nisms by which the commonly used glucocorticoid prednisolone affects insulin sensitivity 
of blood glucose kinetics in mice. For this purpose, mice received 10 mg/kg/day predni-
solone for 7 days. Hepatic and peripheral insulin sensitivity were determined using the 
hyperinsulinemic euglycemic clamp and with an intraperitoneal D-[6,6-2H2]-glucose injec-
tion. Our data revealed that chronic prednisolone treatment reduces insulin sensitivity of 




Male C57Bl/6J mice were obtained from Harlan (Horst, the Netherlands) and housed un-
der conventional conditions, in a 12 hour-12 hour light-dark cycle (lights on 6 am-6 pm). 
Before start of the treatments, mice were allowed to adjust to the environment for at 
least one week. Prednisolone (10 mg/kg/day) or vehicle (gelatin (5 g/l)/mannitol (5g/l)) 
was administered by gavage at 1 pm for 7 days. Except for the fed and 24 hour fasting, all 
experiments started at 8 am after an overnight fast (food removed at 11 pm the day be-
fore) on the day following the last treatment. All experiments were approved by the Ethics 
Committee for Animal Experiments of the State University Groningen. Prednisolone and 
vehicle were kindly provided by Schering Plough, Oss, the Netherlands.
Basal values
Blood glucose concentrations were measured in awake mice in blood drops collected by 
tail tip bleeding with a Lifescan EuroFlash glucose meter (Lifescan Benelux Beerse, Bel-
gium). Mice were sacrificed by cardiac puncture under isoflurane anesthesia. Blood sam-
ples obtained were centrifuged and the retrieved plasma samples were stored at -20 °C 
until analyzed. Organs were quickly removed and snap frozen in liquid nitrogen for RNA 
isolation and determination of metabolite concentrations. 
Hyperinsulinemic euglycemic clamp experiments
To determine insulin sensitivity of glucose metabolism under high insulin concentrations, 
mice were subjected to a hyperinsulinemic euglycemic clamp as previously described 20 
with minor adjustments. Five days before the experiment, i.e., at day 2 of treatment, 
mice were equipped with a permanent jugular vein catheter, with a two-way entrance 




attached to the skull with acrylic glue 21. Treatment was continued during the recovery 
period. Mice were individually housed in small plexiglas cages during the experiment, al-
lowing frequent collection of blood samples in freely moving mice. The mice were infused 
for 6 hours with an insulin solution containing insulin (110 mU/ml, Actrapid, Novo Nord-
isk, Bagsvaerd, Denmark), somatostatin (40 µg/ml, UCB, Breda, The Netherlands), glucose 
(18%) and 2% [U-13C]-glucose (99% 13C atom %excess; Cambridge Isotope Laboratories, 
Andover, MA)) and 1% BSA (Sigma, St. Louis, MO, USA) at a constant rate of 0.135 ml/h. 
The second solution that contained 27% glucose and 3% [U-13C]-glucose was infused with 
an adjustable rate to maintain plasma glucose levels at ~7 mM. For this, blood glucose 
levels were measured every 15 minutes in blood drops collected by tail tip bleeding with a 
Lifescan EuroFlash glucose meter. Every hour, blood spots for GC-MS analysis were taken 
by tail bleeding on filter paper, air-dried and stored at room temperature until further 
analysis. 
Blood glucose kinetics
To determine blood glucose kinetics without inducing hyperinsulinemia, 9-h fasted mice 
were injected intraperitoneally with a low dose of D-[6,6-2H2]-glucose (100 mg/kg). Be-
fore and at the indicated time points after injection, blood glucose concentrations were 
measured in blood collected by tail tip bleeding. At the same time points, a small blood 
spot was taken on filter paper, in which the fractional contribution of D-[6,6-2H2]-glucose 
to the whole blood glucose pool was measured by GC-MS. Whole body glucose turnover 
and clearance were calculated by kinetic analysis of the wash-out of injected D-[6,6-2H2]-
glucose from the circulation. A blood sample was taken by orbital puncture after the test 
for insulin measurements. 
24 hours fasting experiment
Food was removed one hour after the last treatment and mice were fasted for 24 hours. 
Blood glucose levels were measured every 6 hours by tail tip bleeding. At the same time 
points, a small amount of blood was obtained by orbital puncture under light anesthe-
sia. In the dark period, a red light was used to facilitate the procedure. After 24 hours of 
fasting, mice were sacrificed by cardiac puncture under isoflurane anesthesia. The blood 
sample was centrifuged and the retrieved plasma was aliquoted and stored at -20 °C until 
analyzed. Organs were quickly removed, snap frozen in liquid nitrogen for RNA isolation 
and metabolite concentrations. 
Metabolite analysis
Plasma insulin, corticosterone and fibroblast growth factor-21 (FGF21) concentrations 
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were measured using commercially available ELISA kits (Mercodia ultrasensitive mouse 
insulin ELISA, Orange Medical, Tilburg, the Netherlands; Diagnostic System Laboratories 
Benelux, Assendelft, The Netherlands; and Phoenix secretomics, Burlingame, CA, respec-
tively). The HOMA-score was calculated adjusted for basal mouse values taken from vehi-
cle-treated group. Plasma non-esterified fatty acid (NEFA) concentrations were determined 
with a commercially available kit (Diasys, Holzheim, Germany). Plasma β-hydroxybutyrate 
concentrations were measured using a total ketone body kit (Wako Chemicals, Neuss, 
Germany). Liver homogenates for lipid and protein measurements were made in ice-cold 
PBS. Hepatic lipids were extracted from the liver homogenates according to Bligh and 
Dyer 22. Commercially available kits were used for determination of hepatic and plasma 
triglycerides (Roche Diagnostics, Mannheim, Germany), free and total cholesterol (Wako 
chemicals, Neuss, Germany). Hepatic glycogen and glucose-6-phosphate concentrations 
were determined as described before previously 23,24. 
Gene expression
Total liver RNA was isolated using the TRI Reagent method (Sigma) according to manufac-
tures protocol. Integrity and concentration of RNA was determined spectrophotometri-
cally using the Nanodrop spectrophotometer (NanoDropTM 1000 Spectrophotometer, 
Thermo Scientific, Waltham, MA). cDNA was obtained using the reverse transcription pro-
cedure with Moloney Murine Leukemia Virus-RT (Sigma) with random primers according 
to the protocol of the manufacturer. cDNA levels were measured in real-time quantita-
tive PCR amplification using an ABI PRISM 7700 sequence detector (Applied Biosystems, 
Foster City, USA) against a calibration curve of pooled cDNA solutions. Expression levels 
were normalized for RPLP0 levels. The sequences of the used primers and probes for Gr 
(NR3C1; Acc. No. NM_008173) are GGA TAT TCA AGC CCT GGA ATG A (foreward primer), 
ACG TCA GCA CCC CAT AAT GG (reverse primer), and ACC ACC TCC CAA ACT CTG CCT GGT 
GT (probe); for Tat (Acc. No. NM_146214) are CAG CCA CGT GCT TCG AGT AC (foreward 
primer), AAC TCC TGG ATC CGG CTA CAA G (reverse primer), and CAT CAC AGT CCC CGA 
GGT GAT GAT GC (probe); for Per1 are (Acc. No. NM_011065): CTT CTG GCA ATG GCA AGG 
ACT (foreward primer), TGG GCT CTG TGA GTT TGT ACT CTT (reverse primer), and CTG CTC 
TCAG TGG TCT CCA GCA GAG CT (probe); for Acox1 (Acc. No. NM_015729) are GCC ACG 
GAA CTC ATC TTC GA (foreward primer), CCA GGC CAC CAC TTA ATG GA (reverse primer), 
and CCA CTG CCA CAT ATG ACC CCA AGA CCC (probe); for Foxo1 (Acc. No. NM_019739) 
AGA TCT ACG AGT GGA TGG TGA AGA G (foreward primer), GGA CAG ATT GTG GCG AAT 
TGA AT (reverse primer), and CAG CCC GCC GAG CTG TTG CT (probe). The sequence of the 
primers and probes that were used before can be found on www.labpediatricsrug.nl and 
are deposited at RTPrimerDB (www.rtprimerdb.org).




Measurement of mass isotopomer distribution by GC-MS
Extraction of glucose from blood spots on filter paper from the hyperinsulinemic-eugly-
cemic clamp and blood glucose kinetics test, derivatization of the extracted compounds, 
and GC-MS measurements of derivatives was done according to the analytical procedure 
described by van Dijk et al. 25. In short, a disk was punched out of the blood spots, glucose 
was extracted from the disk by incubating it in ethanol/water (10:1 v/v) and glucose was 
derivatized to its pentaacetate-ester. Samples were analyzed by GC-MS with positive ion 
chemical ionization with methane. The fractional isotopomer distribution measured by 
GC-MS (m0-m6) was corrected for the fractional distribution due to natural abundance of 
13C by multiple linear regression as described by Lee et al. 26 to obtain the excess fractional 
distribution of mass isotopomers (M0-M6) due to dilution of infused labeled compounds. 
Calculation of blood glucose metabolism
Formulas for calculating the endogenous glucose production (EGP) and metabolic clear-
ance rate (MCR) under hyperinsulinemic euglycemic clamped conditions were previously 
described 20. For the blood glucose kinetics test a single-pool, first-order kinetic model was 
assumed. The excess fractional distribution of mass isotopomers was used to calculate 
the first order absorption process in an one-compartment model using SAAM-II software 





The formulas used to calculate the concentration vs. time curves and the kinetic parameters in a first order absorption 
process in an one-compartment model.
C(0)ab, initial concentration by extrapolation of the absorption period; C(0)el, concentration by extrapolation of the elimi-
nation period; Clag, concentration at lag time calculated from elimination or absorption curve; D, dose D-[6,6-
2H]-glucose 
administrated; [glc], total blood glucose concentration; kab, absorption rate constant; kel, elimination rate constant; M2, 
mole percent enrichment of blood glucose; tlag, time between administration and appearance in sampled compartment; 
EGP, endogenous glucose production.
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used to calculate the concentration vs. time curves and the kinetic parameters are given 
in Table 1. 
Statistics
All data are represented as mean ± SEM. Statistical analysis for two independent groups 
was performed using Mann-Whitney-U tested with SPSS for Windows software (SPSS, 
Chicago, IL, USA). For multiple comparison statistical analysis were performed by Kruskal-
Wallis test, when this was positive (p<0.05) a pair wise comparison of subgroups accord-
ing to Conover was performed using Brightstat 28. Significance was considered at a level 
of p<0.05. 
Results
Chronic prednisolone treatment increased the HOMA-score in mice
The first experiments were performed to test the consequences of a chronic, 7 day predni-
solone treatment in mice. Activation of the hypothalamic-pituitary-adrenal axis (HPA-axis) 
by prednisolone results in a reduction of plasma corticosterone levels 29 and glucocor-
ticoid-induced apoptosis of thymocytes results in a severely reduced thymus weight 30. 
The 85% decrease in thymus weight and severely reduced plasma corticosterone levels in 
prednisolone-treated mice (Table 2) are therefore indicative for an efficient prednisolone 
treatment.
Blood glucose levels in 9 hour fasted mice tended to be higher upon prednisolone treat-
ment (Table 2). In addition, prednisolone treatment elevated plasma insulin levels. Conse-
quently, the HOMA-score was increased upon chronic prednisolone treatment, suggesting 
insulin resistance. 
Surprisingly, the hepatic expression of the classic GR-target genes Tat (encoding for tyros-
ine aminotransferase) 31 and Per1 (encoding for the clock-gene Period-1) 32 was reduced 
upon prednisolone treatment in the 9-h fasted mice (Figure 1). The expression of genes 
encoding proteins involved in gluconeogenesis, e.g., Pck1, G6pc, and Pdk4, was also sig-
nificantly reduced in the livers of 9 hour fasted prednisolone-treated mice. 








Treatment parameters of 9 hour fasted vehicle- and prednisolone-treated mice.
Values represent means ± SEM; n = 7 (vehicle); n = 8 (prednisolone); *, p < 0.05. The values for plasma FGF21 are from 
pooled plasma samples.
Hepatic gene expression of 9 hours 
fasted mice treated with vehicle 
(white bars) or prednisolone (black 
bars). 
Results were normalized to Rplp0 (ri-
bosomal protein, large, P0 (36B4)) with 
data from vehicle treated mice defined 
as ‘1’. Values are means ± SEM; n = 6 
(prednisolone); n = 7 (vehicle); *, p < 
0.05; Gr, glucocorticoid receptor; Tat, 
tyrosine amino transferase; Per1, pe-
riod-1; Pck1, phosphoenolpyruvate 
carboxykinase 1; G6pc, glucose-6-phos-
phatase, catalytic; Pdk4, pyruvate dehy-
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In order to evaluate the characteristics of the reduced insulin sensitivity upon predni-
solone treatment in more detail, a hyperinsulinemic euglycemic clamp was performed. 
Again, mice treated with prednisolone and fasted for 9 hours had increased blood glucose 
concentrations (Figure 2A). Surprisingly, the Glucose Infusion Rate (GIR) needed to main-
tain euglycemic conditions during the clamping period did not differ between treated 
and non-treated mice (Figure 2C). Prednisolone treatment affected neither the metabolic 
clearance rate (MCR) nor hepatic glucose production (HGP) (Figures 2D and 2E) under the 
hyperinsulinemic conditions. Altogether, these data indicate that the hyperinsulinemic 
euglycemic clamp is not the preferred method to study prednisolone-induced insulin re-
sistance, probably due to the artificially high plasma insulin concentrations. 
To determine hepatic and peripheral insulin sensitivity of glucose kinetics without induc-
ing the high plasma insulin concentrations, 9 hour fasted mice were intraperitoneal in-
Parameters of the hyperinsulinemic euglycemic clamp experiment performed in mice treated with vehicle (white bars) 
or prednisolone (black bars). 
A, Fasting blood glucose concentration; B, Average blood glucose concentration during the steady-state period of the 
experiment (3-6 hours); C, Average Glucose Infusion Rate (GIR) needed to maintain euglycemic conditions during the 
steady-state period of the experiment (3-6 hours); D, Hepatic glucose production (HGP) during the steady-state period of 
the experiment; E, Metabolic clearance rate (MCR) of glucose during the steady-state period of the experiment. Values are 










































































































jected with a tracer amount of D-[6,6-2H2]-glucose. This injection did not affect the blood 
glucose levels (Figure 3A). From the decay of the blood D-[6,6-2H2]-glucose vs. time curve, 
MCR was calculated and this parameter did not differ between vehicle- and predniso-
lone-treated mice (Figure 3B). The HGP was calculated using the MCR and blood glucose 
concentrations and was increased in prednisolone-treated mice (Figure 3C), despite in-
creased plasma insulin concentrations (Figure 3D). The increased HGP at higher plasma 
insulin concentrations indicates hepatic insulin resistance. 
Prednisolone treatment induced a fasting-like phenotype in fed mice and hampered 
the effects of fasting on energy metabolism
The hyperinsulinemic euglycemic clamp induced a state with supraphysiological insulin 
concentrations and therefore mimics a fed situation but the HOMA and blood glucose 
kinetics were calculated under fasted situations with low plasma insulin concentrations. 
We therefore investigated the effects of prednisolone and fasting on glucose metabo-
lism. Mice were fasted for 24 hours after the seventh day of treatment. At the start of 
the fasting period, one hour after the last treatment, prednisolone-treated mice had sig-
nificantly reduced blood glucose levels (Figure 4A). In vehicle-treated mice blood glucose 
concentration showed a clear fasting-induced reduction, but this effect was less clear in 
prednisolone treated mice (Figure 4B). Moreover, the prednisolone-treated mice showed 
a hampered induction of β-hydroxybutyrate levels upon fasting (Figure 4C). Metabolic 
parameters from a different 24 hour fasting experiment are shown in Table 3. In the fed 
Parameters of the blood glucose kinet-
ics test performed in mice treated with 
vehicle (white bars) or prednisolone 
(black bars). 
A, Blood glucose concentrations during 
the test; B, Metabolic clearance rate 
(MCR) of glucose during the test; C, He-
patic glucose production (HGP) during 
the test; D, Plasma insulin concentra-
tions after the test. Values are means ± 
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Parameters of the 24 hours fasting ex-
periment from mice treated with vehi-
cle (white circles and bars) or predni-
solone (black circles and bars). 
A, Blood glucose during the 24 hours 
fasting period, shaded area represents 
the dark period; 
B, Plasma insulin concentrations in fed, 
12 hours and 24 hours fasted mice; 
C, Plasma β-hydroxybutyrate (BHBO) 
concentrations in fed, 12 hours and 24 
hours fasted mice. 
D, Hepatic gene expression of mice 
treated with vehicle (white bars) or 
prednisolone (black bars) terminated 
after a 24 hour fast or at the same time 
point without fasting mice. Results 
were normalized to Rplp0 (ribosomal 
protein, large, P0 (36B4)) with data 
from vehicle treated fed mice defined 
as ‘1’. Values are means ± SEM; n = 6-8; 
*, p < 0.05 prednisolone vs. vehicle; 
#, p < 0.05 12-h or 24-h fasted vs. fed; 
Gr, glucocorticoid receptor; Tat, tyros-
ine amino transferase; Per1, period-1; 
Pck1, phosphoenolpyruvate carboxyki-
nase 1; G6pc, glucose-6-phosphatase, 
catalytic; Pdk4, pyruvate dehydroge-
nase kinase, isozyme 4; Foxo1, forkhead 
box O1; Srebp-1c, sterol-regulatory ele-
ment-binding protein-1c; Ppara, per-
oxisome proliferator-activated receptor 
a; Acox1, acyl-Coenzyme A oxidase 1; 
Fgf21, fibroblast growth factor 21; Cp-
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state, the prednisolone-treated mice had higher plasma NEFA concentrations than the 
vehicle treated mice. During fasting, these concentrations remained unchanged in the 
prednisolone-treated mice, but they rose in the mice that received the vehicle. Prolonged 
fasting in vehicle-treated mice resulted in increased hepatic TG and reduced hepatic gly-
cogen concentrations. In prednisolone-treated mice, neither liver TG nor liver glycogen 
concentrations were affected..
Fasting resulted in an increased Pck1 expression (Figure 4D), but Pck1 expression was 
lower in prednisolone compared to vehicle-treated mice in both fed and fasted condi-
tion. Expression of Srebp-1c was reduced in fed prednisolone-treated mice compared to 
fed control mice. The induction of Foxo1, Pdk4, and G6pc upon fasting was reduced in 
prednisolone-treated mice compared to controls. Again, prednisolone treatment reduced 
the expression of the GR-target genes Tat and Per1. 
Because the results so far suggested a hampered response to fasting upon prednisolone 
treatment, we investigated the hepatic mRNA expression of target genes of peroxisomal 
proliferator activated receptor α (PPARα), the major regulator of gene expression upon 
fasting 33 (Figure 4D). Fasting increased the expression of Pparα and its target genes Acox1 
and Cpt1a but this was not affected in prednisolone-treated mice. Fgf21, on the contrary, 
was strongly induced in prednisolone-treated mice in the fed state. This is in line with the 
fact that fed prednisolone-treated mice had a ~2 fold increase in plasma FGF21 compared 
to fed vehicle-treated mice and that fasting strongly induced plasma FGF21 concentra-





Plasma concentrations of diabetes biomarkers 
Fed samples were taken at 23:00 h, fasted samples at 08:00 h after a 9 hours fast. Values represent means ± SD; n=6.
* p<0.05 prednisolone vs. vehicle, # p<0.05 fed vs. fasted, ND – not detectable.
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Insulin resistance is a well known side effect of glucocorticoid treatment 3,4. As early as 
1983, it was shown that 7 day administration of prednisolone induced insulin resistance 
in healthy human subjects 9. The ‘gold’ standard to study insulin sensitivity is the hyperin-
sulinemic euglycemic clamp. To our surprise, we were not able to detect reduced insulin 
sensitivity in prednisolone-treated mice using this technique (Figure 2). In sharp contrast, 
however, the fasting blood glucose and plasma insulin concentrations (Table 2) suggested 
that prednisolone-treatment did reduce insulin sensitivity in mice. Apparently, induc-
tion of hyperinsulinemia during the clamp masked the effects of prednisolone on mouse 
glucose metabolism. We therefore used a less perturbing method to investigate glucose 
kinetics in this study. By carefully modeling the decay of injected D-[6,6-2H2]-glucose, a 
reduced hepatic insulin sensitivity was detected in prednisolone-treated mice: enhanced 
HGP and unchanged MCR despite elevated plasma insulin concentrations (Figure 3). 
The clearly distinct conclusions generated with the hyperinsulinemic euglycemic clamp 
and the injections with D-[6,6-2H2]-glucose about prednisolone’s effect on insulin sensi-
tivity can be related to the feeding status they symbolize. While the hyperinsulinemic 
euglycemic clamp induces a state of supraphysiological insulin concentrations, the small 
amount of D-[6,6-2H2]-glucose is injected in the blood glucose kinetic experiment did not 
perturb the fasting state. To investigate whether prednisolone affected the response to 
fasting, we performed feeding-fasting transition experiments. 
The increased hepatic Fgf21 expression (Figure 4D), reduced plasma glucose concentra-
tions (Figure 4A), and increased plasma NEFA concentrations (Table 3) in prednisolone-
treated mice in the fed state mimic a fasted condition. The plasma β-hydroxybutyrate lev-
els, in contrast, were not increased under these conditions (Figure 4C), but the relatively 
high plasma insulin levels in the fed prednisolone-treated mice (Figure 4B) might be held 
responsible for reduced ketogenesis. One might expect that the increased plasma NEFA in 
the fed mice upon prednisolone-treatment were the result of the actions of FGF21 on adi-
pose tissue. Plasma FGF21 concentrations were also higher in fed prednisolone-treated 
mice compared to fed vehicle-treated mice (compare Tables 2 and 3). Also the reduced 
blood glucose concentrations do fit with the actions of FGF21 34. Studies with Fgf21 trans-
genic and Fgf21 knockdown mice showed that FGF21 is not required for ketogenesis 35, 
exactly mimicking the fed prednisolone-treated mice in our study: high plasma FGF21 
without elevated plasma β-hydroxybutyrate concentrations (Table 4 and Figure 4C). In 
general, prednisolone-treated mice in the fed state showed a fasting-like metabolic profile 
and fasting did not affect the measured parameters. 




The effects of fasting on the measured parameters of energy metabolism all seem to be 
hampered in the prednisolone-treated mice. The fasting-mediated reductions in blood 
glucose (Figure 4A) and plasma insulin (Figure 4B) and the fasting-mediated induction in 
plasma β-hydroxybutyrate (Figure 4C) and plasma NEFA (Table 3) were all severely ham-
pered in the prednisolone-treated mice. The effects of fasting on the hepatic expression 
of Pck1, G6pc, and Pdk4 were also reduced in the prednisolone-treated mice (Figure 4D). 
PPARα plays an important role in both fasting response and fatty acid metabolism 33. Ber-
nal-Mizrachi et al. 17 showed that Pparα-/- Ldlr-/- mice are protected from dexamethasone-
induced insulin resistance. In our hands, prednisolone had no effects on the expression of 
PPARα target genes (Figure 4D), apart from a major increase in the aforementioned Fgf21 
in the fed state. So far, no GRE has been found in the promoter of Fgf21, suggesting that 
the effects of prednisolone on Fgf21 could be indirect. A recent study by Bougarne et al. 
showed that the enhanced expression of G6pase in HepG2 cells upon dexamethasone is 
reduced when the cells were co-treated with a PPARα agonist 36. Elegant binding stud-
ies confirmed that the transcriptional activity of the GR-GRE complex was reduced when 
PPARα was also activated. In the light of the surprising findings on the Fgf21 expression, 
the interaction between GR and PPARα requires more research
At the gene expression level, many of the effects of chronic prednisolone treatment on 
GR target genes are in contrast to reported effects (Figure1). Although it has repeatedly 
been shown that GR activation leads to up-regulation of Tat 31, Pck1 13, and Per1 32, hepatic 
mRNA levels of these three genes were decreased upon chronic prednisolone treatment 
in the current study. Previous experiments with methylprednisolone in rodents showed 
that hepatic Pck1 was increased in a fast and transient manner 37. Therefore, the reduced 
Pck1 expression in our experiments was very likely a consequence of the chronic treat-
ment protocol, reflecting a compensatory mechanism for the acute effects of predniso-
lone on GR target genes. The half-life of iv injected prednisolone in blood is ~35 minutes 
in mice 38 and the effects on gene expression were studied ~18 hours after the last oral 
prednisolone dose. Therefore, the reduced expression of GR-target genes (Figure 1) might 
be due to the low plasma corticosterone concentrations (Table 2). In addition, preliminary 
data from GR-DNA binding studies showed different effects of chronic and acute predni-
solone treatment. 
Insulin affects transcription of Srebp-1c 39 and the reduction of its expression in fed pred-
nisolone-treated mice compared to fed control mice suggest reduced insulin sensitivity of 
lipid metabolism (Figure 4D). Via reduction of nuclear FoxO1, insulin reduces the expres-
sion of Pdk4 and G6pc. Hence, the reduced induction of these genes upon fasting might 
also suggest that the insulin or fasting-mediated flexibility of this system is hampered 
upon chronic prednisolone-treatment.
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In conclusion, this study revealed that 7 day prednisolone treatment in normal, lean mice 
reduced hepatic insulin sensitivity in fasted mice. Because high insulin concentrations 
mask this effect, the hyperinsulinemic euglycemic clamp is not applicable in this animal 
model. In addition, prednisolone-treated mice in the fed state showed a fasting-like meta-
bolic profile and fasting-mediated changes in energy metabolism are severely hampered 
upon chronic prednisolone treatment. 
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but does not enforce dietary fat-induced insulin resistance
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Synthetic glucocorticoids such as prednisolone have potent anti-inflammatory actions. 
Unfortunately these drugs induce severe adverse effects in patients, many of which re-
semble features of the metabolic syndrome, such as insulin resistance. In this study we 
investigated whether adverse effects of prednisolone on glucose homeostasis are aggra-
vated in mice with compromised insulin sensitivity due to a high-fat diet applying various 
methods to analyze changes in insulin sensitivity in mice. C57BL/6J mice were fed a high-
fat diet for six weeks and treated with either prednisolone (10 mg/kg/d) or vehicle for the 
last 7 days. Insulin sensitivity and blood glucose kinetics were analyzed with state-of-the-
art stable isotope procedures in different experimental conditions. Prednisolone treat-
ment aggravated fasting hyperglycemia and hyperinsulinemia caused by high-fat feeding, 
resulting in a higher HOMA-IR. In addition, prednisolone-treated high-fat diet fed mice 
appeared less insulin sensitive by detailed analysis of fasted blood glucose kinetics. Re-
markably, using hyperinsulinemic-euglycemic or hyperglycemic clamp techniques, neither 
hepatic nor peripheral insulin resistance was worsened in the group that was treated with 
prednisolone. Yet, analysis of hepatic glucose metabolism revealed that prednisolone did 
alter glycogen balance by reducing glycogen synthase flux, under hyperinsulinemic as well 
as hyperglycemic conditions. In addition to elevated insulin levels, prednisolone-treated 
mice showed a major rise in plasma leptin and FGF21 levels. Our data indicate that pred-
nisolone-induced adverse effects on glucose metabolism in high-fat diet fed mice do not 
reflect impaired insulin sensitivity but may be caused by other changes in the hormonal 
regulatory network controlling glucose metabolism such as FGF21 and leptin.





Glucocorticoids are steroid hormones produced by the adrenal gland under control of the 
hypothalamic-pituitary-adrenal axis (HPA-axis) 1. Cortisol and corticosterone are the major 
endogenous glucocorticoids in humans and rodents, respectively. Cortisol is regarded as 
a stress hormone and is involved in regulation of a plethora of processes that modulate 
blood pressure, salt and water balance, immune response, energy metabolism and glu-
cose homeostasis 1,2. Related to their effects on the immune response, synthetic glucocor-
ticoids, (e.g., prednisolone) are widely used as anti-inflammatory and immunosuppres-
sive drugs 3,4. Unfortunately, chronic glucocorticoid treatment is accompanied by many 
adverse effects in humans, among which central obesity, hypertension, hyperlipidemia, 
hyperglycemia and insulin resistance, commonly referred to as Cushing’s Syndrome 5,6. 
These adverse effects also represent components of the metabolic syndrome, a condition 
defined by a combination of symptoms that increase the risk of cardiovascular disease 
and diabetes. The metabolic syndrome is strongly associated with the ‘western’ lifestyle, 
i.e., low physical activity and excess caloric intake. Stress and elevated cortisol levels have 
been reported to contribute to development of the metabolic syndrome 7.
Induction of insulin resistance by prednisolone in humans was established by Pagano et 
al. in 1982 8. A more recent study showed that prednisolone readily induces insulin resist-
ance in humans at a low-dose 9. To be able to overcome the undesired adverse effects of 
glucocorticoids, the underlying mechanisms of their modes of action must be resolved. 
Several studies to this end have been performed in rats, e.g. after treatment with dexa-
methasone 10-13. Reported effects of glucocorticoids in conventional mice, however, are 
highly variable. This is of relevance since genetically-modified mouse models offer great 
possibilities to dissect molecular mechanisms of insulin resistance 14. Orland et al. showed 
strain-specific effects of dexamethasone in db/db mice on either a C57BL/KsJ or C57BL/6J 
background, but four days of dexamethasone treatment did not affect blood glucose lev-
els in the control mice of either strain while serum insulin levels were minimally increased 
15. Dexamethasone-treatment increased plasma blood glucose levels in female Avy/a (vi-
able yellow) mice, but did not further increase plasma glucose levels in (hyperglycemic) 
male Avy/a mice 16. In C57BL/6J mice 5 days of alternate dexamethasone treatment did not 
affect fasting plasma glucose and insulin levels under conditions of high-fat diet-induced 
obesity, although these mice did have a perturbed muscle lipid metabolism 17.
We have recently shown that chronic prednisolone treatment for 7 days in C57BL/6J mice 
kept on a standard laboratory chow does affect hepatic glucose production (HGP) in the 
fasted state in a very subtle manner 18. When the ‘gold standard’ to determine insulin sen-
sitivity, i.e., the hyperinsulinemic-euglycemic clamp (HIEC), was applied, we were not able 
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to demonstrate effects of chronic prednisolone treatment on insulin sensitivity. In fact, 
apparent insulin resistance was only detectable under conditions characterized by physi-
ologically relevant insulin concentrations. A high-fat diet has been shown to induce insulin 
resistance in mice 19 and used for evaluation of glucocorticoid-induced adverse effects on 
insulin sensitivity 17. Feeding mice a high-fat diet compromises insulin sensitivity and we 
hypothesized that this more closely resembles the human situation.
In the present study we therefore investigated whether prednisolone affects insulin sen-
sitivity in mice fed a high-fat diet (36 energy% from lard) and whether we could discern 
effects of prednisolone on hepatic glucose metabolism under these conditions. For this 
purpose, we used state-of-the-art stable isotope techniques to monitor glucose metabo-
lism under three different experimental conditions. First, fasting glucose metabolism was 
evaluated using a novel blood glucose kinetics model. Secondly, hepatic glucose metabo-
lism was studied in more detail using Mass Isotopomer Distribution Analysis (MIDA) 20 
before and during a hyperinsulinemic-euglycemic conditions (HIEC). Thirdly, a similar 
technique was used under hyperglycemic (HGC) conditions to study glucose metabolism 
in a state of elevated glucose concentrations and physiological insulin concentrations. The 
data reported in this paper revealed that prednisolone further increased high-fat diet-
induced insulin resistance as estimated by means of the Homeostatic Model Assessment 
(HOMA-IR) 21 and by a kinetic model of glucose metabolism. Subsequent HIEC and HGC 
studies, however, did not indicate changes in insulin sensitivity, while prednisolone did 
influence hepatic glucose metabolism. These effects of prednisolone on glucose metabo-
lism were associated with markedly elevated plasma leptin and FGF21 levels. Altogether, 
our data indicate that prednisolone alters hepatic glucose metabolism by bringing about 
selective changes in the complex network of hormones that control glucose metabolism.
Material and methods
Animals, treatments and diets
Male C57BL/6J mice were obtained from Harlan (Horst, the Netherlands) and housed un-
der conventional conditions. Mice were fed a high-fat diet (beef tallow, rich in saturated 
fat) 22 for six weeks (Arie Blok Diervoeding, Woerden, The Netherlands). After five weeks 
of diet, the mice received prednisolone (10 mg/kg/d) or vehicle (gelatin (0.5 g/l)/mannitol 
(5g/l)) daily by gavage at 13:00 h for 7 days (n=7-8). All experiments were approved by the 
Ethics Committee for Animal Experiments of the University of Groningen. Prednisolone 
and vehicle were kindly provided by MSD (Oss, the Netherlands). For the infusion studies, 




mice were equipped with a permanent jugular vein catheter, with a two-way entrance 
attached to the skull with acrylic glue as previous described 23. Plasma levels of diabetes 
biomarkers were measured in fed (at 23:00 h) and 9 hours fasted (from 23:00 h till 08:00 
h) mice.
Blood glucose kinetics
To determine blood glucose kinetics in mice multiple times during the high-fat diet mice 
were fasted for 9 hours (23:00 h – 08:00 h). Like previously described 24-26, we used a 
single-pool first-order kinetic model since there is no dynamic insulin action under these 
conditions. After the fasting period the mice were injected intraperitoneally at the start 
of the experiment, after 5 weeks and after 6 weeks with a low dose of D-[6,6-2H2]glu-
cose (100 mg/kg) without inducing hyperinsulinemia. Before (at t=0) and at time points 
10, 20, 30, 40, 50, 60, 75 and 90 minutes after injection, blood glucose concentrations 
were measured in blood collected by tail tip bleeding with a Lifescan EuroFlash (Lifescan 
Benelux, Beerse, Belgium) glucose meter. At the same time points, small blood samples 
were collected on filter paper, in which the fractional contribution of D-[6,6-2H2]glucose 
to the whole blood glucose pool was measured by GC-MS. Whole body glucose turnover 
and clearance were calculated by kinetic analysis of the wash-out of injected D-[6,6-2H2]
glucose from the circulation (supplemental table 1). At the end a blood sample was taken 
by tail tip bleeding for insulin measurements. 
Determination of hepatic carbohydrate fluxes before and during HIEC and HGC
For the HIEC and HGC two separate groups of C57BL/6J mice were operated for jugular 
vein catheterization at day 2 of the treatment with prednisolone. After surgery, mice were 
allowed to recover for 5 days before they were subjected to experiments, resulting in 7 
days of prednisolone treatment. Before the experiments, mice were fasted for a 9 hours- 
(23:00 h– 08:00 h) or a 4-hours period (04:00 h – 08:00 h), for HIEC and HGC, respectively. 
During the experiment, mice were kept in small Plexiglas cages, with a wired floor to al-
low urine sampling and frequent collection of blood samples in freely moving mice 20. To 
determine hepatic carbohydrate fluxes under basal conditions mice were infused for a 
four hours basal period with a solution containing [U-13C]glucose (2.5 mg/ml), [2-13C]glyc-
erol (15 mg/ml), [1-2H]galactose (6 mg/ml) (Cambridge Isotope Laboratories, Andover, 
MA) and paracetamol (1 mg/ml) at an infusion rate of 0.54 ml/h as previously described 
20,27. For the HIEC, solutions were changed after four hours and mice were subjected to a 
four hour hyperinsulinemic period by infusing a solution containing insulin (44 mU/ml, 
Actrapid, Novo Nordisk, Bagsvaerd, Denmark), somatostatin (40 µg/ml, UCB, Breda, the 
Netherlands), [2-13C]glycerol (60 mg/ml), [1-2H]galactose (24 mg/ml), paracetamol (4 mg/
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ml) and 1% BSA (Sigma, St. Louis, MO) at a constant rate of 0.135 ml/h. During hyperinsu-
linemia, euglycemia was kept by infusion a second solution which contained 27% glucose 
(291 mg/ml) and 3% [U-13C]glucose (9 mg/ml) at an adjustable rate to maintain plasma 
glucose levels at 7 mM. For the second experiment, the HGC, infusions were changed after 
four hours and mice were subjected to a four hour hyperglycemic period by infusion of a 
solution containing [U-13C]glucose (10 mg/ml), [2-13C]glycerol (60 mg/ml), [1-2H]galactose 
(24 mg/ml) and paracetamol (4 mg/ml) and 1% BSA at a constant rate of 0.135 ml/h. A 
second solution which contained 27% glucose (291 mg/ml) and 3% [U-13C]glucose (9 mg/
ml) was infused with an adjustable rate to maintain plasma glucose levels at a hypergly-
cemic level of ~17 mM, comparable to the peak blood glucose level measured in control 
mice during an oral glucose tolerance test. During both experiments, blood glucose lev-
els were measured every 15 minutes in blood drops collected by tail tip bleeding with a 
Lifescan EuroFlash glucose meter. Every hour, blood spots for GC-MS analysis were taken 
by tail tip bleeding on filter paper, air-dried and stored at room temperature until further 
analysis. Urine samples were collected on filter paper at hourly intervals. Hepatic car-
bohydrate fluxes as well as whole body glucose turnover and clearance rates during the 
experiment were calculated using MIDA as previous described 27,28. Additionally, after the 
hyperglycemic period a blood sample was taken for insulin measurements.
Indirect calorimetry
Mice fed a high-fat diet for almost 5 weeks were subjected to indirect calorimetry for 7 
days with free access to water and a high-fat diet, while food intake was measured (TSE 
systems GmbH, Bad Homberg, Germany). Three days before the start of the predniso-
lone treatment mice were placed in the calorimetric cages to acclimatize and for basal 
measurement. Upon start of the treatment mice were tracked for the 4 following days. 
For prednisolone treatment by gavage, measurements were shortly interrupted daily be-
tween 12:00 and 13:00 h. Oxygen and carbon dioxide flow rates were measured every 13 
minutes. The respiratory exchange ratio (RER) was calculated using the following equa-
tion:  RER = VO2 /VCO2 in which the VO2 represents the volume rate of oxygen consump-
tion and the VCO2 is the volume rate carbon dioxide production.
Measurement of Mass Isotopomer Distribution by GC-MS
The fractional contributions of stable isotopically-labeled carbohydrates from blood and 
urine samples collected during the HIEC, HGC and during the blood glucose kinetics study 
were extracted, derivatized and measured by GC-MS as previously described by van Dijk 
et al. 20.





Basal values of blood glucose concentrations were measured in conscious mice in blood 
drops collected by tail tip bleeding with a Lifescan EuroFlash glucose meter. Plasma insu-
lin, corticosterone and fibroblast growth factor-21 (FGF21) concentrations were meas-
ured using commercially available ELISA kits (Mercodia ultrasensitive mouse insulin ELISA, 
Orange Medical, Tilburg, the Netherlands; Diagnostic System Laboratories Benelux, As-
sendelft, The Netherlands and Millipore, Amsterdam, The Netherlands, respectively). The 
HOMA-IR was calculated adjusted for basal mouse values taken from a chow-fed vehicle-
treated group as previously described 18 . Plasma non-esterified (or free) fatty acid (NEFA) 
and 3-hydroxybutyrate concentrations were determined with commercially available kits 
(Diasys, Holzheim, Germany, Wako Chemicals, Neuss, Germany, respectively). Hepatic 
lipids were extracted from the liver homogenates according to Bligh and Dyer 29 . He-
patic and plasma triglycerides were measured using a kit from Roche Diagnostics (Man-
nheim, Germany), and free and total cholesterol levels were measured with a kit from 
Wako chemicals (Neuss, Germany). Hepatic glycogen concentrations were determined 
as described 30. Plasma diabetes biomarkers were measured by a commercially available 
multiplex (Bio-plex Pro™ Mouse Diabetes, Bio-Rad, Veenendaal, the Netherlands) meas-
uring insulin, leptin, glucagon, ghrelin, glucagon like peptide-1 (GLP-1), gastric inhibitory 
peptide (GIP), resistin and plasminogen activator inhibitor-1 (PAI1).
Gene expression analysis
RNA was isolated from liver and white adipose tissue and gene-expression was measured 
as previously described 18. Expression levels were normalized for RPLP0 levels. The se-
quence of the primers and probes that were previously used can be found are deposited 
at RTPrimerDB (http://www. rtprimerdb.org). The sequences of the primers and probes 
used for Leptin are (Acc. No. NM_008493.3) AAG ACC ATT GTC ACC AGG ATC AA (forward 
primer) GGT CCA TCT TGG ACA AAC TCA GA (reverse primer) and CAC ACA CGC AGT CGG 
TAT CCG CC (probe).
Statistics
All data are represented as mean ± SEM. Statistical analysis for two independent groups 
was performed using Mann-Whitney U tested with SPSS for Windows software (SPSS 16, 
Chicago, IL, USA). For multiple comparison statistical analysis were performed by Kruskal-
Wallis test, followed by a Mann-Whitney U test corrected for multiple comparisons. For 
paired measurements statistical analysis was performed using a Wilcoxon signed-rank 
test. Significance was considered at a level of p<0.05 and adjusted for multiple compari-
sons.
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Chronic prednisolone treatment aggravates the high-fat diet-induced increase in 
HOMA-IR 
To assess whether chronic prednisolone treatment aggravates high-fat diet-induced in-
sulin resistance, we first examined the effect of prednisolone-treatment on body param-
eters and metabolite concentrations (Table 1). Effective prednisolone treatment was con-
firmed by a severe reduction of thymus weight and a reduction of plasma corticosterone 
concentration by almost 90% due to activation of the HPA-axis. Prednisolone treatment 
did not further affect the increase in body weight in mice fed a high-fat diet for 6 weeks.
After 9h of fasting blood glucose levels were higher upon prednisolone treatment in mice 





Treatment parameters of 9 hours fasted mice
mice fed a high-fat diet for six weeks and treated with either vehicle (control) or prednisolone (10 mg/kg/d) during the last 
seven days. Data are represented as means ± SEM; N=8; * p<0.05. The HOMA-IR was calculated adjusted for basal mouse 
values taken from a chow-fed, vehicle-treated group.




a 2-fold higher HOMA-IR (Table 1). The high-fat diet itself also increased the HOMA-IR to 
3.6 ± 1.3 compared to mice on a chow diet, which had a HOMA-IR of 1.0 ± 0.1 (p= 0.003) 
18. Prednisolone-treatment in mice fed a high-fat diet increased plasma cholesterol and 
triglyceride levels, while plasma NEFA concentration dropped. Remarkably, prednisolone-
treatment resulted in a 10-fold decrease in plasma 3-hydroxybutyrate concentrations and 
almost doubled plasma fibroblast growth factor 21 (FGF21) levels in the fasted state (Ta-
ble 1), but did not influence hepatic cholesterol and triglyceride levels.
In order to evaluate if the prednisolone-induced increase HOMA-IR influenced fasting glu-
cose production and clearance, we analyzed fasting blood glucose kinetics in whole body 
from the wash-out of intraperitoneal injected D-[6,6-2H2]glucose from the circulation. To 
follow the effects of both the high-fat diet and prednisolone treatment in time, mice were 
subjected to this test three times; 1) at the start of the experiment (week 0) before start 
of the diet, 2) after 5 weeks of diet before start of the prednisolone treatment, and 3) 
after 6 weeks of diet and one week of prednisolone treatment. This experimental setup 
allows for sequential analysis of glucose metabolism under basal conditions throughout 
the 6 weeks of diet in the same animals. After 5 weeks on a high-fat diet, blood glu-
cose levels were significantly elevated in high-fat fed mice compared to mice on a normal 
chow diet (Fig. 1A). One-week prednisolone-treatment resulted in an additional increase 
of blood glucose levels compared to mice fed a high-fat diet for 6 weeks. Plasma insulin 
levels followed a similar pattern over time (Fig. 1B), showing that plasma insulin levels 
were elevated upon feeding a high-fat diet. Yet, in mice fed a high-fat diet combined with 
Parameters of the blood glucose kinet-
ics test performed in mice on day 0 
(white bars), after a high-fat diet (grey 
bars) for 5 weeks and after 6 weeks of 
diet treated with vehicle (grey bars) or 
prednisolone (black bars) for the last 
week. 
A, Blood glucose concentrations during 
the test; B, Plasma insulin concentra-
tions after the test; C, Metabolic clear-
ance rate (MCR) of glucose during the 
test; D, hepatic glucose production 
(HGP) during the test. Values are means 
± SEM; n = 8; * p< 0.05 prednisolone vs. 
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prednisolone-treatment plasma insulin levels were even more strongly induced.
The high-fat diet induced a distinct reduction of metabolic clearance rate (MCR) of glucose 
after 35 days and 42 days compared to a chow diet at the start of the experiment (Fig. 
1C). Treatment with prednisolone had no significant additional effect on MCR. Neither the 
high-fat diet nor prednisolone-treatment changed the hepatic glucose production (HGP; 
Fig. 1D). Nevertheless, note that plasma insulin levels were extremely high in predniso-
lone-treated mice fed a high-fat diet. Therefore, when HGP and MCR were related to the 
prevailing insulin levels, mice treated with prednisolone upon a high-fat diet appeared 
insulin resistant which was in line with the increased HOMA-IR.
Prednisolone does not induce insulin resistance according to the HIEC and HGC
To study whether increased blood glucose and plasma insulin concentration in high-fat fed 
mice treated with prednisolone was actually caused by insulin resistance, we combined 
the HIEC to the MIDA technique to measure hepatic glucose metabolism during hyperin-
sulinemia. Again prednisolone treatment led to increased fasting glucose levels (6.1 ± 0.4 
Parameters of the basal and hyperinsulinemic euglycemic (HI) clamp experiment performed in mice on a high-fat diet 
treated with vehicle (white bars) or prednisolone (black bars).
A, Average blood glucose concentration during the steady-state periods of the experiment (2-4 hours and 6-8 hours); B, 
Glucose Infusion Rate (GIR) needed to maintain euglycemic conditions; C, Metabolic Clearance Rate (MCR); D, Hepatic 















vs. 8.8 ± 0.6, veh vs. pred, p=0.004) and glucose levels during the basal period of the test 
tended to be higher (p=0.055) (Fig. 2A). During the basal period glucose infusion rate (GIR) 
was kept at a steady, very low level in both groups for it represents the infusion of the 
stable isotopes solution, as is evident from Fig. 2B. During the hyperinsulinemic period, 
the GIR was adjusted to keep a euglycemic state at a blood glucose level of 7 mM in both 
groups. Surprisingly, prednisolone-treatment on top of a high-fat diet did not influence 
the magnitude of the GIR (Fig. 2B).
Even though blood glucose levels in the basal state tended to be higher in prednisolone-
treated mice compared to controls, both the MCR (Fig. 2C) and HGP (Fig. 2D) were simi-
lar during this period. Upon hyperinsulinemia, the well-documented stimulatory effect 
of insulin on the uptake of glucose in the peripheral tissues and inhibitory effect on the 
hepatic production of glucose were observed in both groups. Prednisolone treatment did 
not further alter the MCR but, strikingly, resulted in a more pronounced suppression of 
the HGP by insulin. 
By means of MIDA the relevant hepatic fluxes constituting hepatic glucose metabolism 





Hepatic glucose fluxes during the basal and hyperinsulinemic (A) and hyperglycemic period (B)
The hepatic carbohydrates fluxes trough glucose-6-phosphatase (G6Pase), glucokinase (GK), Glycogen synthase (GS), gly-
cogen phosphorylase (GP) and gluconeogenesis (GNG). Fluxes are shown in μmol/kg/min. Values represent means ± SEM; 
n=7-8. * p<0.05 prednisolone vs. vehicle, # p<0.05 hyperinsulinemic vs. basal period within treatment.
A
B
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both the glycogen synthase (GS) flux and the gluconeogenic (GNG) flux in the basal period. 
The hyperinsulinemia reduced the glucose-6-phosphatase (G6Pase), the glycogen phos-
phorylase (GP) and GNG flux in both groups. Strikingly, even though GNG has repeatedly 
been reported to be up regulated by GCs 31, it was slightly reduced upon prednisolone 
treatment in both the basal and hyperinsulinemic state in mice on a high-fat diet. In ad-
dition prednisolone treatment led to a reduced GS and GP flux in the hyperinsulinemic 
period, resulting in a similar glycogen balance compared to the vehicle-treated group in 
the hyperinsulinemic period compared to the basal period. From these fluxes, the glucose 
and glycogen balances were calculated (Fig. 2E and F). The glucose balance was reduced in 
both groups during the hyperinsulinemic period, mainly due to a reduction in G6Pase flux. 
This was even more pronounced in the prednisolone-treated group. The initially negative 
glycogen balance, which was more negative in prednisolone-treated mice, turned positive 
upon hyperinsulinemia, even more pronounced in prednisolone-treated mice. The differ-
ences in glycogen balance upon hyperinsulinemia were mainly due to reductions in the 
GP flux, whereas the GS flux was not affected by hyperinsulinemia, but was reduced by 
prednisolone treatment in both periods.
Parameters of the basal and hyperglycemic (HG) clamp experiment performed in mice on a high-fat diet treated with 
vehicle (white bars) or prednisolone (black bars). 
A, Average blood glucose concentration during the steady-state periods of the experiment (1-3 hours and 4-6 hours); B, 
Average Glucose Infusion Rate (GIR) needed to maintain hyperglycemic conditions; C, Metabolic Clearance Rate (MCR); D, 















So far, these data suggest that prednisolone treatment of mice receiving a high-fat diet did 
not decrease insulin sensitivity as measured with the ‘gold standard’ HIEC, although blood 
glucose and plasma insulin levels as well as hepatic glucose metabolism were clearly af-
fected. To evaluate regulation of glucose metabolism during stimulation of endogenous 
insulin production at elevated glucose levels, a HGC combined with hepatic glucose me-
tabolism analysis was performed. To this purpose, mice were fasted for 4 hours, after 
which the groups did not show difference in fasted blood glucose levels (8.6 ± 0.3 vs. 8.2 ± 
0.4, means ± SEM in mM, veh. vs. pred, ns) and in blood glucose levels in the basal period 
(Fig. 3A). To induce hyperglycemia with blood glucose levels up to 17 mM, very similar glu-
cose infusion rates (GIR) were necessary in both groups (Fig. 3B), indicating no differences 
in insulin response since insulin levels during the HGC were similar in both groups (41.8 
mU/L [11.7 – 73.1] vs. 25.9 mU/L [11.6 – 74.0] (after the hyperglycemic period, median 
and ranges, veh. vs. pred, ns). 
In the basal period MCR and HGP were similar in both groups, as expected from the for-
mer experiment. Upon hyperglycemia MCR was increased in both groups, while HGP 
showed a slight decrease in vehicle-treated mice (Fig. 3C and D). Prednisolone treatment 
had no effect on either MCR or HGP. Nevertheless, analysis of hepatic glucose fluxes re-
vealed that the GS-flux was clearly reduced in the hyperglycemic period by prednisolone 
treatment (Table 2B). This resulted in a minor effect on glycogen balance (Fig. 3F). The 
glucose balance was reduced in the vehicle group during the hyperglycemic period (Fig. 
3E), which was mainly due to an increase in the GK-flux, which remained unchanged in 
the prednisolone-treated group. We checked for hepatic mRNA expression levels of genes 
crucially involved in glucose metabolism (Fig. 4); phosphoenolpyruvate carboxykinase 1 
(Pck1) and glucose-6-phosphatase (G6pc) were reduced by a high fat diet as compared 
Hepatic gene expression of 9 hours 
fasted mice on a high-fat diet treated 
with vehicle (white bars) or predniso-
lone (black bars). 
Results were normalized to Rplp0 (ri-
bosomal protein, large, P0 (36b4)) with 
data from vehicle-treated mice on a 
chow diet defined as ‘1’ (dotted line). 
Values are means ± SEM; n = 8; * p < 
0.05 prednisolone vs. vehicle, Gr, glu-
cocorticoid receptor (Nr1c3, nuclear 
receptor subfamily 3, group C, mem-
ber 1); Tat, tyrosine aminotransferase; 
Pck1, phosphoenolpyruvate carbox-
ykinase 1 (cytosolic); G6pc, glucose-
6-phosphatase (catalytic); Gck, glucoki-
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to chow and combined with prednisolone even more so. Glucokinase (Gck) and pyruvate 
kinase (Pklr) mRNA levels were increased by the high-fat diet or prednisolone treatment, 
respectively. Glucorticoid target genes were checked to confirm prednisolone activation. 
Surprisingly, the classical GC target gene tyrosine aminotransferase (Tat) was reduced by 
a high-fat diet and unaltered by prednisolone while Pck1, another classic target gene, was 
even reduced by prednisolone treatment. 
Prednisolone alterations on blood glucose metabolism are insulin independent
The apparent insulin resistance as indicated by an increased HOMA-IR and blood glucose 
kinetics under prevailing insulin concentrations was not revealed when insulin sensitivity 
was more thoroughly studied by the HIEC and the HGC. This suggested that prednisolone 
treatment in mice fed a high-fat diet did not induce a classical insulin resistance measured 
according to generally accepted methods. These findings could imply that other metabolic 
factors might be involved. As shown in Table 1, plasma FGF21 levels were increased upon 
prednisolone treatment, which was confirmed by hepatic gene expression levels of Fgf21 
(Fig. 5A). The main regulator of FGF21 expression PPARα 18 showed no increase in gene 
expression levels and target genes of Pparα, like Acox1 and Cpt1a, were not elevated by 
prednisolone.
Parameters of energy metabolism
A, Hepatic gene expression levels of 
Pparα target genes. B, and WAT gene 
expression levels of leptin, n = 8. Re-
sults were normalized to Rplp0 (ribo-
somal protein, large, P0 (36b4)) with 
data from vehicle-treated mice on a 
chow diet defined as ‘1’ (dotted line). 
C, Respiratory exchange ratio (RER) dur-
ing the first three days of treatment. 
Arrows indicate the time of treatment 
dosing. D, Food intake during treat-
ment measured in indirect calorimetric 
cages. Values are means ± SD; n = 6; * 
p<0.05 prednisolone vs. vehicle, Fgf21, 
Fibroblast growth factor 21; Pparα, per-
oxisome proliferator-activated receptor 
alpha; Acox1, Acyl-Coenzyme A oxidase 













Finally, we analyzed multiple hormones and hormone-like factors in plasma from fed and 
9 hours fasted mice. Table 3 shows that prednisolone-induced plasma leptin levels, both 
in the fed and fasted state, in addition to inducing plasma insulin levels. Other analyzed 
hormones were not affected by prednisolone treatment in the fasted state, but PAI1 was 
increased upon prednisolone treatment in the fed state only. Fasting itself reduced plas-
ma leptin, GLP-1 and GIP. Increased plasma leptin levels were confirmed by leptin gene 
expression levels in white adipose tissue (Fig. 5B). Leptin plays a major role in energy ex-
penditure and as a satiety factor; therefore energy expenditure in mice fed a high-fat diet 
was measured in indirect calorimetry cages. Figure 5C shows a slight increase in respira-
tory exchange ratio (RER) at night in prednisolone-treated mice, indicating that at night 
glucose utilization is increased in mice fed a high-fat diet treated with prednisolone com-
pared to vehicle-treated mice. Food intake, however, was slightly increased upon predni-
solone treatment (Fig. 5D)
Discussion
In an earlier study 18 we showed that, under chow-fed conditions, sustained treatment of 
C57BL/6J mice with prednisolone reduced insulin sensitivity only in a very subtle manner 
under fasting conditions. In this subsequent study we show that in mice challenged with 
a high-fat diet, prednisolone treatment did not aggravate insulin resistance induced by a 
high-fat diet as measured by a HIEC, even though these mice appeared insulin resistant 





Plasma concentrations of diabetes biomarkers 
Fed samples were taken at 23:00 h, fasted samples at 08:00 h after a 9 hours fast. Values represent means ± SD; n=6. * 
p<0.05 prednisolone vs. vehicle, # p<0.05 fed vs. fasted, ND – not detectable.
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concentrations were perturbed. This study clearly shows a disengagement of the HOMA-
IR with outcome of the HIEC and HGC and also documents that prednisolone-induced al-
terations of glucose metabolism in these mice are not directly linked to insulin sensitivity.
Insulin resistance is a well-known side effect of glucocorticoid treatment in humans 8,9,32. 
In addition, it has been shown repeatedly that dexamethasone treatment also induces in-
sulin resistance in rats 11,13,33,34. In mice, however, glucocorticoid-induced insulin resistance 
is not as evident. Most studies on glucocorticoid-induced insulin resistance in mice involve 
specific transgenic mouse strains 15,35 usually in combination with long-term, or high dos-
es, of dexamethasone administration 36,37. Since prednisolone is routinely used for chronic 
treatment in humans 38, we have evaluated prednisolone-induced insulin resistance in 
conventional C57BL/6J mice fed a high-fat diet known to compromise the physiological 
actions of insulin. In order to analyze insulin resistance, which is defined as a decreased 
sensitivity or responsiveness to metabolic actions of insulin 39, in conventional C57BL/6J 
mice, we subjected them to different methods available to assess insulin resistance, in-
cluding the HOMA-IR, HIEC, HGC, basal blood glucose kinetics and analyzed hepatic glu-
cose metabolism by MIDA. 
Like in chow-fed mice 18, we confirmed that chronic, 7 days of prednisolone treatment 
increased the HOMA-IR, in high-fat fed mice while, as expected, the high-fat diet by itself 
already caused an increased HOMA-IR in comparison to chow-fed mice. Note that for the 
calculations of HOMA-IR, the values were adjusted for basal values of glucose and insulin 
concentrations in mice. In addition, when the MCR and HGP calculated from basal whole 
body blood glucose kinetics were related to prevailing insulin levels, prednisolone-treated 
mice appeared to have reduced insulin sensitivity. Yet, similar to our earlier study in chow-
fed animals, when insulin sensitivity was evaluated by the HIEC, the ‘gold standard’ to 
evaluate insulin action on glucose metabolism, prednisolone treatment was found not 
to alter insulin sensitivity since GIR values were similar with and without prednisolone 
treatment. This clearly shows that, although HOMA-IR and HIEC were shown to be well 
correlated in humans 40, there is a disengagement between the HOMA-IR with the HIEC 
in mice, which has previously been reported for rodents 39,41. Nevertheless, assessment of 
hepatic carbohydrate metabolic fluxes by stable isotope techniques under basal, hyper-
insulinemic-euglycemic as well as hyperglycemic conditions revealed that prednisolone 
treatment did alter hepatic glucose metabolism in high-fat fed mice, mainly by reducing 
the glycogen synthase flux. These effects of prednisolone on glucose metabolism are not 
mediated by insulin, as infusion of since insulin infusion during HIEC did not affect the GS-
flux, but in contrast reduced the GP-flux.
In our former study 18, we showed that nutritional status has to be taken into account 




when evaluating prednisolone-induced insulin resistance. In order to accurately assess 
effects of prednisolone on glucose metabolism in mice fed the high-fat diet, we stud-
ied hepatic glucose metabolism under different nutritional conditions, i.e., after four and 
nine hours of fasting and under hyperglycemic and hyperinsulinemic euglycemic condi-
tions. First 9-h fasted state was assessed by measuring blood glucose kinetics by mod-
eling the wash-out of ip injected D-[6,6-2H2]glucose, since this method allows repeated 
measurements over time in the same animals. This is not possible with the HIEC and HGC, 
because these are complex and laborious experiments which require invasive surgery. 
However, to quantitatively assess hepatic glucose metabolism and hepatic and peripheral 
insulin resistance both the HIEC and HGC were combined with a method to study hepatic 
glucose metabolism with stable isotopically-labeled glucose by MIDA 20,27,28. By adapting 
these state-of-the-art methods, both hepatic carbohydrate fluxes and insulin sensitivity 
could be measured at the same time. During the HIEC supra-physiological insulin levels 
were introduced, which can be regarded as a post-prandial condition. Importantly, during 
the HIEC the pancreas is blocked by somatostatin, thereby overruling part of the bodies’ 
natural reaction. As a consequence subtle changes might not be detected under these 
conditions. To aim for a more physiological approach with a normal pancreatic response 
at high glucose levels, the HGC was used. The basal periods of the HIEC and the HGC 
both symbolize a different nutritional status; for the HIEC mice were fasted for 9 hours, 
while for the HGC mice were fasted for only 4 hours. During the basal periods of both 
experiments the sum fluxes from both hepatic glucose sources, i.e., glycogen phosphory-
lase and gluconeogenesis, was identical. However, there is a switch from the glycogen 
phosphorylase to gluconeogenesis with prolonged fasting. This shows that upon fasting, 
first glycogen breakdown takes place after which gluconeogenesis takes over. Note that 
the magnitudes of HGP and MCR in the basal period of both clamp experiments are in the 
same order of magnitude as the HGP and MCR from the fasting blood glucose kinetics, 
confirming the relevance of this experimental procedure. During the HIEC, GIR were equal 
between the groups, however, the HGP was slightly reduced during the hyperinsulinemic 
period in prednisolone-treated mice. Because this was at similar infusion rates of insulin 
the reduced HGP may be explained as increased hepatic insulin sensitivity. 
Relating hepatic gene expression levels of the genes encoding enzymes that catalyze the 
reactions that constitute the hepatic carbohydrate fluxes to the quantitatively measured 
hepatic glucose fluxes is complex; fluxes were measured over a period of time under a 
specific nutritional status, while samples for gene expression levels measurements were 
taken at fixed time points after fasting and treatment. In addition, regulation of metabolic 
fluxes largely depends on the substrate availability and enzyme activity. The observed 
effects of the chronic prednisolone treatment in the current study on mRNA levels of GR 
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target genes are partly contrasting reported effects. Tat 42 and Pck1 43,44 have been shown 
to be classical GR target genes, being up-regulated when GCs are present, but prolonged 
prednisolone treatment, like in our study, resulted in decreased hepatic mRNA levels of 
both genes, as previously reported 18. Up-regulatory effects of GCs on Pck1 have been 
shown to be fast and transient 45. Thus, the reduced Pck1 expression likely reflects the 
reduced plasma GC concentration in prednisolone-treated mice 18-h after the last dose. 
In addition, a study by Magnusson et al. showed actually that major changes in gene ex-
pression of Pck1 do not alter GNG-flux per se 46. 
As previously shown in mice receiving a chow diet, also on a high-fat diet plasma FGF21 
levels were elevated by prednisolone 18. Together with the low plasma 3-hydroxybutyrate 
levels, high FGF21 levels imply a perturbed feeding-to-fasting transition 47,48 also in mice 
fed a high-fat diet. Possibly prednisolone-treated mice might be FGF21 resistant, like in 
obesity 49. In addition, FGF21 has been shown to reduce G6pc and glycogenolysis through 
Ppargc1a 50; prednisolone-treated mice in this study had a reduction in hepatic G6pc gene 
expression levels, which could be mediated via FGF21-Ppargc1a. 
During fasting leptin is reduced, thereby reducing satiety and promoting food intake 51. In 
mice on a high-fat diet, prednisolone treatment increased plasma leptin levels both in the 
fed and the fasted state, but did not reduce food intake. Leptin and glucocorticoids are 
counter regulatory and control satiety and appetite mainly via the hypothalamus 52. More-
over, together with insulin, leptin and glucocorticoids are important factors in an expand-
ing hormonal network regulating glucose metabolism which, in turn, is tightly connected 
to energy homeostasis. It was thought that hepatic leptin signaling did not affect hepatic 
glucose metabolism 53,54, yet, a recent paper showed that the hepatic leptin receptor is in-
volved in diet- and age-related insulin resistance 55, thereby opening a direct role for leptin 
on hepatic glucose metabolism. These data demonstrate that prednisolone, which caused 
a subtle phenotype on glucose metabolism in C57BL/6J mice, closely interacts with mem-
bers of a complex hormonal network influencing glucose metabolism other than insulin.
Although glucocorticoids have been shown to induce insulin resistance in humans and 
rats measured by HIEC, prednisolone treatment in C57BL/6J mice fed a high-fat diet did 
not lead to such a clear insulin resistance phenotype. Nevertheless, fasting glucose and in-
sulin levels, fasting blood glucose kinetics and hepatic glucose fluxes during both hyperin-
sulinemic and hyperglycemic states showed clear signs of an adapted glucose metabolism 
after prednisolone treatment. Thus, this study shows that prednisolone treatment did not 
aggravate high-fat diet-induced insulin resistance, but does alter hepatic glucose fluxes 
independent of insulin action, presumably due to adaptations in the hormonal networks 
regulating glucose control, involving leptin and FGF21.
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The formulas used to calculate the concentration vs. time curves and the kinetic parameters in a first order absorption 
process in an one-compartment model.
Ct, D-[6,6-
2H]glucose concentration at time point t; Mt, fractional contribution of D-[6,6-
2H]glucose at time point t; [glc]t, 
blood glucose concentration at time point t. C(0)ab, initial concentration of D-[6,6-2H]glucose determined by extrapolation 
of the absorption period; C(0)el, initial concentration of D-[6,6-2H]glucose determined by extrapolation of the elimination 
period; kab, absorption rate constant; kel, absorption rate constant. D, dose D-[6,6-2H]glucose administrated; BG, average 
blood glucose concentration during the test; Ra = HGP
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Glucocorticoids (GCs) such as prednisolone are potent immunosuppressive drugs but 
suffer from severe adverse effects, including the induction of insulin resistance due to 
a very broad spectrum of GC target genes. Therefore, development of so-called Selec-
tive Glucocorticoid Receptor Modulators (SGRM) is highly desirable. Here we describe a 
non-steroidal Glucocorticoid Receptor (GR)-selective compound (Org 214007-0) with a 
binding affinity to GR similar to that of prednisolone. Using various cell lines and primary 
human cells, we show here that Org 214007-0 acts as a partial GC agonist, since it re-
pressed inflammatory genes and was less effective in induction of metabolic genes. More 
importantly, in vivo studies in mice indicated that Org 214007-0 retained full efficacy in 
acute inflammation models as well as in a chronic collagen-induced arthritis (CIA) model. 
Gene expression profiling of muscle tissue derived from arthritic mice showed a partial 
activity of Org 214007-0 at an equi-efficacious dosage of prednisolone, with an increased 
ratio in repression versus induction of genes. Finally, in mice Org 214007-0 did not show 
induced fasting glucose and a shift in the glucose / glycogen balance in the liver as seen 
with an equi-efficacious dose of prednisolone. All together, our data demonstrate that Org 
214007-0 belongs to the new class of SGRMs with an increased therapeutic index com-
pared to prednisolone that could contribute to effective anti-inflammatory therapy with a 
lower risk for metabolic side effects.





Synthetic glucocorticoids (GCs), like prednisolone, are among the most widely prescribed 
anti-inflammatory drugs for diseases like rheumatoid arthritis, inflammatory bowel dis-
ease and asthma. However, prolonged and/or high dosage GC treatment is associated 
with severe side effects such as insulin resistance, osteoporosis, skeletal muscle wasting, 
mood disorders and many others 1, 2. The wide range of side effects is not surprising giving 
the essential role of the natural glucocorticoid cortisol in survival. For example, cortisol 
has a major role in blood glucose homeostasis and is essential for induction of stress-cop-
ing mechanisms. Effects of GCs are mediated via the ubiquitously expressed glucocorti-
coid receptor (GR), a member of the nuclear receptor super family. The small lipophilic GC 
molecule diffuses across the plasma membrane and binds to cytoplasmic GR that, upon 
binding of its ligand, alters its conformation and translocates to the nucleus. Within the 
nucleus, ligand-bound GR acts as a transcription factor that regulates expression of a set 
of target genes directly or indirectly. Direct regulation occurs via binding of activated GR 
homodimers to GC-response elements (GRE) in promoter regions of genes, thereby sup-
pressing or inducing gene expression, the latter often termed “transactivation” (TA). Indi-
rect regulation occurs by binding of activated GR to other transcription factors, hence fa-
cilitating or suppressing the action of these transcription factors, the latter often referred 
to as “transrepression” (TR) 3. It has long been thought that the anti-inflammatory activity 
of GCs was mainly linked to TR activity, via interference with the two most important pro-
inflammatory transcription factors, i.e., NFκB and AP-1 4,5. The induction of metabolic side 
effects by GCs was thought to be mainly related to TA activity via the induction of many 
genes encoding enzymes that are active in metabolic pathways like glucose-6-phospha-
tase (G6pc) and phosphoenolpyruvate carboxykinase (Pck1). Because of these two clearly 
separated GC mechanisms of action it has long been hypothesized that it should be pos-
sible to design a GC molecule with preserved TR actions and reduced TA effects, resulting 
in an improved therapeutic index 6,7,8,9. This type of compounds has been referred to as 
dissociated GCs, selective GR agonists (SEGRAs), dissociated agonists of the GR (DAGRs) 
or selective GR modulators (SGRMs). However, selection of novel SGRMs with dissociating 
TA from TR activities in vitro, have so far only resulted in a few compounds with improved 
therapeutic profiles in animal models 6,10,11,12. To date, proof of concept in human remains 
to be obtained.
Due to a better understanding of the molecular interactions between the ligand-bound 
GR and its target molecules, awareness is growing that the concept of dissociation, based 
solely on TA vs. TR, is too simplistic. For example, the anti-inflammatory activity of GCs is 
also partly driven by TA 3,7,13,14,15. Furthermore, besides interference with NFκB and AP-1, 
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GC-bound GR also interacts with less known transcription factors involved in immune re-
sponses like IRF3, NFAT, STATs, GATA3, T-bet and CREB1 11,16. Of note, a recent publication 
indicates that a large number of genes involved in GC-induced side effects is regulated via 
a functional negative GRE in their promoter region 15. Furthermore, a series of studies has 
shown that even subtle changes in the GR-ligand may alter conformation of the ligand-
receptor complex with consequences for co-factor recruitment and hence for function 
of the receptor 9,17,18,19,20,21. Many studies indeed have shown that different ligands result 
in differential co-activator and co-repressor recruitment by GR 12,22,23. However, the final 
activity of agonists, partial agonists and antagonists is also determined by the sequence 
of the target-gene promoter itself 24,15 and the involvement of other components of the 
transcriptional machinery, such as chromatin-remodeling proteins or RNA polymerase II 
9,20,15,25. Finally, the wide array of diverse posttranslational modifications (phosphorylation, 
acetylation, sumoylation) of GR, as well as the interacting factors and, reversibly, the GR-
mediated modulations of kinases (e.g., MAP kinases) and phosphatases involved in in-
flammatory responses, all contribute to the final outcome of cellular activity 3. 
Here we describe a novel non-steroidal, low-molecular weight GR ligand, Org 214007-0, 
with characteristics of a partial GR agonist in vitro that shows sustained full anti-inflam-
matory activity in vivo in mice, without adverse effects on hepatic glucose metabolism.
Materials and Methods
Glucocorticoid receptor binding assay
The glucocorticoid receptor (GR) fluorescence polarisation (FP) binding assay was per-
formed using the commercially available kit from Panvera (Glucocorticoid receptor com-
petitor assay, Green Cat# P2816) (for more detailed information see SI text). 
Assay in U2OS cells
To determine the repressive activity of GR ligands, cell line U2OS GR.G9, the human osteo-
blastic cell line U2OS, stably transfected with human GR, was used. Cells (104 cells/well) 
were incubated in 384-wells plates, in the presence of 50 ng/ml TNFα (R&D systems) / 100 
ng/ml IFNγ (Peprotech) and compound, for 18 hours. Hereafter, a mixture of two different 
antibodies to hMCP-1, one Eu-labeled and one APC-labeled, were added. One hour later 
the time-resolved fluorometric resonance energy transfer (TR-FRET) signal was measured 
(for more detailed information see SI text). 




Assay in CHO cells
For monitoring both human steroid receptor agonistic as well as antagonistic activity of 
compounds, Chinese hamster ovary (CHO) K1 cells stably co-transfected with the specific 
human steroid receptor and its respective reporter construct were used (as previously 
described 45).
For human glucocorticoid receptor (GR)-specific activity CHO-GR B4.8 cells containing 
both recombinant human GR as well as a reporter construct consisting of the mouse 
mammary tumor virus (MMTV) promotor and the luciferase reporter gene, were used. 
Compound was incubated alone (in the agonistic setup) or with 50 nM dexamethasone 
(in the antagonistic setup) overnight. Hereafter, 200 µl medium was removed and 50 µl 
luciferine substrate solution from the LucLite luminescence kit (Packard, Meriden, USA) 
was added. After 10 minutes luminescence of each sample was counted and percentage 
maximal agonistic efficacy was related to the maximal efficacy of prednisolone. Percent-
age maximal antagonistic efficacy was related to the maximal antagonistic efficacy of ref-
erence GR antagonist Org 34116. Similar procedures were followed for the other human 
steroid receptor assays (for more detailed information see SI text).
Gene expression profiling in HepG2 cells
HepG2-8/97-WS.5 cells, deprived from serum for 18 hours, were stimulated with gluco-
corticoid and 0.5 mM cAMP for 6 hours. RNA was isolated and used for double stranded 
cDNA synthesis using the One-Cycle Target Labeling Kit (Affymetrix Santa Clara, CA). This 
cDNA was used as a template for the preparation of biotin-labeled cRNA using the Gene-
Chip IVT Labeling Kit (Affymetrix Santa Clara, CA). Biotin-labeled cRNA was fragmented 
and hybridized at 45°C for 16-17 hours to the Human Genome U133A 2.0 Array or the 
Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA) (for more detailed 
information see SI text). Arrays were stained with phycoerythrin-streptavidin conjugate 
(Molecular Probes, Eugene, OR), and the signals were amplified by staining the array with 
biotin-labeled anti-streptavidin antibody (Vector Laboratories, Burlingame, CA) followed 
by phycoerythrin-streptavidin. The arrays were laser scanned with a GeneChip Scanner 
3000 6G (Affymetrix, Santa Clara, CA) according to the manufacturer’s instructions. Data 
was saved as raw image file and quantified using GCOS (Affymetrix). 
For Q-PCR, cDNA was synthesized and diluted 125 times in milliQ and 5 µL was added to 
12.5 µL of SYBR green mix (Applied Biosystems cat. No. 4309155) , 2.5 µL of each prim-
er (~20 ng/µl) and 2.5 µL of milliQ. The following primer-pairs were used: for GAPDH: 
5’-CCACATCGCTCAGACACCAT-3’ and 5’-CCAGGCGCCCAATACG-3’; for PEPCK: 5’-TCCCATT-
GAAGGCATTATCTTTG-3’ and 5’-GCCAGCTGAGAGCTTCATAGACT-3’; for TAT: 5’-TACAGAC-
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CCTGAAGTTACCCAG-3’ and 5’-TAAGAAGCAATCTCCTCCCGA-3’; for G6Pase: 5’-TGCTGCT-
CAAGGGACTG-3’ and 5’-GAATGGGAGCCACTTGCTG-3’. Quantitative PCR was performed 
on an ABI7900HT real time thermo cycler (Applied Biosystems) and results were analyzed 
by SDS2.1 software (for more detailied information in SI text).
Gene expression profiling in THP-1 cells
THP-1 cells were incubated with glucocorticoid in the presence of either DMSO (control) 
or IFNγ/TNFα (220ng/ml / 375 ng/ml). After 6 hours total RNA was isolated and further 
processed for micro-array hybridization as described before for the HepG2 cells. Expres-
sion of FKBP51, DUSP1 and GILZ was confirmed by Q-PCR according to the same proce-
dure as described for the HepG2 cells. In this case THP1 cells were stimulated with 40 ng/
ml IFNγ and 60 ng/ml TNFα and a whole dose range of prednisolone and Org 214007-
0 was tested. Besides the GAPDH primers (described above) the following primer-pairs 
were used: for FKBP51: 5’-AAAAGGCCAAGGAGCACAAC-3’ and 5’-TTGAGGAGGGGCC-
GAGTTC-3’; for DUSP1: 5’-GTACATCAAGTCCATCTGAC-3’ and 5’-GGTTCTTCTAGGAGTAGA-
CA-3’; for GILZ: 5’-AGTGCCTCCGGAGCCAGC-3’ and 5’-ATGATTCTTCACCAGATCC-3’. Expres-
sion of MCP-1, IL-6 and IL-8 was measured by specific AlphaLISAs (PerkingElmer; #AL244C 
[MCP-1], #AL223C [IL-6] and #AL224C [IL-8]) according to the manufacturer manual. (for 
more detailed information see SI text)
ChIP-SEQ analysis
From the THP1 samples that were used for gene expression analysis after 6 hours, sam-
ples were drawn after 1 hour and used for ChIP – Seq analysis at Genpathway (Carlsbad, 
CA). For precipitation of genomic DNA regions antibody against GR (Santa Cruz sc-8992) 
was used. Details are provided in SI Text. The obtained amplified DNA libraries were sent 
to Illumina Sequencing Services (San Diego, CA) for sequencing on a Genome Analyzer 
II. Sequence files were analyzed with the Genomatix Genome Analyzer Workbench from 
Genomatix (Genomatix Software GmbH, Munich). Sequences were clustered using de-
fault parameter settings and aligned against the human genome version GRCh37/hg19. 
Clusters from the three conditions, DMSO, Prednisolone and Org 214007-0 treated THP-1 
were merged using the Replicate Analysis module from the Workbench package. In short, 
this results in a file with chromosomal coordinates with new merged clusters for each 
position in which a cluster is found for one or more conditions. For each of these merged 
clusters, the reads and normalized enrichment for each of the conditions is given. Ad-
ditionally, for each merged clusters P-values for each pairwise comparison of the three 
conditions were also calculated. 




Human whole blood LPS- or PMA/anti-CD28-induced cytokine release
Peripheral blood from healthy volunteers was collected into lithium heparinised tubes, di-
luted with RPMI 1640 medium (without phenol red) (Gibco BRL) and used within 3 hours 
after collection. Diluted blood (final dilution 5x) was pre-incubated in cell culture 96-wells 
flat-bottom plates (Nunc) together with compound for 1 hour and further incubated 
with 1 µg/ml Lipopolysaccharide (E. coli serotype 0111:B4, Sigma) or 100 ng/ml phor-
bol 12-myristate 13-acetate (PMA, Sigma) / 100 ng/ml mouse anti-human CD28 antibody 
(Sanquin, The Netherlands) for 24 hours in an incubator at 37°C, 6% CO2 and 95% humid-
ity. Hereafter, supernatant was carefully collected and tested at the most optimal dilution 
(predetermined by a titration study on control samples) in a human TNFα-specific ELISA 
(for the LPS stimulated samples) or in a human IL-5-specific or human G-CSF-specific ELISA 
(for the PMA / anti-CD28 stimulated samples) (Duoset, R&D systems USA). 
Animals
All animal procedures and experiments received ethics approval and were according to 
the recognized guidelines. Female Balb/c mice (Charles River, Sulzfeld, Germany), male 
C57BL/6J OlaHsd (Harlan, Zeist, the Netherlands) and male DBA/1J/BOM mice (Bomholt-
gard, Ry, Denmark) were group-housed under controlled conditions with a constant tem-
perature (19–21°C), a 12-h light/dark cycle and ad libitum access to water and standard 
laboratory chow pellets. For MIDA analysis, C57Bl6 mice were equipped with a perma-
nent right jugular vein catheter afterwhich mice were allowed to recover. 
Acute inflammation mouse models
For both the LPS-induced TNFα as well as the anti-CD3 induced IL-2 model, female Balb/c 
mice of 8-12 week old were used. Mice were treated orally with 0.2 ml compound or 
vehicle (water / mannitol (5%) with 5% DMSO / 5% chremophore for the LPS model or 
with 0.5% gelatine for the anti-CD3 model). One hour after oral treatment animals were 
challenged i.p. with 0.2 ml of either 20μg/mouse LPS (Sigma, E. coli serotype 055:B5) or 
5 µg/mouse hamster anti-CD3 monoclonal (BD Biosciences Pharmingen, art. nr. 553057, 
clone 145-2C11). Ninety minutes after LPS injection or 3 hours after anti-CD3 challenge, 
blood samples were collected and serum levels of TNFα or IL-2 were determined via spe-
cific ELISAs (BD Biosciences Pharmingen, San Diego, CA, USA). In the experiment that in-
cluded treatment with RU486 to block GR, mice were dosed subcutaneously with 50 mg/
kg RU486 30 minutes before the oral compound dosing. ED50 and % efficacy (maximal 
percentage inhibition of TNFα or IL-2 release) are determined using a 3 parameter sigmoi-
dal curve calculation. Statistical analysis of the results was performed using an one-way 
ANOVA (log) test.
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The experiment was essentially performed as described previously 46. At day 0 mice were 
immunized at the base of the tail with 100µg bovine type II collagen (UMC Nijmegen, The 
Netherlands) in Complete Freund’s Adjuvant (CFA, Difco) enriched with 2 mg/ml Mycobac-
terium tuberculosis H37RA (Difco). At day 21 mice were boosted by an i.p. injection of 100 
µg bovine type II collagen dissolved in saline. After disease onset, mice with an arthritis 
score ranging from 0.25 to 1.25 were divided into matched groups (n=12). Animals were 
orally treated once daily with vehicle (0.5% gelatin / 5% mannitol in water) or compound 
for 21 to 23 days. The clinical severity of arthritis (arthritis score) was graded and scored as 
described 47. To assess the effects of treatments, the area under the curve (AUC) of arthri-
tis score (subtracting baseline AUC of arthritis score on day 0) was used. One day after the 
final treatment animals were sacrificed and the knee and ankle joints were imaged using 
a Faxitron X-ray, Modl MX-20 digital imaging system and analysed using Specimen (Ver-
sion 2.0.1). The bone destruction was scored on a scale of 0-5 as described previously 47. 
The cumulative scores of 2 joints (right ankle and knee) were used as radiological scores. 
From H&H-stained sections, articular cartilage destruction and inflammatory infiltrate in 
the right knee joint were scored on a scale of 0 – 3. The whole study was carried out in a 
blinded fashion. Statistical analysis was performed using one-way ANOVA. 
Micro array on muscle tissue mRNA from mice
Two and a half hours after the final treatment animals were sacrificed and samples were 
collected from the thigh muscle (musculus tensor fasciae latae and musculus rectus femo-
ris). Samples were stored immediately at -80 ºC and send to Covance (Princeton, New 
Jersey) for RNA extraction and subsequent analysis of gene expression on the Mouse Ge-
nome 430A 2.0 array. For statistical analysis, the .CEL files obtained after hybridization 
were analyzed with the R (www.r-project.org) and the BioConductor software package 
(www.bioconductor.org) as described previously 35. Normalization was done using gcrma. 
Building of the experimental design and calculation of the ratios was done with the limma 
package. Differentially expressed probe sets were selected on basis of the fold change 
and the adjusted p-value (Benjamini-Hochberg correction). Multivariate data analysis and 
clustering was done with standard methods in the R software package (www.r-project.
org).
Mouse fasting glucose and MIDA model for liver glucose metabolism 
For fasting blood glucose levels, male C57Bl/6J OlaHSD mice (n=8 per group, ~25 g) were 
treated daily by oral gavage for 28 days with either prednisolone (1.5 or 10 mg/kg/day), 
an equipotent dose of Org 214007-0 (0.17 or 0.5 mg/kg/day), vehicle (0.5% gelatin / 5% 




mannitol in water) or no treatment as a stress control. Eighteen hours after the last oral 
treatment and 9 hours after start of starvation, blood samples were taken from the tail 
vein and directly used for glucose measurements using “One touch Ultra” glucose me-
ter from Lifescan EuroFlash (Lifescan Benelux Beerse, Belgium). The mouse MIDA study 
was performed as described previously by van Dijk et al. 40,48. Briefly, individually housed 
C57Bl/6J mice (n=8) were treated orally with prednisolone (10 mg/kg/day), Org 214007-0 
(0.5 mg/kg/day) or vehicle (0.5% gelatin / 5% mannitol in water) daily for 7 days. On the 
third day, mice were cannulated in the right jugular vein. After 7 days of treatment, mice 
were placed in small Plexiglas cages, which allowed collection of blood samples frequently 
in freely moving mice. Twenty four hours after the final dose and after a 9 hours starving 
period, a tail vein blood sample was used for a glucose measurement after which mice 
were shortly anesthetized to attach the infusion lines before the experiment. Filter paper 
was placed under the wired floor cages to collect urine samples and replaced hourly. Mice 
received an infusion of a sterilized aqueous solution containing [U-13C]glucose (13 µmol/
ml), [2-13C]glycerol (160 µmol/ml), [1-2H]galactose (33 µmol/ml) and paracetamol (1 mg/
ml) at a rate of 0.54 ml/hr for 6 hours. During the experiment blood glucose was measured 
and blood spots for GC-MS measurements were collected from tail tips just before the 
start of the infusion and at hourly intervals. Blood spots and urine filter papers were air-
dried and stored at room temperature until analysis. Glucose and paracetamol-glucuronic 
acid (Par-GLcUa) were extracted from blood spot and urine filter papers, respectively, de-
rivatised, and measured by GC-MS, essentially as described previously 40,48. The fractional 
isotopomer distribution according to GC-MS was corrected for fractional distribution due 
to the natural abundance of 13C by multiple linear regression to obtain the excess mole 
fraction of mass isotopomers M0-M6 due to incorporation of infused labeled carbohy-
drates. From isotope dilution and infusion rates, the flux rates of the following metabolic 
pathways could be calculated: 1) de novo synthesis of G6P, 2) glucokinase, 3) glucose-
6-phosphatase, 4) glycogenolysis, and 5) glycogen synthesis. The method of calculation 
was performed as described before 40,48,49. 
Results
In vitro studies
Org 214007-0, [(-)-N-(2S,10S,14bS)]-N-(8-cyano-1,2,3,4,10,14b-hexahydro-10-methyl 
dibenzo [c,f]pyrido[1,2-a]azepin-2-yl)-4-methyl-1,2,3-thiadiazole-5-carboxamide], the 
structure of which is shown in Figure 1, has a molecular weight of 430 g/mole (C24H23N5OS). 
Synthesis of Org 214007-0 was performed as described elsewhere 26. Org 214007-0 was 
found to bind to GR as efficient as prednisolone (Ki of 2.2 nM vs. 3.8 nM for prednisolone) 
(Table 1, row A). In spite of this, in comparison to prednisolone, Org 214007-0 showed a 
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stronger potency (5-fold lower EC50), but a clearly lower efficacy (34%, agonistic mode) 
in GRE-mediated induction of gene expression in a human GR transfected cell line (CHO) 
(Table 1, row B), indicative for a partial GR agonistic activity. GR-selectivity of Org 214007-
0 was shown by the absence of any detectable agonistic activity for other human steroid 
receptors. Org 214007-0 only possessed minor antagonistic activity for the human proge-
stagen (B) and mineralocorticoid receptor (data in SI Table S1).
To investigate whether in comparison to prednisolone the partial activity of Org 214007-0 
would be sustained in cells that express endogenous GR, the human hepatocyte cell line 
HepG2 was used. Instead of focusing on a limited set of genes the genome-wide effect 
of both GCs was investigated by micro-array analysis on total mRNA from these cells. As 
shown in Table 1, row C, Org 214007-0 was found to induce expression of a much lower 
number of genes than prednisolone did. The genes regulated by Org 214007-0 represent 
a subset of the genes regulated by prednisolone, confirming partial agonistic activity of 
Org 214007-0 in these cells. For a few genes, i.e., tyrosine aminotransferase (TAT), glucose 
6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK, Pck1), the par-
tial induction by Org 214007-0 in comparison to prednisolone was confirmed for a whole 
dose-range of the compounds using Q-PCR (Fig. S1).
The anti-inflammatory activity of Org 214007-0 in comparison to predisolone was quanti-
fied in a stably human GR transfected cell line (U2OS) stimulated to elicit an inflammatory 
response. Org 214007-0 was shown to inhibit this response with a potency comparable 
to that of prednisolone, while its efficacy was somewhat less compared to prednisolone 
(81%) (Table 1, row D). To determine in one cell system both activities, i.e. the induction 
of gene expression as well as the repression of gene expression under an inflammatory 
condition, Org 214007-0 and prednisolone were tested in the human monocytic THP1 cell 
line. The set of genes induced was defined as genes that were up-regulated at least 2-fold 


























by either compound compared to vehicle in the non-triggered cells. The set of repressed 
genes was defined as genes that were up-regulated at least 2-fold by the inflammatory 
stimulus and subsequently down-regulated at least 2-fold by either prednisolone or Org 





Prednisolone (PRED) and Org 214007-0 in vitro studies , for legend see next page.
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lower than those regulated by prednisolone as shown in Table 1, row E. In both cases, all 
genes that were regulated by Org 214007-0 were also regulated by prednisolone. Shown 
in Figure 2A are the gene sets ranked on basis of the magnitude of up- or down-regula-
tion by prednisolone. The top 30 genes from each set were used for further comparison. 
These data show that, in this cell system, Org 214007-0 possesses on average a two-fold 
lower gene repression activity and an eight-fold lower gene induction activity than pred-
nisolone does. To illustrate this, examples of one gene induced (FKBP51) and one gene 
repressed (CCL8) are shown in Figure 2B. For a small selection of genes, these differences 
in expression levels were confirmed, comparing a whole dose range of Org 214007-0 and 
prednisolone by either Q-PCR (FKBP51, GILZ and DUSP) or by specific AlphaLISAs (MCP1, 
IL6 and IL8) (Table 1, rows F and G). This data shows that Org 214007-0, in comparison to 
prednisolone, has a preference for repressing gene expression rather than activating gene 
expression.
In order to define in more detail the molecular mechanism that underlies the differential 
effects of Org 214007-0 compared to prednisolone on gene expression, we performed 
ChIP-Seq analysis on DNA from these THP-1 cells. Compared to vehicle, the numbers of 
clusters found for Org 214007-0 versus prednisolone under the non-stimulated condi-
tion were 2080 vs. 9413, respectively. An example of these clusters in the FKBP51 gene 







 1 Prednisolone (PRED) and Org 214007-0 in vitro studiesA) GR binding: binding to recombinant human glucocorticoid receptor (GR) assessed by a fluorescence polarization com-
petitor binding assay. Ki = inhibition constant or concentration of compound in the competitive binding assay which would 
occupy 50% of GR if no ligand was present. B) CHO – ind: Induction of gene expression measured in CHO cells stably co-
transfected with human GR and a MMTV promoter – luciferase construct. C) HepG2 – ind: Induction of gene expression 
measured by micro-array analysis of mRNA isolated from HepG2 cells incubated with either 1 µM prednisolone or 1 µM 
Org 214007-0; n= number of genes that were up-regulated at least 2-fold in comparison to cells incubated with vehicle 
only. D) U2OS – rep: Repression of gene expression in U2OS cells overexpressing human GR. INFγ/TNFα - MCP-1 = IFNγ 
(100 ng/ml) / TNFα (50 ng/ml) induced MCP-1 release. E) THP-1: Micro-array analysis of mRNA isolated from THP-1 cells 
incubated for 6 hours with either 1 µM prednisolone or 1 µM Org 214007-0 without or with IFNγ (220 ng/ml) / TNFα (374 
ng/ml) (=IFNγ/TNFα), n= number of genes that were up-regulated at least 2-fold in comparison to cells incubated with 
vehicle only or number of genes that were up-regulated at least 2-fold by INFγ/TNFα and at least 2-fold down-regulated 
by either prednisolone or Org 214007-0. F) THP-1 – rep: Repression of gene expression in THP-1 cells. INFγ/TNFα – MCP-1, 
IL-6, IL-8 = TNFα (60 ng/ml) / IFNγ (40 ng/ml) induced MCP-1, IL-6 or IL-8 release. G) THP-1 – ind: Induction of FK506 bind-
ing protein 51 (FKBP51), glucocorticoid induced leucine zipper (GILZ) and dual specificity phosphatase 1 (DUSP1) in THP-1 
cells. H) hWB - rep: Inhibition of LPS-induced TNFα release or PMA / anti-CD28 induced IL-5 release by primary human 
whole blood cells and hWB – ind: enhancement of PMA / anti-CD28 / compound induced G-CSF release by primary human 
whole blood cells. I) CASM3C – rep: Inhibition of MCP-1 release of coronary artery smooth muscle cells stimulated with a 
cytokine mixture of IL-1β (1 ng/ml), TFNα (5 ng/ml) and IFNγ (100 ng/ml) (=CASM3C) by 1 µM prednisolone or 1 µM Org 
214007-0.  CASM3C – ind: Induction of serum amyloid A (SAA) of the cells mentioned above by 1 µM prednisolone or 1 
µM Org 214007-0. J) HDF3CGF – rep: inhibition of matrix metalloproteinase (MMP-1) release of human neonatal foreskin 
fibroblasts stimulated with the cytokine mixture mentioned above plus required growth factors (=HDF3CGF). HDF3CGF – 
ind: Activation of plasminogen activator inhibitor-1 (PAI-1) by cells mentioned above by 1 µM prednisolone or 1 µM Org 
214007-0. 
IC50 or EC50 values represent the mean concentration of compound (±SD) required to resp. inhibit or effect the response 
to 50%. Maximal efficacy (Max. eff.) is expressed as the mean relative maximal effect (±SD) compared to the maximal ef-
fect by prednisolone (set at 100%). All assays (except for the micro array experiments) are performed at least two times.




2502 vs. 3471. So, under both conditions, Org 214007-0, causes less binding of GR to the 
DNA than prednisolone does. Comparison of the set of 2080 putative binding sites of Org 
214007-0 with the 9413 binding sites of prednisolone showed that 99.5 % of the binding 
sites in the Org 214007-0 set were also contained within the prednisolone set, indicating 
that Org 214007-0 is a genuine GC that does not lead to binding of GR on sites that are not 
targeted by prednisolone. This is in close agreement with the micro-array data in which a 
similar large overlap was shown between the 2 gene sets. The ratio of the read count for 
clusters induced by prednisolone or Org 214007-0 is shown in Figure 3A as a histogram. 
Clearly, most clusters have a ratio greater than 0, indicating that prednisolone leads to 
more GR occupancy than Org 214007-0.
The activity of Org 214007-0 in cell lines needed to be confirmed in human primary cells. 
The effect of Org 214007-0 was tested on the cytokine release of primary human whole 
blood cells treated with either LPS or anti-CD28/PMA. As depicted in Table 1, row H, under 
all conditions the EC50 values for the inhibitions by Org 214007-0 were more or less com-
parable to those of prednisolone, while on maximal efficacies Org 214007-0 again showed 
partial activities in comparison to prednisolone (additional data shown in SI Table S2). In 
addition, Org 214007-0 and prednisolone were compared in some of the Biologically Mul-





Org 214007-0 has a relatively lower impact on induction than on respression of genes  in THP-1 cells as measured by 
micro-array analysis. 
A, Fold changes for the top 30 induced genes (upper figure) and repressed genes (bottom figure) by prednisolone (black) 
and Org 214007-0 (grey). NB. Scales are in 2log. B, Example of an induced gene, FK506 binding protein 51 (FKBP51, top) 
and a repressed gene, chemokine [C-C motif] ligand 8 (CCL8, bottom)  by prednisolone (black bars) and Org 214007-0 (grey 
bars) in comparison to the vehicle control (white bars) under either non-stimulated (left part, control) or stimulated (right 
part, IFNγ/TNFα) condition. 
BA
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assays make use of different types of primary human cells, in this case coronary artery 
smooth muscle cells and neonatal foreskin fibroblasts, in an inflammatory environment 
27, 28. As can be seen in Table 1, rows I and J, Org 214007-0 showed full efficacies in the 
two cell systems, i.e., 98% and 120% repression of MCP1 (Ccl2) and MMP1, respectively. 
Also in these cells, partial induction of protein expression by Org 214007-0 in comparison 
to prednisolone was observed, i.e. 58% for serum amyloid A and 55% for plasminogen 
activator inhibitor-1. Consistently, these data in primary human cells show a relatively 
stronger impact of Org 214007-0 on repression versus induction of gene expression.
In vivo studies
To evaluate how the in vitro profile of Org 214007-0 would translate in vivo with regard to 
both anti-inflammatory efficacy and induction of side effects, the compound was tested 
head-to-head to prednisolone in different in vivo models. Since pharmacokinetic studies 
in mice showed good oral bio-availability of Org 214007-0 and prednisolone (data in SI 
table S3), both compounds were dosed orally in all preclinical mouse models. Firstly, Org 
214007-0 was tested in an acute inflammation model for its potency to inhibit the LPS-
induced raise in serum TNFα. As can be seen in Figure 4A, the potency of Org 214007-0 in 
this model was stronger than that of prednisolone (ED50 0.5 mg/kg vs. 1 mg/kg). Surpris-
ingly, and in contrast to its in vitro repression efficacy on LPS-induced TNFα, the maximal 





GR binding profile of Org 214007-0
A, Ratio of the read count for clusters induced by prednisolone or Org 214007-0. If Org 214007-0 and prednisolone would 
induce an equal number of reads, the histogram would be centered on 0, indicated by the dotted line. There is a clear shift 
to the right from this line (P-value (mean = 0) <0.000001), indicating that prednisolone leads to more GR occupancy than 
Org 214007-0. B, Example profile of the tag clusters in the GR response gene FKBP51. Multiple binding sites are found 
within this gene, each showing denser clusters after treatment with prednisolone than after treatment with Org 214007-0.
A B




90% inhibition of the LPS-induced TNFα release. Administration of GR antagonist RU486 
(mifepristone) to the mice just prior to oral treatment with either Org 214007-0 or pred-
nisolone fully antagonized this inhibition (Fig. S2), confirming that inhibition of the TNFα 
response was indeed mediated via GR. The effect of Org 214007-0 was also tested in a 
T-cell-driven inflammation model using anti-CD3-induced IL-2 release as readout. As can 
be seen in Figure 4B, Org 214007-0 dose-dependently reduced the anti-CD3 induced IL-2 
serum levels with a similar efficacy as prednisolone (75% inhibition) but with a stronger 





Inhibitory properties of Org 214007-0 on TNFα and IL-2 secretion
A, Org 214007-0 and prednisolone are equally effective in inhibiting acute inflammation in the LPS-induced TNFα mouse 
model. Mean percentage inhibition (of each group of n=8) (± SEM) of the LPS-induced TNFα release by the vehicle treated 
group is shown (no TNFα is detectable without LPS injection). ** = significantly different from placebo (p < 0.01; ANOVA-
test). B Org 214007-0 and prednisolone are equally effective in inhibiting acute T cell-driven inflammation in the anti-CD3-
induced IL-2 mouse model, although Org 214007-0 shows a more potent activity in this model. Mean percentage inhibition 
(of each group of n=2) (± SEM) of the anti-CD3-induced IL-2 release relative to a positive control group (treated with 10 mg/
kg A420983, a pan-SRC inhibitor from Abbott) (set at 100%) is shown (no IL-2 is detectable without anti-CD3 injection). ** 
= significantly different from placebo (p < 0.01; ANOVA-test).   
A
B
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although Org 214007-0 behaves as a true partial GR agonist in vitro, it shows full anti-
inflammatory activity as good as prednisolone in vivo.
We next tested the efficacy of the compound in a more relevant chronic disease model in 
which the classical glucocorticoids have proven efficacy. The murine collagen-induced ar-
thritis (CIA) model is a well-accepted model of human rheumatoid arthritis, encompassing 
inflammation of synovial joints, destruction of cartilage and bone erosion. Org 214007-0 
and prednisolone were dosed once daily orally during 3 weeks in a therapeutic manner, 
i.e., treatment started when disease was already established. Both prednisolone and Org 
214007-0 caused a dose-dependent reduction of the disease score (Fig. 5A). Org 214007-0 
was found to be about 3-fold more potent than prednisolone in this model, leading to a 
total suppression of the disease symptoms at a dose of 1.5 mg/kg/day. Besides the clinical 
score of the paws, the two highest doses of Org 214007-0 (0.5 and 1.5 mg/kg/day) also 
showed a significant reduction in bone damage as determined by X-ray on knees and paws 
at the end of the study (Fig. 5B). Finally, histopathologic examination of the inflamed knee 
joints also showed a significant reduction of inflammatory infiltrates, cartilage destruction 
and bone apposition in mice treated with the two highest doses of Org 214007-0 (Fig. S3). 
Altogether these results demonstrate that the anti-inflammatory in vivo efficacy of Org 






Arthritis reducing properties of Org 214007-0
A, Org 214007-0 is equally effective as prednisolone in inhibiting arthritis in CIA model. Mean clinical score of each group 
(n=12), shown as area under the curve (AUC) of the arthritis score monitored every other day during 3 weeks, corrected for 
baseline, is indicated (± SEM). ** = significantly different from placebo (p < 0.01; ANOVA-test). B, Org 214007-0 significantly 
reduces bone destruction at 0.5 and 1.5 mg/kg in the CIA model as measured by X-ray. Mean radiological score (sum of 
the X-ray scores of left and right hindpaws and knees) of each group of mice (n=12) at the end of the CIA experiment is 
indicated (± SEM). ** = significantly different from placebo (p < 0.01; ANOVA-test). 
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214007-0 on induction of gene expression, as observed in vitro, would be conserved in 
vivo. For this purpose, muscle tissue was collected from arthritic mice that were treated 
for 3 weeks with either vehicle only or with dosages of Org 214007-0 and prednisolone 
that were equally effective in inhibiting arthritis. Besides these groups of mice, one group 
of healthy mice was included. Collected tissue was used to isolate mRNA for microarray 
analysis. All genes that were at least 2-fold up-regulated by the disease induction (vehicle 
treated arthritic vs. healthy mice) and that were down-regulated at least 2-fold by either 
Org 214007-0 or prednisolone are shown in Figure 6A (bottom). Among the genes are 
some well-known inflammatory markers as S100A8, S100A9 and Ccl8, the latter shown as 
an example in Figure 6B (bottom). Genes that were at least 2-fold up-regulated by either 
Org 214007-0 or prednisolone in comparison to vehicle treated mice are shown in Figure 
6A (upper part). Among these genes are, a.o., Foxo1 and bona fide GR target genes like 
Fkbp51 and Per2 (shown as an example in Fig. 6B, upper part). As visualized in Figure 6A, 
the fold induction of gene expression by Org 214007-0 was always lower than that caused 
by prednisolone, whereas fold repression of gene expression is more or less equal for Org 
214007-0 and prednisolone. In other words, also in vivo Org 214007-0 shows a relatively 
low effect on induction of gene expression compared to prednisolone at dosages that are 





Org 214007-0 has a relatively lower impact on induction of genes as measured by micro-array analysis on muscle tissue 
mRNA from CIA mice. 
A, Fold changes for the top 30 induced genes (upper figure) and 25 repressed genes (bottom figure) by prednisolone (black) 
and Org 214007-0 (grey). NB. Scales are in 2log. B, Examples of an induced gene (Per-2, top) and a repressed gene (CCL8) 
regulated in CIA mice treated with prednisolone (P) or Org 214007-0 (O) in comparison to the vehicle treated CIA mice (V) 
and naïve healthy mice (V, white bars)
BA
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Org 214007-0 induces less fasting 
glucose compared to prednisolone at 
equi-efficacious dosages. 
Mice (n=8 per group) are not treated 
(white bars, dashed) or treated once 
daily, for 28 days with either vehicle 
only (white bars), prednisolone 0.5 mg/
kg/day (dark grey bars, dashed) or 1.5 
mg/kg/day (black bars), or Org 214007-
0 0.17 mg/kg/day (grey bars, dashed) 
or 0.5 mg/kg/day (grey bars). Both the 
two lowest doses of each compound 
are equi-efficacious in suppression of 
CIA as well as the two highest doses. 
Blood glucose levels (mean ± SEM) 
were measured at day 8, 15, 22 and 
29, after 9 hours of fasting. * p < 0.05, 
** p < 0.01, *** p < 0.001: significantly 






Org 214007-0 has no effect on hepatic 
glucose fluxes
Org 214007-0, at a dose that is equi-
efficacious to prednisolone, does not 
effect the rates of the hepatic enzyme 
fluxes in mice as determined by Mass 
Isotopomer Distribution Analysis 
(MIDA). MIDA, as described in detail in 
Materials and Methods, was performed 
in mice treated p.o., once daily, for 7 
days with either vehicle (white bars), 
10 mg/kg prednisolone (dark grey bars) 
or 1.5 mg/kg Org 214007-0 (light grey 
bars). The glucokinase flux rate was not 
changed by Org 214007-0, but signifi-
cantly differed from the effect by pred-
nisolone (##: p=0.01 vs. prednisolone). 
The glycogen synthase flux rate was 
significantly decreased by prednisolone 
(**: p=0.005 vs. vehicle), whereas Org 
214007-0 had no significant effect on 
this flux, but differed significantly from 
prednisolone (##: p=0.002 vs. predniso-
lone). Neither Org 214007-0 nor pred-
nisolone, at equi-efficacious dosages, 










Finally, we assessed whether Org 214007-0 indeed has a favorable therapeutic index with 
respect to its (side-) effects on glucose metabolism. For this purpose, mice were treated 
daily with either vehicle, Org 214007-0 or prednisolone for 28 days and fasting blood glu-
cose levels were determined at several time points. As shown in Figure 7, the fasting blood 
glucose levels in mice treated with prednisolone in comparison to vehicle-treated mice 
were already significantly elevated (p<0.01) from day 8 on. Interestingly, equipotent doses 
of Org 214007-0 did not affect fasting blood glucose levels. To evaluate the effects of the 
compound on hepatic glucose metabolism, a study employing a specific mass isotopomer 
distribution analysis (MIDA) approach was performed. Mice were dosed for 7 days with 
Org 214007-0 or prednisolone, again at dosages equally efficacious in inhibiting arthritis 
in the CIA model, or vehicle only. Also in this study, the fasting blood glucose levels in 
mice treated with prednisolone were significantly elevated compared to vehicle-treated 
mice (p<0.05), while Org 214007-0 did not affect fasting blood glucose level (Fig. S4). The 
hepatic flux rates calculated from the MIDA results are shown in Figure 8. The glucokinase 
and glycogen synthase flux rates were significantly decreased by prednisolone whereas 
Org 214007-0 had no significant effects. These differences in flux rates resulted in differ-
ences in glucose and glycogen balances as shown in Figure 9. Since prednisolone treat-
ment caused no change in the gluconeogenic flux (from pyruvate to glucose-6-phosphate) 
(Figure 8) nor in the blood glucose metabolic clearance rate (Figure 9), the effect of pred-
nisolone on the glucokinase and glycogen synthase flux rates may explain the increase 
in fasting glucose levels in prednisolone-treated mice. Org 214007-0 did not alter these 
Org 214007-0, at a dose equi-effica-
cious to prednisolone, does not cause 
a shift in the glucose / glycogen balance 
in the liver as determined in MIDA (de-
tails in legend Figure 8). The glucose 
balance, which represents the differ-
ence between the glucose-6-phopha-
tase and glucokinase flux, is not af-
fected by Org 214007-0 treatment but 
is significantly changed by the pred-
nisolone treated group (*: p=0.046 vs. 
vehicle.; ##: p=0.004 vs. prednisolone). 
The glycogen balance, representing the 
difference between the glycogen syn-
thase and glycogen phophorylase flux, 
is not effected by Org 214007-0 treat-
ment but is significantly changed by the 
prednisolone treated group (*: p=0.024 
vs. vehicle.; ##: p=0.005 vs. predniso-
lone). Neither Org 214007-0 nor pred-
nisolone, at equi-efficacious dosages, 
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balances, confirming a significantly different mode of action of glucose metabolism in 
comparison to prednisolone.
Taken together, the in vitro partial GR agonistic profile of Org 214007-0 translates in vivo 
into a full anti-inflammatory compound with less adverse effects on glucose metabolism 
in mice. Org 214007-0 therefore represents a new class of SGRMs with an improved thera-
peutic index in comparison to prednisolone. This class of compounds is highly interesting 
for further development towards improved oral SGRMs for clinical use.
Discussion
About two decades ago, the concept of a “dissociating glucocorticoid” was defined, based 
on the discovery of the two different mechanisms of glucocorticoids action: transrepres-
sion versus transactivation. This concept was enforced by the finding that DNA-binding 
of the GR-ligand complex was not required for transrepression 5,29. Since then, drug dis-
covery programmes have been initiated on dissociating glucocorticoids (nowadays often 
referred to as SGRMs), resulting in the development of a number of compounds that in-
deed show improved TR/TA ratio in vitro (reviewed in 11). However, only a limited number 
of compounds also show an dissociating profile in vivo when tested in preclinical animal 
models. This field of research and the hypothesis that an improved TR/TA ratio is benefi-
cial in the clinic still awaits its validity, since proof of concept in man has not been shown 
yet. In addition it is now evident that the simple concept of TR versus TA activity requires 
revision based on new insights in the complexity of the mechanisms of GC action. Besides 
that, networks of hormonal regulation and metabolic processes are strongly intercon-
nected 1,2,3. Because of the complexity of GC biology, preclinical models are crucial to es-
tablish whether in vitro results translate into an improved profile of a SGRM in vivo. Most 
frequently, mouse models are being used to evaluate both the anti-inflammatory effects 
and the metabolic side effects. The latter requires specific knowledge and experimental 
techniques concerning (assessment of) glucose metabolism in the mouse. For example, 
fasting insulin and glucose levels measured in mice treated with GC clearly depend on 
time of fasting and time of blood sampling 30 and often seem to display patterns different 
from those in humans 31 .
In this paper we provide an extended in vitro characterization combined with specific in 
vivo data on a SGRM that belongs to a new chemical class of non-steroidal low molecular 
weight compounds, i.e., Org 214007-0. Org 214007-0 binds with high affinity to GR, com-
parably to prednisolone. In vitro, Org 214007-0 behaved as a partial GR-selective agonist 
with a potency comparable to prednisolone. The maximal efficacy on induction of gene 




expression by Org 214007-0, in comparison to prednisolone, is partial. The maximal ef-
ficacy on repression of inflammatory responses by Org 214007-0 is also partial but closer 
to that of prednisolone. This typical in vitro profile of Org 214007-0 was confirmed in 
several cell lines (HepG2, THP-1) for the total array of GC modulated genes. In addition, 
this unique profile of Org 214007-0 was confirmed in several types of human primary cells 
under different pro-inflammatory conditions. 
Although Org 214007-0 binds GR with the same affinity as prednisolone, the conformation 
of the GR-Org 214007-0 complex leads to a lower binding affinity to the DNA GR-binding 
sites in comparison to the GR-prednisolone complex, as was shown by a ChIP-Seq study. 
These data are in agreement with the partial activity of Org 214007-0 on gene induction. 
Structure modeling of the GR-Org 214007-0 complex indeed indicates a conformation 
that changes the position of AF2 helix 12 of the GR molecule. Since co-modulator binding 
depends on the position of this helix, this will probably effect recruitment of co-activators 
and thereby gene induction activity 21,32.
The in vivo activity of Org 214007-0 was tested in several mouse models. Two acute in-
flammation models demonstrated the anti-inflammatory activity of Org 214007-0 at the 
level of both monocytic cells (LPS-induced TNFα model) and T cells (anti-CD3-induced 
IL-2 model). Strikingly, Org 214007-0 was found to behave as a potent and full GR agonis-
tic anti-inflammatory agent in these models. Even more importantly, this strong potency 
and full anti-inflammatory efficacy was sustained in a chronic disease model, i.e., the CIA 
model. Microarray analysis on muscle RNA from these mice showed that the efficacy in 
suppression of the CIA disease score was in line with a reduction of disease-related or 
pro-inflammatory genes like TLR4 ligand S100A8/S100A9 33 and monocyte chemotactive 
protein-2 (chemokine[C-C]-ligand 8 or Ccl8) 34. More importantly, the partial activity of 
Org 214007-0 on gene induction, as observed in vitro, was sustained in the CIA model, 
since the GR-dependent induction of genes was always lower upon Org 214007-0 treat-
ment compared to prednisolone. A large part of the induced genes are well-known GR-
regulated genes like Fkbp51, Foxo1, phenylethanolamine-N-methyltransferase (Pnmt), 
Ddit4 (or Redd1), Lcn2 (or Lipocalin 2) and Per2 7,35. This latter gene belongs to the class 
of circadian clock genes and has recently been described as a primary GR target gene 
involved in glucose homeostasis 36. It is tempting to speculate that a less pronounced 
induction of Per-2 by Org 214007-0 compared to an equi-efficacious dose of prednisolone 
contributes to a better metabolic side effect profile of Org 214007-0. However, a func-
tional metabolic side effect profile could not be derived from our CIA model, since we 
have not seen any induction of either glucose or insulin at a dose of 1.5 mg/kg/day pred-
nisolone in our CIA experiments. Other groups have described increased fasting glucose 
or insulin levels in mice treated with prednisolone in acute inflammation models 6,37 and 
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in a chronic disease model 38. Riether et al. 38 showed that 30 mg/kg prednisolone induced 
significantly elevated serum insulin levels in a mouse CIA experiment. However, the dose 
of prednisolone used by Riether et al. is much higher than the dose (1.5 mg/kg/day) that 
is fully efficacious in our CIA model. To gain direct insight in potentially disqualifying side 
effects of Org 214007-0 on glucose metabolism, we have carefully evaluated its effect on 
glucose metabolism in the liver, by a mass isotopomer distribution analysis (MIDA) ap-
proach. MIDA has successfully been applied to study glucose metabolism in humans 39 
and was adapted for use in mice 40. Using this method it was found that prednisolone ad-
ministration of 10 mg/kg/day for 7 days significantly reduced glycogen storage in the liver 
by reducing glucokinase and glycogen synthase fluxes, while a dose of Org 214007-0 that 
was equi-efficacious in reducing arthritis did not. Surprisingly, hepatic gluconeogenesis 
was not affected by prednisolone treatment while the commonly accepted idea is that 
GCs stimulate gluconeogenesis via induction of genes like PEPCK (Pck1) and G6pase. How-
ever, induction of these gluconeogenic genes appears to represent an acute effect of GCs. 
Studies on glucose metabolism after a more chronic GC treatment in man 31,41,42 or mice 30 
also showed a lack of effect on hepatic gluconeogenesis and rather point at an effect on 
glucose disposal. In addition, it is known that PEPCK (Pck1) gene expression only margin-
ally controls the gluconeogenesis flux 43,44. So, in contrast to prednisolone, Org 214007-0 
did not have any impact on in vivo glucose metabolism in the mouse, since no effects on 
fasting blood glucose levels or on hepatic glucose metabolism were found.
Thus, Org 214007-0, is a non-steroidal SGRMs, with an improved therapeutic index com-
pared to prednisolone. Progress in development of this new class of SGRMs could lead to 
future availability of effective anti-inflammatory drugs with a lower risk for metabolic side 
effects.
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Glucocorticoid receptor binding assay
The glucocorticoid receptor (GR) fluorescence polarisation (FP) binding assay was performed using the commer-
cially available kit from Panvera (Glucocorticoid receptor competitor assay, Green Cat# P2816). Briefly, recombi-
nant human GR was added to a fluorescent glucocorticoid ligand (Fluormone™ GS1) in the presence of competi-
tor test compounds in black round bottom 384 well microtitre plates for 1.5 to 2.5 hours at roomtemperature. 
Fluorescence polarization was measured on an Analyst with suitable 485nm excitation and 535nm emission 
interference filters for FP. 
Assay in U2OS cells
To determine the repressive activity of GR ligands, cell line U2OS GR.G9, the human osteoblastic cell line U2OS, 
stably transfected with human GR, was used. Cells (104 cells/well) in Dulbecco’s MEM / HAM F12 medium sup-
plemented with 5% charcoal treated bovine calf serum (Hyclone) (v/v) and Penicillin (10 U/ml) -Streptomycin 
(10 µg/ml) were incubated in 384-wells plates, in the presence of 50 ng/ml TNFα (R&D systems) / 100 ng/ml 
IFNγ (Peprotech) and compound, for 18 hours in a humidified atmosphere at 37°C under 6.5% CO2. Hereafter, a 
mixture of 2.2 nM anti-hMCP-1 labeled with fluorescent donor Europium (Eu) and 16.6 nM anti-hMCP-1 labeled 
with fluorescent acceptor Allophycocyanin (APC) was added to each well and left at roomtemperature for 1 
hour. Finally, the time-resolved fluorometric resonance energy transfer (TR-FRET) signal was measured with the 
Victor2TM V, 1420 Multilabel Counter (Wallac). Using 4-parameter curve fitting, IC50 values for the compounds 
were determined. Besides IC50, also percentage maximal efficacy of each compound related to the maximal ef-
ficacy of the reference prednisolone was given. 
Assay in CHO cells
For monitoring both human steroid receptor agonistic as well as antagonistic activity of compounds, Chinese 
hamster ovary (CHO) K1 cells stably co-transfected with the specific human steroid receptor and its respective 
reporter construct were used (as previously described 45).
For human glucocorticoid receptor (GR)-specific activity CHO-GR B4.8 cells containing both recombinant human 
GR as well as a reporter construct consisting of the mouse mammary tumor virus (MMTV) promotor and the 
luciferase reporter gene, were used. Compound was incubated alone (in the agonistic setup) or with 50 nM 
dexamethasone (in the antagonistic setup) in microtiter white culture plates seeded with 2.4 x 104 cells / 200 µl 
Dulbecco’s MEM/Nutrient Mix F12 medium (Gibco) supplemented with 5% charcoal treated defined bovine calf 
serum supplement (DBCSS, Hyclone, Utah, USA), and 10 U/ml Penicillin-10µg/ml Streptomycin (GibcoBRL) over-
night at 37°C in the dark under a humidified atmosphere flushed with 5% CO2 in air. Hereafter, 200 µl medium 
was removed and 50 µl luciferine substrate solution from the LucLite luminescence kit (Packard, Meriden, USA) 
was added. After 10 minutes (when cell lysis was complete) luminescence of each sample was counted using a 
Topcount microplate luminescence counter. Percentage maximal agonistic efficacy was related to the maximal 
efficacy of dexamethasone. Percentage maximal antagonistic efficacy was related to the maximal antagonistic 
efficacy of reference GR antagonist Org 34116. EC50 value was calculated by 4-parameter curve fitting using the 
effect of 6 compound concentrations.
Similar procedures were followed for the other human steroid receptor assays containing combinations of hu-
man progesterone receptor B (PR-B) and MMTV-Luc, human androgen receptor (AR) and MMTV-Luc, human 
chimeric glucocorticoid-mineralocorticoid receptor (GGM, Trapp et al. (1994), Neuron 13: 1457) and MMTV-Luc, 
human estrogen receptor alpha (ERα) and rat oxytocin-Luc 45, and human estrogen receptor beta (ERβ) and rat 
oxytocin-Luc, respectively.
Gene expression profiling in HepG2 cells
HepG2-8/97-WS.5 cells were seeded at 2.105 cells/mL in a 24-well plate in DMEM/F12 medium (Gibco), supple-
mented with 80 U/mL penicillin, 80 µg/mL streptomycin and 5% Fetal Bovine Serum (Invitrogen). The following 
day, cells were washed once with PBS and medium was replaced by serum-free medium for 18 hours. Hereafter, 
cells were stimulated with glucocorticoid and 0.5 mM cAMP for 6 hours. RNA isolation was carried out by TRI-
ZOL (Invitrogen) treatment. To enhance the A260/A230 ratio, samples were cleaned using the RNeasy mini kit 
(Qiagen) with an additional DNase step on column to ensure DNA-free RNA. RNA quantity and quality were de-




termined using the Agilent Nanodrop bioanalyzer. For all samples subjected to micro-array hybridization, the RIN 
(RNA integrity number) was 9.0 – 10. Double-stranded cDNA was synthesized from 1.5 μg total RNA using the 
One-Cycle Target Labeling Kit (Affymetrix Santa Clara, CA), and used as a template for the preparation of biotin-
labeled cRNA using the GeneChip IVT Labeling Kit (Affymetrix Santa Clara, CA). Biotin-labeled cRNA was frag-
mented at 1 μg/μl following the manufacturer’s protocol. After fragmentation, cRNA (10μg) was hybridized at 
45°C for 16-17 hours to the Human Genome U133A 2.0 Array or the Human Genome U133 Plus 2.0 Array (Affym-
etrix, Santa Clara, CA). Following hybridization, the arrays were washed, stained with phycoerythrin-streptavidin 
conjugate (Molecular Probes, Eugene, OR), and the signals were amplified by staining the array with biotin-
labeled anti-streptavidin antibody (Vector Laboratories, Burlingame, CA) followed by phycoerythrin-streptavidin. 
The arrays were laser scanned with an GeneChip Scanner 3000 6G (Affymetrix, Santa Clara, CA) according to the 
manufacturer’s instructions. Data was saved as raw image file and quantified using GCOS (Affymetrix). 
For Q-PCR, cDNA was synthesized by the use of 1 µg RNA that was added to 1 µg of random primer (Promega) 
in a total volume of 15 µL, heated to 70 ºC for 10 min and cooled on ice. M-MLV reverse transcriptase (200 
units) (Promega), 10 nmol of each dNTP and RT buffer was added to a total volume of 25 µL and incubated for 
10 min at 22 ºC, 50 min at 55 ºC and 15 min at 75 ºC. cDNA samples were stored at -20 ºC. For Q-PCR, cDNA 
was diluted 125 times in milliQ and 5 µL was added to 12.5 µL of SYBR green mix (Applied Biosystems cat. No. 
4309155) , 2.5 µL of each primer (~20 ng/µl) and 2.5 µL of milliQ. The following primer-pairs were used: for 
GAPDH: 5’-CCACATCGCTCAGACACCAT-3’ and 5’-CCAGGCGCCCAATACG-3’; for PEPCK (of PCK1): 5’-TCCCATTGAA-
GGCATTATCTTTG-3’ and 5’-GCCAGCTGAGAGCTTCATAGACT-3’; for TAT: 5’-TACAGACCCTGAAGTTACCCAG-3’ and 
5’-TAAGAAGCAATCTCCTCCCGA-3’; for G6Pase (of: G6PC?): 5’-TGCTGCTCAAGGGACTG-3’ and 5’-GAATGGGAGC-
CACTTGCTG-3’. Quantitative PCR was performed on an ABI7900HT real time thermo cycler (Applied Biosystems) 
and results were analyzed by SDS2.1 software.
Gene expression profiling in THP-1 cells
THP-1 cells (106 cells/ml) were incubated with a single high dose (1 µM) of either prednisolone or Org 214007-0 
in the presence of either DMSO (control) or IFNγ/TNFα (220ng/ml / 375 ng/ml). After 6 hours (predetermined 
optimal time-point for maximal induction of most GR-regulated genes), total RNA was isolated and further pro-
cessed for micro-array hybridization as described before for the HepG2 cells. For a selection of the GC-regulated 
genes the expression profile was confirmed. In these experiments THP1 cells were stimulated with 40 ng/ml IFNγ 
and 60 ng/ml TNFα and a whole dose range of prednisolone and Org 214007-0 was tested. Expression of FKBP51, 
DUSP1 and GILZ was measured by Q-PCR according to the same procedure as described for the HepG2 cells. In 
this case the following primer-pairs were used: for GAPDH: 5’-CCACATCGCTCAGACACCAT-3’ and 5’-CCAGGCGC-
CCAATACG-3’; for FKBP51: 5’-AAAAGGCCAAGGAGCACAAC-3’ and 5’-TTGAGGAGGGGCCGAGTTC-3’; for DUSP1: 
5’-GTACATCAAGTCCATCTGAC-3’ and 5’-GGTTCTTCTAGGAGTAGACA-3’; for GILZ: 5’-AGTGCCTCCGGAGCCAGC-3’ 
and 5’-ATGATTCTTCACCAGATCC-3’. Expression of MCP-1, IL-6 and IL-8 was measured by specific AlphaLISAs 
(PerkingElmer; #AL244C [MCP-1], #AL223C [IL-6] and #AL224C [IL-8]) according to the manufacturer manual. 
Briefly, 5 μL of sample was added to 20 μL of a mix (freshly prepared) AlphaLISA Anti-Analyte Acceptor beads (10 
μg/mL final) and Biotinylated Antibody Anti-Analyte (1 nM final) into a 384-well white OptiPlate-384. Samples 
were incubated for 60 min at 23˚C. StreptAvidin-Donor beads (40 μg/mL final) were added and incubated for 
another 30 min at 23˚C in the dark. Plates were measured using an EnVision-Alpha Reader.
ChIP-SEQ analysis
Cells were fixed with 1% formaldehyde for 15 min and quenched with 0.125 M glycine. Chromatin was isolated 
by adding lysis buffer, followed by disruption with a Dounce homogenizer (cells) or motor pestle (tissue). Lysates 
were sonicated and the DNA sheared to an average length of 300-500 bp. Genomic DNA (Input) was prepared by 
treating aliquots of chromatin with RNase, proteinase K and heat for de-crosslinking, followed by ethanol pre-
cipitation. Pellets were resuspended and the resulting DNA was quantified on a NanoDrop spectrophotometer. 
Extrapolation to the original chromatin volume allowed quantitation of the total chromatin yield.
An aliquot of chromatin (28.5 ug) was precleared with protein A agarose beads (Invitrogen). Genomic DNA 
regions of interest were isolated using 4 ug antibody against GR (Santa Cruz sc-8992). Complexes were washed, 
eluted from the beads with SDS buffer, and subjected to RNase and proteinase K treatment. Crosslinks were re-
versed by incubation overnight at 65 C, and ChIP DNA was purified by phenol-chloroform extraction and ethanol 
precipitation.
Quantitative PCR (QPCR) reactions were carried out in triplicate on specific genomic regions using SYBR Green 
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Supermix (Bio-Rad). The resulting signals were normalized for primer efficiency by carrying out QPCR for each 
primer pair using Input DNA. ChIP and Input DNAs were prepared for amplification by converting overhangs into 
phosphorylated blunt ends and adding an adenine to the 3’ ends. Illumina adaptors were added and the library 
was size-selected (175-225 bp) on an agarose gel. The adaptor-ligated libraries were amplified for 18 cycles. The 
resulting amplified DNAs were purified, quantified, and tested by QPCR at the same specific genomic regions as 
the original ChIP DNA to assess quality of the amplification reactions. Amplified DNAs (DNA libraries) were sent 





Activity of Org 214007-0 for the other human steroid receptors, stably co-transfected with their respective reporter read-
outs in CHO cells. The data are expressed as the mean (±SD) of the relative agonistic or antagonistic activity as compared 





Org 214007-0, in comparison to prednisolone, partially induces expression of GC-regulated genes in the human HepG2 
cell line. HepG2 cells were incubated with either vehicle, Org 214007-0 or prednisolone for 6 hours. RNA was isolated and 
expression of tyrosine aminotransferase (TAT), glucose 6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase 
(PEPCK)  was quantified by Q-PCR, expressed as fold induction in comparison to vehicle treated cells.








The anti-inflammatory effect of Org 214007-0 is mediated through the glucocorticoid receptor. Mice were treated p.o. 
either with vehicle, Org 214007-0 (0.5, 1, 2 or 4 mg/kg) in a co-treatment schedule with either a vehicle or RU486 (50 mg/
kg) s.c. injection. TNFa was quantified 1.5 h after LPS challenge. Data is represented as mean ± SEM. An one way ANOVA 





Repressive activity of 10 µM Org 214007-0 in comparison to 10 µM prednisolone on cytokine release of human whole 
blood cells stimulated with LPS for 24 hours. The data are expressed as the mean percentage inhibition (±SD) by Org 
214007-0 compared to that by prednisolone (set at 100%);  n = number of experiments.
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Pharmacokinetic parameters of Org 214007-0 and prednisolone in mice 
For each time-point 3 female Balb/c mice are used. Tmax = Time of maximum observed concentration (in case of i.v. admin-
istration Tmax = 0 h); time is expressed in hours (h). Cmax = concentration corresponding to Tmax and expressed in nmol/
ml, for i.v. dosing Cmax is extrapolated to T=0. T 1/2 eli(mination) (terminal half-life) = ln(2)/λz expressed in h(ours). AUClast 
= Area under the curve from the time of dosing (Dosing-time) to the last measurable concentration. AUCinf = predicted 
Area Under the Curve from the time of dosing extrapolated to infinity and expressed in “h*nmol/ml”. Vz = Volume of dis-
tribution based on the terminal phase = Dose / λz* AUCinf and expressed inL/kg. Cl = total body clearance = Dose / AUCinf 
and expressed in L/h/kg. MRTinf = mean residence time (MRT) extrapolated to infinity for non-infusion models, expressed 
in h. Vss = gives an estimate of the volume of distribution at steady-state and is expressed in L/kg. F = % bioavailability; 
assuming linear kinetics, the % bioavailability after oral administration is calculated by dividing the AUCinf obtained after 
oral administration by the mean expected normalized AUCinf after i.v. administration of that dose (x 100%) (AUCiv = 100% 
by definition). The bioavailability is expressed in %. i.v. = intraveneously, p.o. = per oral.








Org 214007-0 significantly reduces all parameters scored by histological examination of the knee joints of CIA mice. At the 
end of the CIA study (after 3 weeks of daily oral treatment with equipotent dosages of  prednisolone and Org 214007-0) 
knee joints were fixed in 4%-buffered formaldehyde and decalcified. After decalcification the joints were washed, dehy-
drated and embedded in paraffin. Serial sections of at least 7 μm were stained by Hematoxylin-Eosin (for cellular infiltration 
and exudate formation into the joint space and bone apposition), or by toluindin blue staining (for proteoglycan depletion 
and cartilage and / or bone destruction of the joint). Org 214007-0, at 0.5 and 1.5 mg/kg, significantly reduced the forma-
tion of new bone (bone apposition), the infiltration of inflammatory cells in the joint cavity (exudate) or joint tissue (infil-
tration), cartilage destruction and proteoglycan depletion in the articular cartilage (PG depletion). Each of the histological 
parameters is scored at a scale of 0 – 3. Mean score of each group of mice (n=12) is indicated (± SEM). ** = significantly 
different from vehicle (p < 0.01; ANOVA-test). 
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Org 214007-0, at a dose that is equi-
efficacious to prednisolone, induces 
less fasting glucose. Mice (n=8 per 
group) were treated p.o., once daily, 
for 7 days with either vehicle (V), 10 
mg/kg prednisolone (P) or 1.5 mg/kg 
Org 214007-0 (O).  Blood glucose levels 
(mean ± SEM) were measured at day 
8, after 9 hours of fasting. ** p < 0.01: 
significantly different (Student’s t-test) 
from vehicle-treated group;  # p < 0.05 
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Prednisolone and other glucocorticoids (GCs) are potent anti-inflammatory drugs, but 
chronic use is hampered by metabolic side effects. Therefore, there is an urgent medi-
cal need for improved GCs that are as effective as classical GCs but have a better safety 
profile. A well-established model to assess anti-inflammatory efficacy is the chronic colla-
gen-induced arthritis (CIA) model in mice, a model with features resembling rheumatoid 
arthritis. Models to quantify undesired effects of glucocorticoids on glucose kinetics are 
less well-established. Recently, we have described a model to quantify basal blood glu-
cose kinetics using stably-labeled glucose. In the present study, we have used this blood 
glucose kinetic model in the CIA model treated with prednisolone to enable quantification 
of both efficacy and adverse effects in one animal model. Arthritis scores were decreased 
after treatment with prednisolone, confirming the anti-inflammatory properties of GCs. 
Insulin secretion and hepatic glucose production were increased, but this did not result 
immediately in hyperglycemia or insulin resistance, indicating a highly adaptive compen-
satory mechanism in these mice. In conclusion, this model allows for studying effects of 
(novel) GC compounds on the development of arthritis and glucose kinetics in a single 
animal. This integrative model provides a valuable tool for investigating (drug-induced) 
metabolic dysregulation in an inflammatory setting. In addition, the blood glucose kinetic 
model might also be useful in translational studies into metabolic side effects of GCs in 
RA patients. 





Prednisolone and other glucocorticoids (GCs) are very potent immunosuppressive and 
anti-inflammatory compounds that are among the top 10 most prescribed drugs 1. Ex-
ogenous GCs are used in daily clinical practice to treat (chronic) inflammatory, autoim-
mune and allergic disorders, to attenuate organ rejection after transplantation, to treat 
brain edema, shock and various blood cancers 2. Most of the effects of GCs are mediated 
through binding of GCs to the glucocorticoid receptor (GR), which is found in almost all 
human tissues. 
Although very effective in reducing inflammation, prolonged treatment at medium or high 
dose of GCs is hampered by a wide range of metabolic side effects such as derangements 
of glucose metabolism, induction of insulin-resistance, beta-cell dysfunction, hyperlipi-
demia, fat redistribution and central obesity leading to serious conditions that are strongly 
associated with elevated risk for cardiovascular disease and type 2 Diabetes in humans 3-5. 
The mechanisms of action underlying these metabolic side effects are largely unknown. 
Seen this wide range of GC-induced side effects, there is a high medical need for improved 
anti-inflammatory drugs that are as effective as classical GCs but show less metabolic side 
effects. This type of experimental compounds are often referred to as selective GR modu-
lators (SGRMs) 4. Given the complexity of glucocorticoid actions, the use of animal models 
is required to investigate these mechanisms and several models have been applied to 
study the efficacy and/or metabolic side effects of new pharmaceutical compounds in vivo 
6,7 . Preclinical efficacy of experimental GCs is often measured in collagen-induced arthritis 
(CIA) mice, an inflammatory model with features resembling rheumatoid arthritis (RA) 8,9. 
Arthritis can be induced in susceptible strains of mice by immunization with type II col-
lagen, the major component of articular cartilage, and has histopathologic and serological 
features in common with RA 10,11. 
Regarding in vivo investigation of (compound-induced) metabolic dysregulation such as 
insulin resistance, a number of methods have been developed to measure glucose and 
insulin kinetics, of which the hyperinsulinemic euglycemic clamp (HIEC) is considered as 
the ‘gold standard’. With respect to mice studies, the HIEC is difficult to use for longitudi-
nal studies, since it can only be performed once in a single animal 12. In addition, arthritic 
mice in the CIA model are severely ill,and therefore these mice can not be subjected to 
the invasive HIEC protocol. To overcome these drawbacks, a new method was developed 
in which stably-labeled glucose (D-[6,6-2H2]-glucose) is used in combination with a single-
pool, first order kinetic model to determine blood glucose kinetics 13. This model is espe-
cially of interest for longitudinal studies, due to the ability of repeated measurements. 
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An animal model to study both efficacy and glucocorticoid-induced metabolic side ef-
fects in an inflammatory setting is currently not available. Therefore, in the present study, 
we aim to develop an inflammatory model which can be used to investigate both effi-
cacy and metabolic safety of GCs in the same animal at the same time by performing the 
blood glucose kinetics in the CIA mice model. To validate this model and to investigate 
the mechanisms involved in GC-induced metabolic dysfunction in an inflammatory set-
ting, we performed two consecutive CIA experiments. First, we assessed the effects of 
several doses of prednisolone (0, 1.5, 10 and 30 mg/kg/day) on efficacy and metabolic 
safety after 0, 7 and 21 days of treatment. Secondly, in order to distinguish between GR-
mediated effects of prednisolone and indirect effects on glucose kinetics resulting from its 
anti-inflammatory efficacy, we compared effects of prednisolone to those of ORG 37663. 
This compound has previously been described to be effective for the treatment of arthritis 
in CIA mice 6, but did not mediate its effect through the GR. Comparing the results from 
the prednisolone-treated subgroup to the subgroup treated with the non-GR mediated 
anti-inflammatory compound ORG 37663 allowed us to distinguish between GR-mediated 
and non-GR-mediated effects. 
The results from this study revealed that it was possible to measure both efficacy and 
metabolic side effects of prednisolone in one experimental set-up, without affecting the 
severity of disease. Arthritis scores were decreased in arthritic mice after treatment with 
both prednisolone and ORG 37663. Concerning effects on glucose metabolism, there 
was a decrease in insulin sensitivity in both arthritic and non-arthritic control mice after 
treatment with prednisolone for three weeks, while ORG 37663 increased insulin sensitiv-
ity. These effects on insulin sensitivity were mainly due to increased insulin secretion in 
the prednisolone treated animals. The integration of the CIA model with the injection of 
D-[6,6-2H2]-glucose not only provides a valuable tool for both studying the efficacy and 
metabolic side-effects of experimental glucocorticoids at the same time in one model, but 
may prove a useful translational model for the metabolic side effects of GCs in patients 
suffering from RA or other (auto)immune diseases.
Methods
Animals
All experiments were approved by the Animal Welfare Committee of Merck, Oss, The 
Netherlands. Male DBA/1J mice were obtained from Bomholtgard (Ry, Denmark). Animals 
were housed and maintained at 23 °C with ad libitum access to water and food in a 12 




hour-12 hour light-dark cycle (lights on 6 am-6 pm).
Therapeutic murine collagen-induced arthritis
The murine CIA model was performed as previously described 14. In brief, DBA/1J mice 
were immunized at the base of the tail at the age of eight weeks with 200 μg bovine type 
II collagen in complete Freud’s adjuvant enriched with 2 mg/ml M. tuberculosis (H37Ra). 
Three weeks after immunization the animals were boosted with an intra-peritoneal injec-
tion of 200 μg collagen type II, dissolved in saline. The clinical severity of arthritis (arthritis 
score) was graded per inflamed digit (a scale of 0 to 2 for each paw). Mice were scored 
on alternative days, resulting in mean scores with an overall maximum of 8 per animal. To 
assess the effects of treatment, the area under curve (AUC) of the mean arthritis of each 
animal with baseline correction (subtracting baseline AUC of arthritis score on day 0) was 
used. After disease onset, animals with an arthritis score ranging from 2 to 4 were divided 
into separate groups of 12 mice so that the mean arthritis score of all experimental groups 
was comparable at the start of the treatment (day 0). Mice were considered to have ar-
thritis when significant changes in redness and/or swelling were noted in the digits or in 
other parts of the paws. 
Treatment and experimental regimes
For the first experiment, a total of 40 arthritic animals were divided into an experimental 
and a control group of 20 mice each. Both groups were orally treated once a day for 21 
days with placebo (0.5% gelatin and 5% mannitol in water) and arthritis development 
was monitored. In the experimental group (n=20) mice were subjected to a blood glucose 
kinetics test three times at (on day 0, 7 and 21) while mice in the control group were not 
subjected to the blood glucose kinetics tests. 
For the second experiment, arthritic animals were treated orally once a day for 21 days 
with either 1.5, 10 or 30 mg/kg prednisolone in vehicle (0.5% gelatin and 5% mannitol in 
water) or vehicle alone. In total, 48 arthritic mice (12 per treatment group) were included. 
For control groups, mice were mock immunized with saline at the base of the tail at the 
age of eight weeks and three weeks later mock boosted with saline. Mice were further 
treated according the same experimental protocol and handled exactly the same as the 
mice that developed arthritis. In this study, these mice are referred to as non-arthritic 
control mice.
For the third experiment, arthritic mice were treated orally once a day for 21 days either 
with prednisolone (10 mg/kg) or ORG 37663 (12 mg/kg) in vehicle (0.5% gelatin and 5% 
mannitol in water) or placebo alone. The dose of 12 mg/kg/day for ORG 37663 was se-
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lected because this dose is comparable to a dose of 10 mg/kg/day prednisolone regard-
ing efficacy. In total, 36 arthritic mice (12 per treatment group) and 36 control mice, like 
described above, were included in this consecutive experiment.
All experimental treatments were conducted in a blinded fashion. At the end of the exper-
iment, serum samples and hind knees and paws samples were obtained. Hind knees and 
paws were evaluated using X-ray analysis to assess bone destruction 15. X-ray photographs 
were examined with a Faxitron X-ray MX-20 (0.02 mm resolution) and bone destruction 
was scored on a scale from 0 to 5 ranging from no damage to complete destruction 16.
Blood glucose kinetics
The fasted blood glucose kinetic test was performed three times; at day 0 (before predni-
solone treatment, but after disease onset) and after 7 and 21 days of treatment. For each 
experiment, mice were fasted for 9 hours, body weights were measured and mice were 
injected intraperitoneally with a small volume of 2.0 mg D-[6,6-2H2]glucose in 0.20 ml by 
intraperitoneal injection (~450 µmol/kg BW) which did not cause changes in blood glucose 
and plasma insulin concentrations. Before and at 10, 20, 30, 40, 50, 60, 75 and 90 minutes 
after D-[6,6-2H2]-glucose administration, blood glucose concentrations were measured in 
a blood drop collected by tail tip bleeding using a glucocard X-meter (A. Menarini Diag-
nostics; Valkenswaard; The Netherlands). At the same time points, a small blood spot was 
taken on filter paper and stored at room temperature until further analysis of D-[6,6-2H2]-
glucose label distribution. After the test blood samples were taken by tail tip bleeding for 
C-peptide measurements. 
Measurements of mass isotopomer distribution by GC-MS
Whole body glucose turnover and clearance were calculated by kinetic analysis from the 
wash-out of injected D-[6,6-2H2]-glucose from circulation. The blood spots on filter paper 
were used for this. Extraction of glucose from filter paper, derivatization of the extracted 
compounds and gas chromatography-mass spectrometry (GC-MS) measurements of the 
blood were performed as previously described by Van Dijk and colleagues 17. In short, a 
disk was punched out of the blood spots, glucose was extracted from the disk by incubat-
ing it in ethanol/water (10:1 v/v) and glucose was derivatized to its pentaacetate-ester. 
Samples were analyzed by GC-MS with positive ion chemical ionization with ammonia. 
The fractional isotopomer distribution measured by GC-MS (m0-m6) was corrected for the 
fractional distribution due to natural abundance of 13C by multiple linear regression as 
described by Lee et al. 18 to obtain the excess fractional distribution of mass isotopomers 
(M0-M6) due to dilution of infused labeled compounds. 




Calculation of blood glucose kinetics
For calculating the blood glucose kinetics parameters EGP (Endogenous Glucose Produc-
tion) and MCR (Metabolic Clearance Rate), a single-pool, first-order kinetic model was 
assumed 19-21. The excess fractional distribution of mass isotopomers (M2)was used to cal-
culate the first order absorption process in an one-compartment model using SAAM-II 
software (version 1.2.1; SAAM Institute, University of Washington, Seattle, WA, USA 22. 
The formulas used to calculate the concentration vs. time curves and the kinetic param-
eters are outlined in Table 1.
C-peptide measurements 
In this study we measured C-peptide concentrations as a marker for insulin production, 
since the half-life of C-peptide is longer when compared to the half-life of insulin. Pe-





The formulas used to calculate the concentration vs. time curves and the kinetic parameters in a first order absorption 
process in an one-compartment model. 
Ct, D-[6,6-
2H]-glucose concentration at time point t; Mt, fractional contribution of D-[6,6-
2H]-glucose at time point t; [glc]t, 
blood glucose concentration at time point t. C(0)ab, initial concentration of D-[6,6-2H]-glucose determined by extrapolation 
of the absorption period; C(0)el, initial concentration of D-[6,6-2H]-glucose determined by extrapolation of the elimination 
period; kab, absorption rate constant; kel, absorption rate constant. D, dose D-[6,6-2H]-glucose administrated; BG, average 
blood glucose concentration during the test; Ra = EGP
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retrieved serum samples were stored at -20 °C until analyzed. C-peptide concentrations 
were measured using a commercially available ELISA kit (mouse C-peptide ELISA; Alpco 
immunoassays, Salem, NH, USA). 
Calculation of HOMA-IR
The Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) model combines 
fasting glucose and insulin concentrations to calculate insulin resistance 23. Besides us-
ing insulin, it is also possible to calculate the HOMA-IR using C-peptide concentrations 
Wallace 2004. The HOMA-IR expresses changes in insulin sensitivity and β-cell function 
relative to a population in which these parameters are considered to be normal. In this 
study, we assume that that the group of healthy mice, treated with placebo, had an insulin 
resistance (IR) of 1 (no insulin resistance). This group is used as the reference group. The 
reference value can be calculated from median blood glucose concentration (6.6 mM) 
during the blood glucose kinetics protocol and the median plasma C-peptide concentra-





In which [Glu] is the blood glucose concentration in mM and [C-peptide] is the C-peptide 
plasma concentration in pM. An HOMA-IR > 1 indicates induction of insulin resistance and 
an HOMA-IR < 1 indicates improved insulin sensitivity. 
Statistical analysis
All data are represented as mean ± SD except for the arthritis data which is represented 
as mean ± SEM. Data were analyzed using, where appropriate, the Student’s t-test or 
ANOVA followed by the Tukey post hoc test (SPSS, Chicago, IL, USA). A p-value <0.05 was 
considered significant. 
Results
The blood glucose kinetics test does not interfere with arthritis development
Before reliable statements could be made regarding prednisolone-induced effects on ar-
thritis development and glucose kinetics in mice, we wanted to confirm that the blood 
glucose kinetics protocol itself did not influence arthritis development. Therefore, we first 
investigated if performing this protocol three times in arthritic mice would affect arthritis 
development. Figure 1 shows that a triple blood glucose kinetic test in three weeks did not 
affect AUC of arthritis scores and X-ray scores in the CIA mouse model. 




Assessing both the effects of arthritis development and prednisolone treatment on 
glucose kinetics 
Blood glucose kinetics were used to assess both arthritis-induced and prednisolone-in-
duced metabolic dysfunction and was performed three times: at day 0 (before predni-
solone treatment) and after 7 and 21 days of treatment. Bodyweights were significantly 
lower in arthritic mice when compared to non-arthritic mice (p=0.0011) (Fig. 2A). This de-
crease in bodyweight is caused by the active inflammatory state of these arthritic mice as 
was previously reported 24. Even though arthritic mice have lower bodyweights compared 
to control mice, treatment with several doses of prednisolone for 21 days did not have any 
effect on bodyweight in both groups (Fig. 2A). 
Prednisolone treatment induced apoptosis of thymocytes, thereby severely reducing 
thymus weight dose-dependently 25. No differences in thymus weight were observed be-
tween arthritic and non-arthritic mice. Treatment with 1.5, 10 and 30 mg/kg prednisolone 
per day reduced thymus weight respectively with 68%, 80% and 89% in the non-arthritic 
control group and with 70%, 81% and 85% in the arthritic group (Fig. 2B). These reduc-
tions are indicative for sufficient prednisolone exposure in these treatment groups.
To confirm the anti-arthritic properties of prednisolone, arthritic mice were monitored for 
arthritis score and X-ray score. Prednisolone dose-dependently reduced disease severity 
since a significant reduction of the AUC arthritis score covering the entire treatment pe-
riod was observed (Fig. 2C). X-ray analysis of the arthritic joints indicate severe cartilage 
and bone destruction in the placebo-treated arthritic animals. In line with previous results 
6, prednisolone significantly reduced the rate of cartilage and bone destruction in a dose-
dependent manner (p=0.0029) (Fig. 2D). As expected, the control mice that were mock 
immunized with saline and three weeks later mock boosted with saline, did not develop 
arthritis.
No differences were observed in blood glucose concentrations between arthritic and non-
arthritic mice treated with placebo for 21 days (p=0.1050) (Fig. 3A). A small but signifi-
Arthritis development
Arthritis development in mice sub-
jected to blood glucose kinetics three 
times and in mice in which no experi-
ments were performed. A, AUC of the 
overall arthritis score after 21 days. B, 
X-ray analysis to assess bone destruc-
tion. Results are presented as mean ± 
SEM (n=20). No significant differences 
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cant dose-dependent decrease in blood glucose concentrations was observed after three 
weeks of prednisolone treatment in both non-arthritic and arthritic mice (resp. p=0.0064 
and p=0.0012) (Fig. 3A). 
The glucose kinetics parameters MCR (Metabolic Clearance Rate) and EGP (Endogenous 
Glucose Production) were calculated by modeling the wash-out of injected D-[6,6-2H2]-
glucose. EGP was not different between arthritic and non-arthritic mice (p=0.2429) before 
treatment. A trend towards a decreased EGP was observed after 7 days of prednisolone 
treatment (Table 2). After 21 days of treatment, prednisolone-treatment slightly but sig-
nificant decreased EGP both in non-arthritic (p=0.006) and arthritic mice (p=0.0007) (Fig. 
3C). MCR showed to be increased in placebo-treated arthritic mice (p=0.0004) when com-
pared to non-arthritic placebo-treated mice but no differences were observed in MCR 
between the prednisolone treatment groups in both non-arthritic and arthritic mice after 
three weeks of treatment (Fig. 3B). Interestingly, even though no effects were seen upon 
three weeks of prednisolone treatment between the groups, MCR is lowered in both the 









Effects of prednisolone on bodyweight, thymus weight and arthritis development after 21 days of treatment
A, Bodyweight B, thymus weight C, AUC of the overall arthritis score D, X-ray analysis to assess bone destruction. Results 
are represented as means ± SD for bodyweight and thymus weight and as mean ±SEM for AUC arthritis score and X-ray 
score and are outlined for each experimental group (n=12). * Significant difference p≤0.05, ** significant difference p≤0.01, 
*** significant difference p≤0.001
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Surprisingly, after three weeks of treatment, plasma C-peptide concentrations of placebo 
treated arthritic mice were significant lower than those of placebo-treated non-arthritic 
mice (p=0.0006) (Fig. 3D). C-peptide concentrations were strongly increased in a dose-
dependent manner by prednisolone in both non-arthritic and arthritic mice, implying in-
creased plasma insulin concentrations. This effect of prednisolone on plasma C-peptide 
concentrations was already observed after one week of treatment (data not shown).
From the fasting blood glucose and C-peptide concentrations, the HOMA-IR was calcu-
lated to evaluate insulin resistance. Remarkably, the HOMA-IR (Fig. 3E) suggests that pla-
cebo-treated arthritic mice are 2.3-2.5 times more insulin sensitive than placebo-treated 
non-arthritic animals. This decrease in HOMA-IR is the direct result of the low C-peptide 
concentrations as measured in the placebo-treated arthritic mice. According to the HO-
MA-IR data, prednisolone treatment reduced insulin sensitivity according to HOMA-IR in 










Effects of prednisolone on glucose kinetics after 21 days of 
treatment
A, Blood glucose concentrations B, EGP levels C, MCR D, C-
peptide concentrations E, C-peptide HOMA-IR. Results rep-
resent means ± SD and are outlined for each experimental 
group (n=12). * Significant difference p≤0.05, ** significant 
difference p≤0.01, *** significant difference p≤0.001




After treatment with prednisolone (30 mg/kg/d) for 21 days, both groups were equally 
resistant to insulin (Fig. 3E).
Assessing the effects of ORG 37663 treatment on glucose kinetics
To be able to distinguish between GR-mediated and non-GR-mediated effects, we per-
formed a second experiment in which non-arthritic and arthritic mice were treated with 
ORG 37663. This compound is a steroid that was previously shown to have anti-inflamma-
tory properties and effectively reduces arthritis in the CIA model. ORG 37663 mediates its 
effects through a mechanism that is independent of GR binding 6. Therefore, ORG 37663 
was used in a head-to-head comparison to prednisolone in one experiment to study to 
what extent effects of prednisolone on glucose kinetics are due to its anti-inflammatory 
properties or due to a direct effect through GR. 
Similar to the first experiment, bodyweights were significantly lower in arthritic mice com-
pared to non-arthritic mice (p=0.0001) (Fig. 4A). Non-arthritic mice showed to have lower 









Effects of ORG 37663 and prednisolone on bodyweight, thymus weight and arthritis development after 21 days of treat-
ment
 
A, Bodyweight B, thymus weight C, AUC of the overall arthritis score D, X-ray analysis to assess bone destruction. Results 
are represented as means ± SD for bodyweight and thymus weight and as mean ±SEM for AUC arthritis score and X-ray 
score and are outlined for each experimental group (n=12). * Significant difference p≤0.05, ** significant difference p≤0.01, 
*** significant difference p≤0.001
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4A). No differences in thymus weight were observed between arthritic and non-arthritic 
mice. In the non-arthritic control group treatment with 10 mg/kg prednisolone or 12 mg/
kg ORG 37663 per day reduced thymus weight respectively with 84% and 78% (Fig. 4B). 
In the arthritic group thymus weight was reduced with 86% and 76%, again indicative for 
sufficient compound exposure. In the arthritic mice, both arthritic score and X-ray score 
were significantly decreased (p<0.0001 and p=0.0279 respectively) after treatment with 
either prednisolone or ORG 37663 (Fig. 4C-D).
Arthritic mice showed slight but significant lower blood glucose concentrations after ORG 
37663 treatment (p=0.036) (Fig. 5A). In the non-arthritic mice no statistical difference in 
blood glucose concentrations were detected between the treatments (Fig. 5A). Yet, EGP 
was decreased after treatment with either prednisolone or ORG 37663 in non-arthritic 
mice (p=0.0003), while in arthritic mice, a trend towards decreased EGP levels after both 










Effects of ORG 37663 and prednisolone on glucose kinetics 
after 21 days of treatment. 
A, Blood glucose concentrations B, EGP levels C, MCR D, C-
peptide concentrations and E, C-peptide HOMA-IR. Results 
represent means ± SD and are outlined for each experimen-
tal group (n=12). * Significant difference p≤0.05, ** signifi-
cant difference p≤0.01, *** significant difference p≤0.001




37663 both had a lower MCR compared to placebo treated mice (p<0.0001), while this 
effect was not observed in the arthritic mice after treatment (Fig. 5B). As was observed in 
the prednisolone dose-response experiment, C-peptide concentrations from arthritic mice 
treated with placebo were significant lower compared to the non-arthritic mice treated 
with placebo after three weeks of treatment (Fig. 5D). The ORG 37663 compound caused 
a major decrease in C-peptide concentrations in both non-arthritic mice (p<0.0001) and 
arthritic mice (p<0.05) (Fig. 5D). As a consequence of the low C-peptide concentrations 
after treatment with ORG 37663, both arthritic and non-arthritic mice showed a tremen-
dous increase in insulin sensitivity as calculated by the HOMA-IR (Fig. 5E). These data 
indicate that treatment with ORG 37663 improved insulin sensitivity in mice.
Discussion
There is an urgent need for improved GCs that are as effective as classical GCs, but have a 
better safety profile. However, an in vivo inflammatory model in which (experimental) GCs 
can be studied for both their effectiveness and the induction of metabolic side effects is 
currently unavailable. Goal of the present study was to develop such an in vivo inflamma-
tory model for metabolic adverse effects. Therefore we have integrated a single-pool, first 
order kinetic protocol to examine blood glucose kinetics, in the well-established collagen-
induced arthritis (CIA) mice model, an inflammatory model which is often used to monitor 
efficacy of experimental anti-inflammatory compounds. In general, trends in effects of 
prednisolone on glucose kinetics were similar in both arthritic mice and in the non-ar-
thritic control group. Also the effects of ORG 37663, a non-GR mediated compound, were 
similar in both arthritic and non-arthritic groups. This indicates that the arthritic state of 
the animals does not interfere or changes the effect of prednisolone on glucose kinetics. 
Importantly, this also indicates that we have successfully performed blood glucose kinet-
ics in the CIA model enabling the quantification of both efficacy and adverse effects on 
glucose metabolism in one animal.
This study showed that prednisolone decreased disease severity and joint destruction in 
arthritic mice, thereby confirming the anti-inflammatory properties of this compound. Re-
garding the induction of metabolic effects, prednisolone slightly decreased fasted glucose 
concentrations and EGP, but strongly increased insulin production (as measured by the 
increase in C-peptide concentrations) at the same time in both non-arthritic and arthritic 
mice. This resulted in an increased HOMA-IR after prednisolone treatment, indicating the 
induction of insulin resistance. The additive value of the applied blood glucose kinetic 
model, i.e., the injection of D-[6,6-2H2]-glucose, is that this allowed for discrimination of 
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the changes in glucose metabolism in peripheral tissues and the liver since the MCR re-
flects peripheral glucose metabolism and EGP (can be regarded as hepatic glucose pro-
duction in fasted conditions) reflects hepatic glucose metabolism. To our knowledge, no 
animal model was previously described which enables quantification of both anti-arthritic 
efficacy and longitudinal tissue-specific metabolic adverse effects in one animal in one 
chronic treatment protocol. In the field of GCs and the search for compounds with im-
proved efficacy/safety profiles (SGRMs), such a model would potentially be of great value 
since it closely mimics the clinical RA practice. 
The ‘gold standard’ to investigate and quantify insulin resistance is the hyperinsulinemic 
euglycemic clamp (HIEC) 26. However, seen from the perspective of laboratory animal 
welfare, performing such clamp studies within an inflammatory mice model such as the 
CIA model is impossible. Measuring glucose kinetics by modeling the wash-out of ip in-
jected D-[6,6-2H2]-glucose is performed under fasted conditions whereas the HIEC utilizes 
steady-state insulin concentrations that are supraphysiological 13,27. Thus, the wash-out of 
ip-injected glucose presumably reflects a more physiological relevant situation. In addi-
tion, unlike the HIEC the blood glucose kinetics can be applied repeatedly and is therefore 
applicable in longitudinal studies, such as the CIA model described here.
GCs are well known to reduce insulin sensitivity and induce β-cell dysfunction. In line 
with our results, several studies reported increased insulin secretion in both wild-type 
rodents 28 and healthy humans 29,30 after prolonged exposure to GCs. Also in RA patients 
an association between the use of GCs and decreased insulin sensitivity was reported 31. 
To compensate for this insulin resistance, the pancreatic islets enhance their cell mass and 
insulin secretion. However, when the functionally expansion of islet β-cells fails to com-
pensate for the degree of insulin resistance, insulin deficiency and ultimately GC-induced 
diabetes will develop. Both the non-arthritic and arthritic mice in this study were, after 21 
days of prednisolone treatment, still able to compensate for their prednisolone-induced 
insulin resistance, resulting in no effects on blood glucose concentrations. Most likely, the 
treatment period (3 weeks) in this combined model is too short to study a next stage in 
the development of diabetes, i.e., hyperglycemia and beta-cell dysfunction. Further stud-
ies will be needed to challenge this.
Both non-arthritic and arthritic mice were included in this study in order to distinguish be-
tween inflammation-induced and GC-induced metabolic dysfunction. Our results showed 
that arthritic mice produce less C-peptide than non-arthritic mice after treatment with 
placebo. This discrepancy in C-peptide production is probably due to differences in pro-
inflammatory cytokine levels between healthy and arthritic mice. It is known that arthritic 
mice have elevated circulating levels of the pro-inflammatory cytokines TNFα and IL-1β 14. 




Impaired function and cell death of both human and rodent β-cells after exposure to TNFα 
and IL-1β is well established 32-36. Several potential mechanisms have been suggested for 
these effects including activation of MAP kinases, c-jun N-terminal kinase, p38, ERK, NF-κB 
and altered gene expression 36. Recently, Muayed and co-workers reported reduced insu-
lin secretion in murine and rat islet cells after TNFα and IL-1β mediated down regulation 
of ZnT8, a zinc transporter important for normal β-cell physiology 37. Nonetheless, based 
upon the unchanged glucose concentrations, the untreated arthritic mice in our study 
were still able to compensate for the inflammation-induced reduction of insulin secretion. 
Both highly arthritic mice and mice treated with a high dose of prednisolone are able to 
compensate for reduced insulin secretion and/or reduced insulin sensitivity by keeping 
the MCR steady and even reduce EGP, which indicates a highly adaptive compensatory 
mechanism in these mice. It stresses the fact that cytokines such as TNFα and IL-1β or 
glucocorticoids do not operate in isolation but in a complex network of potentiating and 
inhibiting metabolic, inflammatory and endocrine modulating phenotypic outcome.
To be able to study to what extent effects of prednisolone on glucose kinetics are due to 
its anti-inflammatory properties or due to a direct effect through GR, mice were also treat-
ed with ORG 37663 and directly compared to prednisolone. ORG 37663 mediates its ef-
fects through a mechanism that is independent of GR binding. Treatment with ORG 37663 
resulted in lower C-peptide concentrations when compared to prednisolone treatment in 
both non-arthritic and arthritic mice. This indicates that prednisolone mediates its effects 
on insulin secretion directly via GR and not via indirect anti-inflammatory effects. 
To conclude, we successfully integrated the whole body glucose test in the CIA mice mod-
el, which enabled us to measure both efficacy and metabolic adverse effects of (experi-
mental) GCs in an in vivo inflammatory setting. Thereby, it may prove a useful translational 
model for GC-induced metabolic derangements in patients suffering from RA or other 
(auto)immune diseases. This study showed that both inflammation and glucocorticoids 
affect insulin secretion and sensitivity but this did not lead immediately to the develop-
ment of hyperglycemia and type 2 Diabetes Mellitus. This emphasizes the highly adap-
tive character of these mice and the complex network of several integrated mechanisms 
underlying the development of GC-induced and/or inflammation-induced metabolic dys-
function.
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Synthetic glucocorticoids, such as prednisolone, are potent anti-inflammatory drugs. 
Their use, however, is limited by the severe side effects they may induce. Many of the side 
effects resemble features of the metabolic syndrome, such as weight gain, insulin resist-
ance and dyslipidemia. Glucocorticoids act via the glucocorticoid receptor (GR) either in a 
dimeric or monomeric manner. In order to segregate monomeric from dimeric GR effects 
on dyslipidemia, we treated GRdim mice, that carry a mutation in the dimerization loop 
of the DNA binding domain, with prednisolone for six days. This treatment did not influ-
ence fasting glucose levels in GRdim mice, but strongly increased plasma triglyceride and 
cholesterol levels. This was already apparent after one day of treatment. Prednisolone 
treatment resulted in a dramatic 9-12 fold increase of triglycerides and free cholesterol in 
the VLDL-sized lipoprotein fractions of prednisolone-treated GRdim mice. Surprisingly, he-
patic cholesterol(ester) content did not change. The unusual lipid profile was not caused 
by cholestasis as plasma bile acid concentration did not increase. Hepatic gene expression 
levels of lipoprotein lipase (Lpl) were 23 times induced, but when plasma LPL activity was 
blocked, there was only a slight increase in VLDL-TG production. In conclusion, this study 
shows that prednisolone treatment in GRdim mice leads to formation of an atypical VLDL 
particle containing high levels of triglyceride, phospholipids and free cholesterol. These 
results indicate an important role of monomeric GR in regulation of lipid metabolism and 
this may contribute to unravelling the mechanisms underlying glucocortoid-induced side 
effects.





Synthetic glucocorticoids (GCs) are worldwide the most prescribed drugs for auto-immune 
disorders, such as inflammatory bowel disease, asthma and rheumatoid arthritis, because 
of their potent action to reduce inflammation 1. However, their use is limited by the many 
adverse effects they induce such as osteoporosis, insomnia, depression, insulin resistance, 
weight gain and dyslipidemia 2,3. Interestingly, the latter three are also components of the 
metabolic syndrome, a cluster of metabolically related factors that together increase the 
risk for cardiovascular disease and Diabetes Mellitus type II 4. 
GCs act via the glucocorticoids receptor (GR), a member of the nuclear receptor family 
5,6 which is ubiquitously expressed. In the cytoplasm of a target cell GCs bind to the GR, 
upon which the GR can be imported into the nucleus. Once in the nucleus the GR requires 
homodimerization to bind to glucocorticoid response elements (GRE) of target genes on 
the DNA, a process called transactivation. Ligand-activated GR can also reside within the 
cytoplasm, where it can monomerically interact with other proteins, like PI3K and JNK, to 
interfere in the inflammation response 7,8. Another monomeric action of GR takes place 
inside the nucleus, by binding of GR monomers to pro-inflammatory transcription factors, 
such as NF-κB and AP-1 9,10 causing transrepression. The ability to dissociate the transac-
tivating effects from transrepression was shown in vitro 11. Development of GRdim mouse 
that carry a point mutation in the dimerization interface of the DNA binding domain re-
sulting in a defective dimerization domain 12, allowed for the discrimination between mo-
nomeric and dimeric effects of the GR in vivo 13. 
In particular GRdim mice were still able to exert certain GC-induced anti-inflammatory re-
sponses, like AP-114 and NF-κB 15 thereby being able to prevent irritant skin inflammation, 
showing that these anti-inflammatory properties of GCs are acting via GR monomers. 
However, not all anti-inflammatory properties of GCs were preserved in GRdim mice, since 
in GRdim mice GCs do not prevent contact hypersensitivity 16, or prevent LPS-induced sepsis 
(Kleyman et al. FASEB J in press) 13 or arthritis (Baschant et al. PNAS in press). Traditionally 
dimerization-induced gene expression was attributed to side effects, due to GR dimer-in-
duced gene expression for instance 17. Interestingly, GCs still induced osteoporosis in GRdim 
mice 18, whereas metabolic side effects have been poorly investigated so far. A micro-array 
study on mRNA expression in livers of prednisolone-treated WT and GRdim mice revealed 
a clear dissociation of direct and indirect GR target genes 17, however there were no dif-
ferences between vehicle-treated WT and GRdim mice in gene-expression patterns. Upon 
prednisolone-treatment ~500 probe sets were significant regulated in WT mice, while 
only 34 probe sets were regulated in GRdim mice, showing that the effects of the GRdim 
mutation only become apparent upon stimulation with a GR ligand. 
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In Cushing’s syndrome, i.e., excess of either endogenous GCs or exogenous GCs, hepatic 
fat accumulation has been shown 19,20 and dyslipidemia has repeatedly been reported as 
an adverse effect of GC treatment 21,22. Moreover, Lemke et al. revealed that hepatic GR 
controls expression of genes involved in fatty acid oxidation and lipolysis pathway and 
that dyslipidemia in db/db mice can be reversed by deleting hepatic GR 23. The micro-array 
study of Frijters et al. 17 showed that genes involved in lipid and glucose metabolism were 
among the differentially regulated gene sets. We therefore hypothesized that the adverse 
effects on lipid and glucose metabolism caused by chronic prednisolone treatment should 
be abolished in GRdim mice. In the current study we assessed the effects of prednisolone 
treatment in GRdim mice on lipid metabolism. Surprisingly, prednisolone treatment led to 
excessive dyslipidemia in GRdim mice.
Materials and methods
Animals and treatment
Female GRdim mice 12 on a BALB/c background and their wild type littermates (n=5-7) were 
housed at the Leibniz Institute for Age Research, Fritz Lipmann Institute, Jena, Germany or 
transported to the animal facility of the University Medical Center Groningen and housed 
under IVC conditions, in a 12 hour-12 hour light-dark cycle (lights on 7 am-7 pm). The 
mice had free access to water and a standard laboratory chow (RMH-B, Abdiets, Woerden, 
The Netherlands). Female mice of 3 months were continuously treated with prednisolone 
for 7 days by subcutaneous implantation of slow-release pellets, resulting in a calculated 
dose of 12.5 mg/kg/day (15 mg; 60 day release; Innovative Research of America Inc.). All 
experiments were approved by the Ethics Committee for Animal Experiments of the State 
University Groningen and with permission of the responsible authorities of Thüringen.
Plasma lipid and lipoprotein analysis
Before and during prednisolone treatment orbital blood samples were taken from 4-hour 
fasted mice, plasma was separated and samples were stored at -20 ˚C for plasma lipid 
analysis. Plasma triglycerides and total cholesterol was measured by commercially availa-
ble kits (Roche/Hitachi, Roche Diagnostics-GmbH, Mannheim). Plasma phospholipids, free 
cholesterol and non-esterified fatty acids were measured by commercially available kits 
from Diasys (Diagnostic Systems-GmbH, Holzheim, Germany). Plasma lipoproteins from 
pooled plasma samples were separated using fast protein liquid chromatography (FPLC) 
on a Superose 6 column (GE Healthcare, Uppsala, Sweden) 24. In the resulting fractions 
triglycerides, total and free cholesterol and phospholipids were analyzed as described 




above. From the FPLC fractions Apolipoprotein (Apo)A and ApoB were analyzed by west-
ern blot analysis from (Meridian) and (Calbiochem), respectively. The VLDL core:surface 
ratio was calculated by the sum of triglycerides and cholesterylesters (core) from the FPLC 
fractions 8-15 divided by the sum of free cholesterol and phospholipids (surface) of these 
fractions. Hepatic lipids were extracted from the liver homogenates according to Bligh and 
Dyer 25 and measured using similar kits for plasma lipid analysis.
VLDL production
A separate group of mice were fasted for 4 hours and injected intraperitoneally with Polox-
amer 407 (1g/kg BW) dissolved in saline as previously described 26. Orbital blood samples 
were taken at time points 0h, 1h, 2h, 3h and 4 hours after injection from which plasma was 
separated and stored at -20 ˚C until analysis of triglyceride content as described above. 
VLDL-TG production rate was calculated from the slope of the TG concentration vs. time 
curve from the last 2 hours, corrected for amount of plasma/kg bodyweight.
Bile cannulation
After 7 days of prednisolone or vehicle treatment mice were subjected to bile cannula-
tion. Mice were anaesthetized by an ip injection of Hypnorm (1mL/kg) (fentanylcitrate 
0.315 mg/mL and fluanisone 10 mg/mL, VetaPharma, Leeds, UK) and diazepam (10 mg/
kg) (Centrafarm, Etten-Leur, The Netherlands). The gallbladder was cannulated as de-
scribed previously 27. For correct measurements, bile of the first 5 min was discarded after 
which bile was collected for 30 minutes, during which mice were placed in a humidified 
incubator to maintain body temperature. Bile flow was determined gravimetrically, as-
suming a density of 1 g/ml for bile. The collected bile was analyzed for bile acid profile, 
cholesterol and phospholipid content as previously described 28.
Gene expression
For analysis of hepatic gene expression, hepatic RNA was isolated from snap frozen, 
crushed livers using the TriReagent method (Sigma, St. Louis, MO, USA) according to man-
ufactures protocol. Using a Nanodrop spectrophotometer the integrity and concentra-
tion of RNA was determined (NanoDropTM 1000 Spectrophotometer, Thermo Scientific, 
Waltham, MA). cDNA was obtained using the reverse transcription procedure with Molo-
ney murine leukemia virus-RT (Roche Diagnostics, Mannheim, Germany; Greiner BioOne, 
Alphen a-d Rijn, The Netherlands) with random primers according to manufactures proto-
col. cDNA levels were measured in real-time quantitative PCR amplification using an ABI 
PRISM 7700 sequence detector (Applied biosystems, Foster City, USA) against a calibra-
tion curve of pooled cDNA solutions. Expression levels were normalized for Rplp0 (ribo-
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somal protein, large, P0 (36b4)). The sequence of all primers and probes are deposited at 
RTPrimerDB (http://www.rtprimerdb.org).
Statistics
All data are represented as mean ± SEM. Statistical analysis for multiple comparison were 
performed by Kruskal-Wallis test, followed for two independent groups by Mann-Whit-
ney-U tested, corrected for multiple testing, using SPSS for Windows software (SPSS, Chi-
cago, IL, USA). Significance was considered at a level of p<0.05. 
Results
GRdim mice are hypersensitive for prednisolone-induced dyslipidemia
At baseline, all mice had similar bodyweights (Table 1). Seven days of prednisolone treat-
ment reduced bodyweight in WT mice compared to baseline by almost 10% (Table 1), 
while in GRdim mice prednisolone-treatment did not alter bodyweight. Yet, food intake 
was similar in all groups. Prednisolone treatment had no effect on fasting plasma glucose 
levels in either WT or GRdim mice. However, fasting insulin levels were drastically increased 
by prednisolone treatment in WT mice almost 9-fold, suggestive for insulin resistance, 





Plasma parameters of vehicle or prednisolone-treated WT and GRdim mice
* p  <0.05 ctrl vs prednisolone; # p <0.05 between genotype .




a modest 2-fold increase. At baseline, GRdim mice had slightly elevated plasma levels of 
triglycerides, cholesterol and non-esterified free fatty acids (NEFA). Surprisingly, predni-
solone treatment strongly increased plasma lipids in GRdim mice; total plasma cholesterol 
were increased 2-fold, triglycerides as much as 8-fold compared to untreated GRdim mice. 
In WT mice prednisolone treatment increased plasma lipid levels to a considerably lesser 
extent (Table 1). 
In order to determine the effect of prednisolone on lipoprotein distribution, plasma sam-
ples from untreated and 7-days prednisolone-treated WT and GRdim mice were pooled and 
fractionated by fast protein liquid chromatography (FPLC). Separation of plasma lipopro-
teins revealed that the majority of triglycerides in prednisolone-treated GRdim mice, was 
present in the VLDL-sized fractions. In contrast, prednisolone treatment in WT mice ap-
peared to reduce TG in the VLDL-sized fractions (Fig. 1A). In addition, phospholipid levels 










Plasma lipoprotein profiles 
A, triglycerides B, phospholipids C, total cholesterol D, 
free cholesterol and E, and cholesterylesters separated by 
fast protein liquid chromatography (FPLC) of control (open 
symbols) WT (black) and GRdim (grey) mice and prednisolone 
(closed symbols) treated mice. The signs above indicate the 
very low density lipoprotein (VLDL), low density lipoprotein 
(LDL) and high density lipoprotein (LDL) sized fractions.
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while in WT mice most of the phospholipids were present in the HDL-sized fractions (Fig. 
1B). In WT mice, prednisolone slightly increased phospholipid levels in the HDL-sized frac-
tions. Total cholesterol levels revealed a similar pattern, i.e., high total cholesterol levels 
in the VLDL-sized fractions of prednisolone-treated GRdim mice versus a slightly increased 
total cholesterol level in prednisolone-treated WT mice (Fig. 1C). Cholesterol in the VLDL-
sized fractions of prednisolone-treated GRdim mice was mainly in its free form (Fig. 1D), 
while there was an increase in cholesterylesters (Fig. 1E) in the HDL-sized fractions of 
prednisolone-treated WT mice. In the prednisolone-treated GRdim mice the peak of cho-











Plasma lipoprotein profiles of total cholesterol, free cholesterol, and cholesterylesters
A, total cholesterol of WT mice B, total cholesterol of GRdim mice C, free cholesterol of WT mice D, free cholesterol of GRdim 
mice E, cholesterylesters of WT mice and F, cholesterylesters of GRdim mice  separated by FPLC. Black lines indicate day 
0, before treatment of each genotype and light to dark grey lines indicate day 1 to 6 of prednisolone treatment in each 
genotype. The signs above indicate the very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density 
lipoprotein (LDL) sized fractions.




In order to reveal whether the increase in VLDL-associated triglycerides, phospholipids 
and cholesterol levels in prednisolone-treated GRdim mice were direct effects of predni-
solone treatment or due to accumulation over time, we evaluated plasma samples from 
WT and GRdim mice during the six days of prednisolone treatment. Plasma samples were 
taken on day 0, before treatment and at day 1, 2, 3 and 6 of treatment, after which plasma 
samples were pooled and fractionated by FPLC. Figure 2 shows the FPLC profiles of total 
cholesterol, free cholesterol and cholesterylesters from WT (Fig. 2A, C and E) and GRdim 
mice (Fig. 2B, D and F) during prednisolone treatment. The slightly increased cholestery-
lester levels in the HDL-sized fractions in WT mice, were already apparent after 1 day of 
treatment and did not drastically change over time (Fig. 2E). In GRdim mice, the increased 
free cholesterol peak in the VLDL-sized fractions was already present after a single day 
of prednisolone-treatment and remained high during the entire treatment period (Fig. 
2D). In contrast, the increase in cholesterylesters in GRdim mice appeared after 3 days of 
prednisolone-treatment and shifted towards the LDL-sized fractions upon 6 days of treat-
ment (Fig. 2F). There is a clear temporal effect on this parameter of prednisolone treat-
ment. The increase in triglycerides and phospholipids in the VLDL-sized fractions of GRdim 
mice followed a similar pattern as free cholesterol, i.e., after a single day of prednisolone 
treatment phospholipids and triglycerides were increased (data not shown).
Since apolipoprotein A-I (ApoA-I) is specific for HDL particles, a Western blot of ApoA-I 
was performed on the FPLC fractions that contained the highest HDL-cholesterol concen-
trations from plasma samples of six day prednisolone-treated WT and GRdim mice in order 
to confirm the presence of HDL lipoproteins (Fig. 3). In WT mice, the cholesterol peak was 
present between fractions 20 and 27 (Fig. 1C); in these fractions ApoA-I protein levels 
were detectable by Western blotting, confirming the presence of HDL particles. However, 
in the plasma samples from GRdim mice, that showed a cholesterol peak between fractions 
15 and 25, no ApoA-I was detected below fraction 23, which could indicate a shift from 
HDL towards LDL and not the presence of very large HDL particles. In addition, plasma of 
Western blot analysis of Apolipropro-
tein A1 (ApoA-I) from the higher FPLC 
fractions of WT (upper panel) and GRdim 
mice (lower panel) treated with predni-
solone for 6 days. 
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GRdim mice treated with prednisolone contained a large amount of ApoA-I in fractions 27-
30, indicating a high concentration of small pre-β HDL lipoproteins. 
Prednisolone treatment in GRdim mice does not lead to Lp-X formation
The drastic increase of free cholesterol and phospholipids in the VLDL fractions might 
indicate the presence of lipoprotein-X (Lp-X), which is a particle of VLDL -size that con-
tains large amounts of free cholesterol and phospholipids. Lp-X is primarily formed during 
cholestasis, when hepatobiliary secretion of phospholipids and cholesterol is hampered 
29. To investigate the possible occurrence of cholestasis we determined plasma bile acids 
levels (Fig. 4A). Interestingly, the concentration of plasma bile acids was not significantly 
altered in prednisolone-treated GRdim mice and even tended to be reduced (Fig. 4A). Pred-
nisolone-treatment did not alter hepatic cholesterol and phospholipids in either genotype 
(table 2). Hepatic triglyceride levels were also not affected by prednisolone in WT mice 
either. Surprisingly, opposite to increased plasma triglyceride levels, hepatic triglyceride 
levels were reduced in livers of GRdim mice. 
Bile formation was studied in detail by performing a bile duct cannulation. 7 Days of pred-
nisolone treatment significantly increased bile flow in WT mice, but not in GRdim mice 
(Fig. 4B). Biliary output of cholesterol (Fig. 4C) and phospholipids (Fig. 4D) were simi-
lar in untreated mice and increased upon prednisolone treatment, independently of the 
genotype. Total bile acids in bile where increased in GRdim mice treated with prednisolone 
Bile acid parameters
A, Plasma bile acids B, bile flow C, bil-
iary cholesterol output D, biliary phos-
pholipid output from WT and GRdim 
mice untreated (white bars) or treated 
for six days with prednisolone (black 













(Supplemental Figure 1). Upon analysis of the bile acid profile, except for ursodeoxycholic 
acid (UDCA), no significant differences were observed. Interestingly, prednisolone treat-
ment increased the UDCA content considerably in both genotypes (Supplemental Figure 
1). Taken together, no signs of cholestasis were found. In addition, the large amount of 
triglycerides in the VLDL-sized fractions is unusual for Lp-X and the therefore the lipopro-
teins formed in GRdim mice upon prednisolone treatment, are very unlikely to represent 
‘classical’ Lp-X.
Since the formation of Lp-X was excluded, we hypothesized that the lipoprotein particle 
formed in the VLDL fractions of GRdim mice upon prednisolone treatment could be a result 
of an increased number of (smaller) VLDL particles. The amount of ApoB protein was 
analyzed by Western blotting (Fig. 5 A) in FPLC fractions. In the fractions 8-15 representing 
the VLDL-sized particles, GRdim mice contained more ApoB, both ApoB48 and ApoB100, 
indicating the presence of more particles, since each particle only contains a single ApoB 
molecule. Moreover, the VLDL core-surface ratio (Fig. 5B) was reduced in prednisolone-
treated GRdim mice, which implicates that these particles are probably smaller in size. In 
addition, the appearance of more ApoB in the higher FPLC fractions of prednisolone-treat-
ed GRdim mice confirms the finding of reduced ApoA-I, i.e., the fact that these mice have 
more LDL-sized particles in their circulation.
To find the mechanism of the increased amount of ApoB in plasma, we measured hepatic 
expression of genes involved in lipid and cholesterol metabolism (Table 3). No differences 
were seen on ApoB gene expression, but this is not surprising since ApoB secretion is 
mostly posttranslational regulated 30. Strikingly, in prednisolone-treated GRdim mice ex-






Western blot analysis of Apoliproprotein B (ApoB100 and ApoB48) 
A, the lower FPLC fractions of WT (upper panel) and GRdim mice (lower panel) treated with prednisolone for 6 days. 
Numbers above indicate the fraction obtained by FPLC. B, Core:surface ratio from control (white bars) and prednisolone 
(black bars) treated WT and GRdim mice.
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mice. In contrast, hepatic lipase (Hl) was decreased by prednisolone treatment in both 
genotypes. Prednisolone itself increased ApoA-I expression in both genotypes to a similar 





Hepatic gene expression of control WT and GRdim mice and prednisolone-treated WT and GRdim mice
*, p<0.05 vs. sham same genotype; #, p<0.05 vs. sham wild-type. Results were normalized to Rplp0 (ribosomal protein, 
large, P0 (36b4)) with data from control wild type mice defined as ‘1’. Values are means ± SD; n = 4-5; *, p<0.05 vs control 
same genotype; #, p<0.05 vs WT control; Tat, tyrosine amino transferase; Pck1, phosphoenolpyruvate carboxykinase 1, 
cytosolic (Pepck); Abcg5, ATP binding cassette, sub-family G, member 5; Abcg8, ATP binding cassette, sub-family G, mem-
ber 8; Bsep, bile salt export pump (Abcb11); Cyp7a1, cytochrome P450, family 7, subfamily a, polypeptide 1; Cyp8b1, cy-
tochrome P450, family 8, subfamily b, polypeptide 1; Fxr, Farnesoid-X receptor (Nr1h4, nuclear receptor subfamily 1, group 
H, member 4); Mdr2, multidrug resistance transporter 2 (Abcb4); Ntcp, (Slc10a1) solute carrier family 10 (sodium/bile 
acid cotransporter family), member 1; Lcat, lecithin-cholesterol acyltransferase; Acat1, acetyl-CoenzymeA acyltransferase; 
Abca1, ATP binding cassette, sub-family A, member 1; ApoA-I, apolipoprotein A1; Pltp, phospholipid transfer protein; Sr-
b1, (Scarb1, scavenger receptor classB, member1);ApoB, apolipoprotein B; Hl, (Lipc) lipase, hepatic; Lpl, lipoprotein lipase; 
Mttp, microsomal triglyceride transfer protein.




transferase (Lcat) in untreated GRdim mice compared to WT controls, no differences were 
seen upon prednisolone treatment. 
LPL exerts an important role in VLDL catabolism and the gene encoding LPL is highly in-
duced in the GRdim mice upon prednisolone treatment. Inhibition of LPL activity by Polox-
amer P407 is commonly used to measure the rate of hepatic VLDL production. TG levels 
at the start of the experiment confirmed the excessive increase in plasma TG in predni-
solone-treated GRdim mice (Fig. 6A, insert). The accumulation of newly produced VLDL-TG 
was slightly increased in GRdim mice (Fig. 6A). From the slope of t120-240 the VLDL produc-
tion rate was calculated. GRdim mice treated with prednisolone show a trend of increased 
production (p=0.054) (Fig. 6B), which could cause the increased levels of triglycerides, 
free cholesterol and phospholipids in the VLDL-sized fractions.
Discussion
It has been hypothesized that GR dimerization fulfils an important role in glucocorticoid-
induced side effects and that lack of GR dimerization may improve the therapeutic profile 
of glucocorticoid treatment. Therefore, there is major interest in development of so called 
dissociating glucocorticoids as new pharmaceuticals 5. So far, the glucocorticoid-induced 
side effects examined in these dissociating studies focused mainly on osteoporosis and 
insulin resistance 3,31. In the present study we examined the effect of blocking GR dimeri-







A, VLDL-TG secretion of WT (grey lines) and GRdim mice (black lines) after control (white bars – open symbols) or predniso-
lone treatment (black bars – closed symbols). VLDL secretion was measured after Poloxamer administration and is depicted 
as a percentage of t=0). Triglycerides levels from t=0 are depicted in the insert. B, VLDL-secretion rates were calculated 
from the slope of the curve
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excessive dyslipidemia in Balb/C mice, implying an important role for GR dimerization in 
the control of lipid homeostasis in mice. 
We hypothesized that the lack of GR dimerization would reduce the adverse effects caused 
by prednisolone treatment. This did seem to be the case for insulin resistance, since pred-
nisolone treatment induced fasting hyperinsulinemia in WT mice, but not in GRdim mice. 
At the baseline of the present study we matched WT and GRdim mice for bodyweight. 
Since the GRdim mice were slightly lighter, these mice were on average 3 weeks older to 
result in the same bodyweight. Prednisolone treatment reduced bodyweight in WT mice, 
which, opposite to weight gain in humans, has been reported previously for rodents 32. In 
GRdim mice, prednisolone did not reduce bodyweight. Food intake was similar between all 
groups, indicating that prednisolone might have an effect on energy expenditure in WT 
mice, which was abolished in GRdim mice.
In this study an abnormal lipoprotein profile was observed in prednisolone-treated GRdim 
mice consisting of two major components. Firstly, high amounts of triglycerides, phospho-
lipids and free cholesterol were present in the VLDL-sized fractions. Secondly, there was 
a shift in cholesterylesters form HDL towards LDL in GRdim mice treated with prednisolone 
compared to WT prednisolone-treated mice. The peak of VLDL-sized triglycerides, free 
cholesterol and phospholipids was already apparent after a single day of prednisolone 
treatment, while the shift from HDL toward LDL cholesterylesters occurred over time, 
indicating two independent mechanisms accounting for these effects. 
The high amount of VLDL-sized free cholesterol and phospholipids could indicate the pres-
ence of Lp-X, a lipoprotein particle containing high amounts of free cholesterol and phos-
pholipids, often formed during cholestasis. Since no signs of cholestasis were found on 
liver lipids, plasma bile acids and bile formation, the presence of Lp-X was excluded. In 
addition to cholestasis, lecithin-cholesterol acyltransferase (LCAT)-deficiency could also 
cause the formation of Lp-X particle 33,34. Although there were no differences on Lcat gene-
expression levels, it could still be that LCAT activity was diminished in GRdim prednisolone-
treated mice. This could be due to a factor interfering with LCAT. For functional activity, 
LCAT requires ApoA-I to bind to the HDL-particle for cholesterol transfer. Screening of the 
micro-array dataset from Frijters et al. 17 revealed an upregulated expression of serum 
amyloid A1 (SAA1), a protein involved in acute inflammation. This protein is known to be 
able to replace ApoA-I from HDL-particles 35, thereby blocking LCAT activity. A diminished 
function of LCAT could explain the lack of cholesterylesters in plasma of prednisolone-
treated GRdim mice. In addition, we checked for ApoA-I by Western blotting, but we could 
not detect ApoA-I in the VLDL-sized fraction in both genotypes. In the HDL-sized fraction, 
however, a clear shift of ApoA-I was found towards the higher fractions in prednisolone-




treated GRdim mice, indicative for a higher concentration of small pre-β HDL lipoproteins 
and a shift from HDL towards LDL and not the presence of very large HDL particles.
Although the high plasma TG levels point to diminished activity of LPL in plasma of pred-
nisolone-treated GRdim mice we found up-regulated gene-expression levels of hepatic Lpl. 
These data were confirmed by a Chip-Seq analysis (Rao et al., unpublished data) per-
formed on livers from vehicle and prednisolone-treated WT and GRdim mice. This study 
revealed that, in contrast to the general assumption that dimerization of GR is essential 
for direct activation or repression of GR-target genes, also monomeric GR could actively 
induce gene-expression. The classical promoter of GR-target genes, called the glucocor-
ticoid response element (GRE) could indeed only be activated by dimerized GR and clas-
sical target genes were not activated in GRdim mice. However, in livers from prednisolone-
treated GRdim mice a subset of genes was up-regulated, implying that the GR with the 
point mutation A458T might gain some transcriptional activity depending on promoter 
contexts. One of the target genes from this subset was Lpl.
By blocking LPL, VLDL-TG secretion was measured and a small increase was found in 
prednisolone-treated GRdim mice. In principle, this small increase could over time result 
in a large accumulation of VLDL-sized particles. However, the strong induction in plasma 
triglycerides, phospholipids and free cholesterol levels in the VLDL-sized fractions were 
already present after a single day of treatment and did not further increase during pro-
longed treatment suggesting that the increase in VLDL-like particles must have been due 
to inhibition of VLDL breakdown. The increased amount of ApoB could result in more and 
smaller particles as shown by the VLDL core:surface ratio. Possibly these smaller particles 
interact less with LPL inhibiting their degradation. It has been shown previously that GCs 
can increase the amount of ApoB proteins, both by an increased secretion and reduced 
clearance in rat hepatocytes treated with dexamethasone 36.
Overall, the data described in this study reveal that to our surprise prednisolone-treat-
ment leads to excessive dyslipidemia in GRdim mice, indicating an important role of mono-
meric GR in regulation of lipid metabolism and this may contribute to unravelling the 
mechanisms underlying glucocortoid-induced side effects.
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The bile acid profile from bile of con-
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The overarching aim of the studies described in this thesis was to better understand un-
derlying mechanisms of GC-induced metabolic derangements. We focused specifically on 
in vivo studies of insulin resistance and dyslipidemia in mice as major adverse effects as-
sociated with chronic prednisolone treatment seen in humans. For in-depth analysis of 
GC-induced derangements in glucose metabolism, we chose to study the effects of GCs 
in (genetically-engineered) mice with state-of-the-art stable isotope methods. To this pur-
pose, multiple mouse models and methodologies to evaluate glucose metabolism have 
been applied. The studies described in this thesis reveal the complexity of GC-induced 
adverse effects in mice. In the general discussion multiple factors adding to this complex-
ity will be discussed; these factors should be considered for future studies. Firstly, in this 
thesis several methods to measure insulin resistance have been applied, including a novel 
method introduced in chapter 2. Some pro’s and con’s of the methodologies described 
will be discussed. Secondly, there is a great variety of synthetic GCs and different modes of 
administration to choose as a treatment regime for mice, which should be chosen wisely. 
Thirdly, various mouse strains tend to respond differently to GC-treatment, therefore an 
overview is given of different studies analyzing the effects of GC-treatment on glucose 
metabolism involving different mouse strains. Then shortly the effects of glucocorticoids 
on lipid metabolism will be handled. Finally, there are many other factors that should be 
taken into account when investigating adverse effects of GCs, which will be discussed in 
this chapter. These discussion points then lead to the perspectives for future studies.
Choosing the proper methodology to measure insulin resistance
Insulin resistance constitutes a clinically undesired situation in which insulin-sensitive tis-
sues, like liver, muscle and adipose tissue, have a reduced response to circulating insulin 
levels. Insulin resistance leads to high blood glucose levels and is usually characterized 
by both high glucose and insulin levels 1. However, there are multiple methodologies to 
measure or diagnose insulin resistance and in this part of the discussion the advantages 
and disadvantages of these methodologies will be discussed. It should be realized that 
insulin resistance in itself is not a disease but a physiological state preceding diabetes mel-
litus type 2 and comprises a component of the metabolic syndrome. The metabolic syn-
drome, in turn, constitutes a risk for diabetes mellitus type 2 and cardiovascular disease. 
While diabetes mellitus type 2 in humans is diagnosed by fasting blood glucose levels >7 
mM, a 2-hour plasma glucose of 11,1 mM during an oral glucose tolerance test or a HbA1c 
> 6,5% 2, the most commonly used manner to express insulin resistance is the HOMA-IR, 
in which fasting blood glucose and fasting plasma insulin measurements are related to 
each other by a formula introduced by Matthews et al. 3. This HOMA-IR is relative easy to 




perform, since only fasting blood glucose and insulin levels need to be collected, however 
it does not give detailed information on tissue specific insulin sensitivity. In this thesis mul-
tiple methods have been used to analyze glucose metabolism and tissue specific insulin 
resistance. In chapter 2 an adaptation to HOMA-IR is described, which adjusts the HOMA-
IR to the basal blood glucose and plasma insulin levels of mice and hence allows for the 
use of an HOMA-IR in mice. Two traditional techniques to more specifically study insulin 
resistance by the effects of insulin action are the oral glucose tolerance test (OGTT) and 
the insulin tolerance test (ITT) 4. These techniques involve stimulation of glucose metabo-
lism, either by administering an oral high bolus of glucose (for the OGTT), or by a single 
ip. injection of insulin (for the ITT), after which glucose levels are monitored to result in 
a glucose curve. The area under this curve is a measure for insulin resistance. As a pilot 
experiment we performed oral glucose tolerance tests in mice treated with prednisolone 
for four weeks (Fig. 1, not published). The high dose of prednisolone (10 mg/kg/d) clearly 
increased fasted blood glucose levels (Fig. 1A), suggesting insulin resistance. However, the 
glucose curve of the OGTT from prednisolone treated mice peaked at a lower glucose lev-
el, resulting in a reduced area under the curve which implies increased insulin sensitivity. 
As Fig. 1B shows, there were no differences in glucose curve on day 0 before treatment, 
while the 10 mg/kg/day prednisolone treatment reduced the glucose curve at day 7 (Fig. 
1C), which was still present at day 21 (Fig. 1D). To make a validated statement on insulin 
resistance, one should take blood samples during the OGTT to determine insulin levels. At 
the time of this pilot study, this was technically not possible because the amount of blood 
Effects of 4-week prednisolone op glu-
cose levels
A, Fasting glucose levels during four 
week treatment B, glucose curve of oral 
glucose tolerance tests on day 0 (before 
treatment) C,  glucose curve of oral glu-
cose tolerance tests on day 7 and D, 
glucose curve of oral glucose tolerance 













needed to be collected for insulin measurements was too high for mice. However, due 
to improvement of sensitivity of insulin measurement techniques this problem has been 
overcome nowadays. 
To study insulin resistance in detail, the hyperinsulinemic euglycemic clamp (HIEC) is 
regarded as the ‘gold standard’ 5,6. The HIEC, adapted for use in mice in our laboratory 
7, was used in chapter 3 and 4 to evaluate GC-induced effects on insulin sensitivity in 
C57BL/6J mice in detail. By continuous infusion of insulin a high plasma insulin level is cre-
ated (hyperinsulinemic). Simultaneously, glucose is infused to maintain blood glucose at a 
steady level (euglycemic). In this protocol the infusion rate of glucose (GIR) is a measure 
for insulin sensitivity as insulin sensitive tissues take up more glucose. And therefore more 
glucose is needed to maintain euglycemia. By adding glucose tracers to this protocol (i.e., 
stable isotopes) one can discriminate between fluxes into and out of hepatic and periph-
eral tissue (muscle, adipose tissue) 8, divided in hepatic glucose production and metabolic 
clearance rate. In order to more specifically analyze hepatic glucose metabolism we used 
Mass Isotopomer Distribution Analysis (MIDA) 8,9 in chapter 4 and 5, which is a technique 
for in-depth analysis of hepatic glucose fluxes of (part of the) glycolysis, glycogenolysis, 
and gluconeogenesis. This measurement has been previously described for analysis of 
hepatic glucose fluxes in a 9-hours fasted state 10,11, but in order to acquire knowledge of 
hepatic glucose fluxes during hyperinsulinemia, we combined the standard HIEC with the 
MIDA in chapter 4. 
In addition to the generally accepted methods to evaluate insulin resistance, we devel-
oped a simple stable isotope based technique to assess glucose kinetics under 9-hours 
fasted conditions. This method is described in chapter 2 and used in chapter 3, 4 and 6. 
Using this method we were able to measure glucose metabolism in a stable, fasted state 
with limited inconvenience for the experimental animals. The test can be repeated in a 
single animal multiple times, leading to a significant reduction in numbers of animals used 
per experiment. For the analysis of fasted blood glucose kinetics, mice were injected ip. 
with a small amount of stably-labeled glucose (D-[6,6-2H2]glucose, ~500 µmol kg
-1 BW), 
after which blood glucose levels are measured and blood spots are taken on filter paper 
every 10 minutes for the next 90 minutes. From the wash-out of injected D-[6,6-2H2]-
glucose from the circulation the whole body glucose turnover and clearance rates can be 
calculated by kinetic analysis. This method does not disturb fasting glucose metabolism or 
insulin secretion; therefore one single measurement of plasma insulin levels after the test 
is sufficient to make a validated statement on insulin resistance, that can be related to cal-
culated values of glucose production and glucose clearance (HGP and MCR, respectively). 
However, one should realize that although the basal blood glucose kinetics together with 
the prevailing insulin levels gives good insight in glucose metabolism insulin resistance. 




However, because insulin is a hormone that is secreted upon stimulation of the pancre-
atic beta-cells after feeding, the meaning of increased insulin concentrations in a fasted 
state is debatable, since these levels are often still below the insulin concentration after a 
meal. Therefore, the method of fasted blood glucose kinetics also had it’s disadvantages 
and is not a perfect method for analyzing insulin resistance. In a situation of insulin resist-
ance fasted insulin levels might still play an active role. The HOMA-IR, the fasting blood 
glucose kinetics and the MIDA methods are measurements performed during a basal, i.e., 
fasted state. It should be realized that the perfect method probably does not exist as each 
method has its advantages and disadvantages. 
The methods described above all yield a measure for insulin resistance. Many papers de-
scribe a good correlation between the surrogate indices, such as the HOMA-IR, with the 
GIR during hyperinsulinemic euglycemic clamp studies in humans 12,13. For rodent models 
developed to resemble human metabolic diseases, comparisons of the correlation be-
tween surrogate indices, such as HOMA-IR, and the HIEC are scarce. The group of Quon 
showed that the correlation between HOMA-IR and the GIR during HIEC is very moderate 
in mice as well as in rats 14,15. The studies described in chapter 3 and 4 reveal that the 
HOMA-IR and HIEC are disconnected for prednisolone-treated C57BL/6J mice, therefore 
the HOMA-IR is not a good predictive value for insulin resistance in mice.
Choosing a glucocorticoid treatment protocol
The most commonly used GCs in clinical practice are prednisolone and dexamethasone. 
While dexamethasone is a very potent anti-inflammatory drug, often used to treat acute 
sepsis, prednisolone is less potent but the preferred GC for treatment of chronic inflam-
matory diseases, such as rheumatoid arthritis and inflammatory bowel diseases. The fo-
cus of the experiments described in this thesis is on prednisolone, because we aimed to 
approach the human situation as much as possible and it is during chronic treatment that 
side effects on glucose and lipid metabolism cause major problems.
The mode by which the GCs are administered to the animal is subject to debate. In many 
studies, GCs were injected intraperitoneally, however, this way of administration is un-
desirable in patients. For continuous administration in animal studies, GCs can also be 
administered via long-term continuous release pellets, which also reduce the stress of 
dosing and handling. These pellets are implanted subcutaneously, where matrix-driven 
delivery takes place. The idea behind this method is that the pellet would release a con-
stant and continuous dose of prednisolone. However, in our hands, the levels of predniso-
lone retrieved in plasma of pellet-implanted animals varied highly. Moreover, a pilot study 
to test continuous prednisolone administration via osmotic pumps in rats also did not 




result in administration of a constant dose (M-J. van Lierop, MSD, personal communica-
tion). In the clinic, prednisolone is given orally, usually once a day. Therefore, we chose to 
administer prednisolone daily by gavage in a vehicle solution containing 0.5% gelatin/5% 
mannitol. To make sure that this vehicle containing a sugar alcohol has no effect on glu-
cose metabolism, it was first compared to water (Fig. 1). Compared to an oral bolus of 
water, the vehicle had no effect on glucose metabolism as measured by fasting blood glu-
cose levels and oral glucose tolerance test. Nevertheless, a major drawback of this mode 
of treatment is the daily handling and the stress mice perceive while being strained for 
oral gavage. In addition, timing of treatment dosing can affect the circadian rhythm in a 
different manner, which will be discussed further on. Overall, it is clear that the mode of 
administering can have a great effect on treatment outcome.
Choosing the right mouse model
The fact that GCs exert their effects in many different organs and tissues, which, in addi-
tion, show complex interaction with each other, makes it difficult to evaluate GC-induced 
effects on various aspects of metabolism in artificial in vitro models. Several descriptive 
studies have been performed in healthy human volunteers 16-18 and in patients 19-21, but 
more in-depth, fundamental research requires application of animal models. Rodents 
comprise the most widely used animal species, thanks to their fast reproduction rates, 
their relative small size and easy housing. Since the introduction of genetic modification, 
mice are more and more preferred over rats. In addition, in our laboratory, state-of-the-
art stable isotope methods to quantify glucose and lipid metabolism for use in mice have 
been developed and extensively tested. Therefore, we have chosen to assess GC-induced 
adverse effects on glucose and lipid metabolism in mice. 
Our goal was first to assess GC-induced adverse effects in ‘normal’ mice, with the pos-
sibility to take it one step further in arthritic mice or in transgenic mice. We choose the 
C57BL/6J mouse strain as our ‘normal’ mice, because this strain is one of the most exten-
sively used mouse strains for metabolic studies. Moreover, C57BL/6J mice are known to 
be susceptible to diet-induced obesity and insulin resistance. Unfortunately, within the 
C57BL/6J mice, there are still quite some differences between breeding lines from differ-
ent suppliers (e.g., Harlan vs. Charles River). Mice described in this thesis are C57BL/6J 
mice from Harlan. We also used mice from the DBA/1J strain, which is the only strain 
susceptible to collagen-induced arthritis (CIA), in order to test the effects of sustained 
prednisolone treatment in an inflammation model. Finally, experiments were done in GR-
dim mice on a BALB/c background, since this transgenic model is not viable on a C57BL/6J 
background. The results of evaluation of prednisolone-induced effects on insulin sensitiv-
ity in these different mouse strains are summarized in Table 1, in which also an overview 




of multiple published studies is given in which the effects of GCs on glucose metabolism 
and insulin resistance have been assessed in different mouse strains.
Experimental animal models of GC-induced insulin resistance 
Many studies have been performed in animals in which dexamethasone has been used 
to induce insulin resistance, however, most of these experiments have been performed 
in rats as mentioned in the introductory chapter 1. Although Stojanovska et al. describe 





Effects of glucocorticoids on glucose metabolism in different mouse models and strains
Fasting glucose levels or insulin resistance remained similar ↔, reduced ↓or increased ↑ upon prednisolone treatment. 
*[PC] Personal communication from A. Rauch (Leibniz Institut Jena) data from WT GRdim mice on a FVB background, [UD]- un-
published data, [#] – chapter number in this thesis, (O)- adminatration by oral gavage, (p)- administration by subcutaneous 
pellet. Yellow viable – Obese mice, Avy/a ♂ were already hyperglycemic.




with dexamethasone in rats are debatable; one study showed insulin resistance to be due 
to a dexamethasone-induced reduction in muscle specific glucose uptake, while no physi-
ological signs of insulin resistance were present, either at fasting glucose or insulin levels, 
nor was insulin resistance assessed by OGTT or HIEC 31. Moreover, Severino et al. claimed 
that dexamethasone treatment is a good model to study GC-induced insulin resistance, 
but only showed a small effect on insulin levels and no effect blood glucose levels and do 
not assess insulin resistance in more detail 32. Nevertheless, daily treatment of rats with 1 
mg/kg of dexamethasone is generally accepted to induce insulin resistance.
A similar model for mice has not been published yet as a generally accepted model for 
GC-induced insulin resistance. Table 1 gives an overview of multiple studies in which the 
effects of GCs on glucose metabolism and insulin resistance have been assessed in dif-
ferent mouse strains. From this overview it is clear that the effects of GCs on glucose 
metabolism in mice are highly variable. Besides the experiments described in this thesis 
and personal observations (first four lines of Table 1), the only published study in which 
(methyl)-prednisolone was used, showed no effects of the drug on outcome of the oral 
glucose tolerance test 29. All other studies published have been performed using dexa-
methasone. Moreover, the ‘gold-standard’ HIEC has, to our knowledge, not been per-
formed in GC-treated mice, probably because the HIEC is a technically complex method 
to perform in mice. 
In the studies presented in Table 1, insulin resistance is mostly evaluated by OGTT or ITT. 
These methods deliver valuable information on the uptake and clearance of glucose and 
insulin, respectively. Nevertheless, interpretation of these tests can be complicated. Gou-
narides et al. treated high fat-fed mice with dexamethasone for 5 days 26. These authors 
performed an OGTT before and after treatment in dexamethasone- and saline-treated 
mice and represent their data as the difference between baseline and post-treatment val-
ues of both groups. This resulted in a large difference between saline and dexamethasone 
treatment (~ Δ-100 mM vs. ~ Δ80 mM, saline vs. dex at t=120) however, closer analysis 
of the data revealed a peculiar great difference before and after saline treatment (glu-
cose value of ~520 mM vs. ~420 mM at t=120, pre vs. post saline treatment; ~500 mM 
vs. ~580 mM at t=120, pre vs. post dexamethasone treatment), which underlies a great 
part of the overall difference between dexamethasone and saline treatment. In this study 
dexamethasone did not increase plasma insulin levels, while in several other studies 27,28 
dexamethasone treatment did result in elevated plasma insulin levels, like prednisolone-
treatment did. However, this increase in insulin levels does not necessarily mean that 
these mice were insulin resistant, as shown in chapter 3 and 4. It could be that there is a 
shift in the homeostatic balance, meaning that at an increased insulin set-point, all tissues 
respond in a similar manner.




Table 1 also reveals that in mice on a diabetes-prone background, like the female Avy/a 
mice or the LDLR-/- mice, GCs appeared to be able to induce insulin resistance. In addition, 
there is a great difference between the different strains of inbred mice. Figure 2 shows 
the family tree of inbred mouse strains, in which the mouse strains described in this thesis 
are circled, thereby showing how these three mouse strains are genetically related each 
other.
From this family tree, which is based on genetic screening of different inbred mouse 
strains, it is obvious that the three mouse strains used in this thesis are very distinct from 
each other, which might underlie the differences in susceptibility to GC-induced adverse 
effects on glucose metabolism. Another genetic screening, focusing specifically on the 
susceptibility for diet-induced obesity (DIO) and insulin resistance in multiple inbred 
mouse strains with a great variety in the genetic background, very well describes different 
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strain is highly sensitive to develop DIO, while the BALB/c strain that originates from A/J 
mice, resistant to DIO. Similarly, the DBA/1J strain is also not sensitive to DIO 34. These 
different susceptibilities for diet-induced insulin resistance might reflect the differences in 
susceptibility for GC-induced effects on glucose metabolism, although induction of insulin 
resistance via GCs most likely involves different pathways than induction of insulin resist-
ance via high fat diet feeding.
Retrospectively, C57BL/6J mice might not have been the perfect mouse strain to evaluate 
GC-induced insulin resistance. However, as Table 1 shows, none of the strains tested so 
far would qualify as such. The ideal follow-up would be an extensive screening with pred-
nisolone and dexamethasone in different mouse strains with one type of assessment of 
insulin resistance, for which the hyperinsulinemic euglycemic clamp would be the method 
of choice. 
Also take into account…
Besides carefully choosing the method to analyze insulin resistance, the GC treatment and 
the animal model, one should take into account that many other factors are involved in GC 
action and glucose metabolism. 
First of all, the development of diabetes mellitus type 2 is not solely a result of insulin 
resistance in insulin sensitive organs, but more specifically the failure of the pancreas to 
compensate for the lack of effect of the prevailing insulin concentrations. When insulin re-
sistance evolves and insulin sensitive tissues, like liver, muscle and adipose tissue, do not 
respond adequate to the prevailing insulin levels, the pancreas will compensate for this 
lack of insulin action by secretion of more insulin. The pancreas consists for a large part of 
exocrine mass producing digestive enzymes, in which the islets of Langerhans reside that 
function as an endocrine gland 36. The islets of Langerhans account for 1-1.5 % of the total 
pancreas and consist of 4 different cell types: α-cells producing glucagon, PP-cells releas-
ing pancreatic polypeptide, δ-cells producing somatostatin and β-cells producing insulin. 
However, over time as the metabolic tissues become more insulin resistant, the β-cells 
will get exhausted and will be unable to continue increasing their insulin secretion. This 
process is referred to as β-cell dysfunction. β-cells also express glucocorticoid receptors 
(GR) 37 and the effects of GCs on β-cell function are highly contradictory. Like GC-induced 
insulin resistance, most studies on the effects of GC on β-cell function have been per-
formed in dexamethasone-treated rats. Dexamethasone treatment leads to an increased 
glucose-stimulated insulin secretion (GSIS) of isolated pancreatic islets of Langerhans from 
rats treated for several days 38-40. In a personal observation, we saw that islets from 7 day 
prednisolone treated C57BL/6J also showed increased GSIS. However, isolated islets from 




conventional and Ob/Ob mice, cultured with dexamethasone demonstrated reduced GSIS 
41,42, which has also been shown for isolated rats islets cultured with dexamethasone 43. In 
addition, aged mice over-expressing pancreatic GR had impaired β-cell function 44. There 
is a clear difference between direct and indirect effects of GCs on insulin secretion by 
islets, as shown by the in vitro studies in which islets were cultured with GCs and in vivo 
studies in which the animals were treated with GCs. Moreover, the in vivo studies were 
short-term which could imply that β-cell function is increased to overcome the peripheral 
insulin resistance in the first period and that the β-cells are still able to compensate. It 
could be that prolonged GC treatment would finally lead to exhausted islets and lead to 
β-cell dysfunction. Overall, these data show that GCs have an effect on the pancreas that 
need to be further studied, but still needs to be taken into-account when studying GCs 
induced insulin resistance.
Secondly, besides the metabolic tissues (liver, muscle and adipose tissue) and the pan-
creas, the brain plays an important role in GC-regulated energy metabolism and food 
intake, and thereby glucose metabolism and insulin resistance. The hypothalamus is an 
important region in the brain, linking the nervous system to the endocrine system and 
plays a major role in the GCs system 36. The hypothalamus is involved in metabolic func-
tions such as blood pressure homeostasis, temperature regulation and food intake, but 
also in memory processes, emotion and day night rhythm, since the suprachiasmatic nu-
clei (SCN) which is regarded as the central clock, is localized in the hypothalamus 45. Here 
the effects of GCs on circadian rhythm and neuro-endocrine regulators of food intake will 
be discussed.
It is known that the circadian clock induces a circadian rhythm in cortisol secretion, while 
on the other hand changes in GC homeostasis alter the circadian rhythm. This is clear by 
the fact that one of the side effects in patients on GC treatment is insomnia 46. In addition, 
it has been shown that GR binds actively to the promoter of the Period 1 (Per1) gene, an 
important regulator of the circadian clock 47 and Per1 knockout mice have a disturbed 
rhythm in cortisol secretion 48. In addition, to add to the complexity and interrelating ef-
fects of GCs and circadian rhythm, it has been shown that GR expression shows a circa-
dian rhythm in adipose tissue, but not in liver and muscle 49. GC treatment reduces the 
endogenous cortisol production by the negative feedback route of the HPA-axis, thereby 
taking over the circadian rhythmicity of cortisol production. Cortisol in humans normally 
peaks early in the morning, therefore timing of GC-treatment is essential to not interfere 
in the circadian rhythm 50. Besides GCs, food intake also has a considerable effect on circa-
dian rhythm 51. Food intake is regarded as a dominant clock regulator (Zeitgeber) 52; when 
nocturnal animals only had access to food during day time, they inverted their peripheral 
circadian rhythm. Moreover, GC are known for their ability to increase appetite, resulting 




in increased food intake 53 in humans also at night, thereby interfering with the circadian 
rhythm. When studying GC-induced alterations of glucose metabolism, one should take 
the circadian rhythm into account. Treatment timing should compensate the reduced cor-
tisol levels, preferably dosing GC just before normal peak levels would occur. Additionally, 
it would be very elegant to monitor circadian differences of activity and time of food in-
take. In the studies described in chapter 3 and 4, prednisolone was administered at 13:00 
pm, being a bit early for replacements of normal corticosterone levels, which peaks just 
before the dark (active) period at 18:00 54. In addition, we monitored activity and food 
intake during prednisolone treatment, while the mice were subjected to the calorimetric 
cages in chapter 4, although no significant differences were found.
In chapter 3, it was revealed that increased fasting glucose levels were more a result of 
an altered feeding-fasting response than caused by GC-induced insulin resistance, making 
the nutritional status an important factor when studying GC-induced effects on insulin 
sensitivity and glucose metabolism. The nutritional status is dependent on the (timing of) 
food intake in mice. Besides the hyperglycemic clamp, all experiments analyzing glucose 
metabolism in this thesis were performed in overnight fasted mice, to ascertain a simi-
lar nutritional status. Nevertheless, hormones involved in the neuro-endocrine regula-
tory network of food intake, such as insulin and leptin were increased upon prednisolone 
treatment. These neuro-endocrine factors execute part of their role in the hypothalamus. 
Although it has been assumed that the brain is insulin insensitive, it is now known that in-
sulin receptors are expressed in many regions, especially in the hypothalamus, hippocam-
pus and cerebral cortex 55. Insulin can cross the blood-brain barrier via active receptor-
mediated transport. Central insulin does not affect glucose uptake in the brain itself, but 
mediates whole body energy balance via a complex neuro-peptidergic signaling network 
in the hypothalamus 56. In addition, central insulin seems to play a role in memory per-
formance and locomotor activity 57,58. Moreover, there is evidence that central insulin re-
sistance can evolve, as shown by a study of Hallschmid et al. in which intranasal insulin 
treatment reduced bodyweight in normal-weight, but not in overweight subjects 59. Even 
though central insulin resistance is a highly unexplored field, it might be that GCs might 
alter central insulin sensitivity. Zakrzewska et al. have shown that central administration 
of dexamethasone in rats clearly increased plasma insulin levels three-fold 60. 
In chapter 4 we show that prednisolone increased plasma leptin levels. In this same study 
from Zakrzewska, leptin was found to be induced four-fold in rats treated with dexameth-
asone intracerebroventricularly (i.c.v.) 60. Leptin is a hormone produced by adipocytes and 
typically present in circulating levels proportional to the adipose mass 61. Leptin is involved 
in regulation of appetite and energy metabolism and suppresses appetite via the leptin 




receptor on neuropeptide Y (NPY) secreting neurons in the hypothalamus 62. GCs and lep-
tin have counter regulatory effects and are highly interacting; not only central GCs, but 
also peripheral GCs increase leptin secretion independently of the amount of adipose 
tissue as described by us in chapter 4 and others 63. The Ob gene regulating leptin levels 
contains an GRE 64 and GC treatment increases Ob gene expression 65. On the other hand, 
leptin treatment was able to increase corticosterone levels upon stress 66 and acutely re-
duces corticosterone in mice 67,68. These data show that GCs are highly interacting with 
other hormone signaling pathways and have counter-regulatory effects, most of which 
take place in the hypothalamus. 
Lastly, in chapter 3 and 4 we found that fibroblast growth factor 21 (FGF21) was increased 
by prednisolone treatment. FGF21 has been discovered in 2000 as a novel member of the 
fibroblast growth factor family 69, although recently it has been found that FGF21 func-
tions as an endocrine factor instead of a growth factor by Inagaki and colleagues 70. FGF21 
is predominantly expressed mostly by tissues involved in regulation of metabolism, such 
as the liver 69, brown adipose tissue 71,72, muscle 73 and pancreas 74. FGF21 plays a dominant 
role in energy regulation during fasting 70,75,76. It has also been suggested that FGF21 might 
function as a neuro-endocrine regulator, since central administration of recombinant hu-
man FGF21 improves insulin sensitivity in diet-induced obese rats 77. These data show that 
FGF21 plays an important role in processes in which GCs also interact. We were the first 
to report the effect of GCs on increasing FGF21 expression and plasma concentrations. 
This opens a completely new field to explore GC-related effects on glucose metabolism 
via FGF21.
Overall, the data described above show that there are complex interactions between GCs, 
circadian rhythms, food intake and hormonal regulation. In order to study one of these 
mechanisms, as was done in this thesis for the effects of GCs on glucose metabolism, one 
should make sure that the other factors are not affected. Especially when evaluating insu-
lin resistance by HOMA-IR, it should be taken into account that the relationship between 
fasting glucose levels and plasma insulin levels only has meaning for insulin sensitivity 
when other metabolic regulators, like FGF21 and leptin, remain unaffected.
Future implications
As discussed above, there are differential effects between prednisolone treatment in hu-
mans and mice, not only on the induction of insulin resistance, but also on changes in 
bodyweight. While visceral obesity and weight gain are among the many side effects of 
chronic GC treatment in humans 78,79, mice do not gain weight upon GC treatment but, 




in contrast, even lose weight 23 (and personal observation after 4 weeks of prednisolone 
treatment), which is also the case in rats 80. In multiple humans studies, insulin resistance 
has been assessed by the hyperinsulinemic euglycemic clamp 16,18, in healthy volunteers 
treated with GCs clearly proving GC-induced insulin resistance. This was also shown in pa-
tients 81. Unfortunately, as the studies in this thesis describe, the effects of GCs on glucose 
metabolism remain partly unclear, although it is obvious from the HIEC studies in chapter 
3 and 4 that prednisolone-treatment does not lead to ‘classical insulin resistance’.
On the other hand, in humans GC-induced insulin resistance is also variable. First of all, 
not all patients receiving chronic GCs develop insulin resistance. A recent study by Hoes 
et al. showed that chronic rheumatoid arthritis (RA) patients receiving GCs are equally 
insulin sensitive and glucose tolerant as RA patients that do not receive GCs 82. Moreover, 
not all patients react similar to GC treatment, with the one patient having no or hardly any 
side-effects, while in the other patient, treatment had to be stopped because of extreme 
side effects 83. This might be due to the effect of genetic background which varies highly 
between humans, as was also seen in GC treatment in mice between different strains. 
In addition, GC resistance is a rare hereditary disease highly dependent on genetic back-
ground of patients, determining the outcome of GC treatment. For some of these patients 
polymorphisms in the GR have been found 84,85. It has been hypothesized that GR polymor-
phisms underlie GC-induced adverse effects on glucose and lipid metabolism. Herein lies 
the future for personalized medicine 
Overall, the in vivo studies performed in this thesis contribute to an improved understand-
ing of GC-induced effects on glucose metabolism; however, we could not confirm ‘classical 
insulin resistance’ induced by GCs in mice according to the ‘gold standard’ measurement 
by the HIEC. This leads to the question whether mice are the right model to study GC-
induced metabolic adverse effects. For fundamental research questions, in which insights 
of molecular pathways are involved, mice are still a preferred animal model, due to the 
possibility of genetic engineering. However, the studies described in this thesis did not 
suggest an optimal mouse model for GC-induced metabolic adverse effects, focussing 
on physiological resemblance of adverse affects as seen in humans. Nevertheless, to our 
knowledge these studies are the first to provide in-depth analysis of the effects of GCs on 
glucose metabolism and insulin resistance in mice. Many techniques were used to assess 
insulin resistance under different conditions, to ascertain that ‘classical insulin resistance’ 
was not detected in prednisolone-treated C57BL/6J mice. Moreover, this last chapter 
gives a valuable overview of studies published so far on the effects of GCs on glucose me-
tabolism in mice. The studies described in this thesis provide an important step in the rec-
ognition of the value of mice studies in GC-related adverse effects. For future studies one 
should carefully choose the proper animal model, depending on the research question.
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Synthetic GCs such as prednisolone have potent anti-inflammatory actions and are widely 
prescribed for treatment of chronic inflammatory diseases such as rheumatoid arthritis 
and inflammatory bowel diseases. Unfortunately, these drugs can elicit severe adverse 
effects, many of which resemble features of the metabolic syndrome such as weight gain, 
hyperglycemia, insulin resistance and dyslipidemia. The combination of these symptoms 
is also referred to as Cushing’s syndrome. The work described in this thesis focuses on the 
metabolic effects of prednisolone treatment in mice and how these adverse effects are 
brought about.
In order to evaluate in vivo glucose metabolism and insulin resistance repeatedly in a ba-
sal, fasted condition, a method in which blood glucose kinetics can be assessed without 
perturbing glucose homeostasis, is described in chapter 2. This model, in which glucose 
kinetics are described by single-pool, first order kinetics, was performed in mice in which 
insulin resistance was induced by feeding a high fat diet for 5 weeks. We confirmed that 
a 5 week high fat diet induced insulin resistance by hyperglycemia and hyperinsulinemia, 
resulting in increased HOMA-IR. In addition, a high fat diet reduced glucose clearance 
rate, the disposition index and both hepatic and peripheral insulin sensitivity (IS). To com-
pensate for this insulin resistance, β-cell function was slightly increased. In conclusion, 
chapter 2 describes a novel method in which it is possible to combine the calculated insu-
lin sensitivity in fasting conditions with blood glucose kinetics in the same situation. 
This novel method was employed in chapter 3 focusing on the consequences of chronic 
prednisolone treatment on insulin sensitivity and blood glucose kinetics in C57BL/6J mice. 
Prednisolone treatment led to hyperglycemia and hyperinsulinemia, resulting in an in-
creased HOMA-IR, but this apparent reduced insulin sensitivity could not be confirmed 
with a hyperinsulinemic euglycemic clamp. Application of our newly developed method 
revealed that prednisolone-treated mice show an increased hepatic glucose production 
under basal conditions at higher insulin levels, indicative for reduced insulin sensitivity. 
In addition, prednisolone-treated mice had higher plasma FGF21 concentrations in the 
fed and fasted condition and showed hardly any reduction in blood glucose levels upon 
fasting, revealing that the apparent insulin resistance induced by prednisolone-treatment 
was more likely due to an altered feeding-to-fasting transition. 
Insulin resistance can be induced by a western type diet, therefore in chapter 4 we investi-
gated whether adverse effects of prednisolone are aggravated in mice with compromised 
glucose metabolism due to high fat diet feeding. Prednisolone treatment aggravated fast-
ing hyperglycemia and hyperinsulinemia caused by high-fat feeding, resulting in a higher 




HOMA-IR. In addition, basal glucose kinetics revealed a similar glucose production and 
clearance rate at high insulin levels, implying reduced insulin sensitivity. Remarkably, us-
ing hyperinsulinemic-euglycemic or hyperglycemic clamp techniques, neither hepatic nor 
peripheral insulin resistance was enhanced in the group that was additionally treated with 
prednisolone. Yet, analysis of hepatic glucose metabolism revealed that prednisolone did 
alter glycogen balance by reducing glycogen synthase flux, under hyperinsulinemic as well 
as hyperglycemic conditions. In addition to elevated insulin levels, prednisolone-treated 
mice showed a major rise in plasma leptin and FGF21 levels. These data indicate that 
prednisolone-induced adverse effects on glucose metabolism in high-fat diet fed mice do 
not reflect impaired insulin action but may be caused by changes in the hormonal regula-
tory network controlling glucose metabolism.
In view of the severe adverse effects of prednisolone and dexamethasone in humans, the 
development of new GC with less or no adverse effects is highly desirable. Chapter 5 de-
scribes a non-steroidal glucocorticoid receptor (GR)-selective compound (Org 214007-0) 
with a binding affinity to GR similar to that of prednisolone. Using various cell lines and 
primary human cells, we showed that Org 214007-0 acts as a partial GC agonist, since 
it repressed inflammatory genes and was less effective in induction of metabolic genes. 
More importantly, in vivo studies in mice indicated that Org 214007-0 retained full effi-
cacy in acute inflammation models as well as in a chronic collagen-induced arthritis (CIA) 
mouse model to reduce inflammation. Gene expression profiling of muscle tissue derived 
from arthritic mice showed a partial activity of Org 214007-0 at an equi-efficacious dos-
age of prednisolone, with an increased ratio in repression versus induction. Finally, pred-
nisolone, but not Org 214007-0 induced elevated fasting blood glucose levels in mice, 
a phenotype accompanied by a shift in the hepatic glucose / glycogen balance. These 
data demonstrate that Org 214007-0 belongs to the new class of selective glucocorticoid 
receptor modulators (SGRM’s) with an increased therapeutic index compared to predni-
solone that could contribute to effective anti-inflammatory therapy with a lower risk for 
metabolic side effects.
For evaluation of novel GCs, it is highly preferable to be able to measure both efficacy and 
metabolic safety in the same animal. Preclinical efficacy of newly developed compounds 
can be assessed in DBA/1J mice with collagen-induced arthritis (CIA), a model with fea-
tures resembling rheumatoid arthritis in humans. However, adverse effects on metabo-
lism of novel GCs have never been tested in this disease model. Therefore the method 
described in chapter 2 was applied in the CIA model. Arthritis scores were decreased after 
treatment with prednisolone, confirming the anti-inflammatory properties of GCs. Insulin 
secretion and hepatic glucose production were increased, but this did not result imme-
diately in hyperglycemia or insulin resistance, indicating a highly adaptive compensatory 




mechanism in these mice. In conclusion, this model allows for studying effects of (novel) 
GC compounds on the development of arthritis and glucose kinetics in a single animal. 
This integrative model provides a valuable tool for investigating (drug-induced) metabolic 
dysregulation in an inflammatory setting. 
Finally, in order to discriminate between dimeric and monomeric actions of the GR upon 
activation by prednisolone in the development of metabolic adverse effects, GRdim mice 
were applied in chapter 7. These transgenic mice have a defect in the dimerization do-
main, abrogating dimeric GR gene-controlled transcription. GRdim mice were treated with 
prednisolone for six days, which did not influence fasting glucose levels but strongly in-
creased their plasma triglyceride and cholesterol levels, i.e., a dramatic 9-12 fold increase 
for triglycerides and free cholesterol in the VLDL-sized lipoprotein fraction. Surprisingly, 
hepatic cholesterol and phospholipids levels did not change. The unusual lipid profile was 
not caused by cholestasis as plasma bile acid concentration did not increase. Hepatic gene 
expression levels of lipoprotein lipase (lpl) were 23 times induced, yet when LPL activity 
was blocked by Polaxamer, there was only a slight increase in VLDL secretion. The study 
described in this chapter showed that sustained prednisolone treatment in GRdim mice 
leads to formation of atypical VLDL particles. These results indicate an important role for 
monomeric GR in regulation of lipid metabolism and may contribute to unravelling the 
mechanisms underlying GC-induced side effects.
Overall, the studies described in this thesis show that the effects of prednisolone on the 
induction of insulin resistance in mice is not as straight-forward as reported in humans and 
rats. Chapter 8 discusses this aspect extensively. Prednisolone treatment caused hypergly-
cemia and hyperinsulinemia in C57BL/6J mice, but ‘classical insulin resistance’ according 
to the HIEC could not be documented. Prednisolone-treatment of DBA/1J or BALB/c mice 
did lead to hyperinsulinemia without hyperglycemia; yet, in these mice the HIEC was not 
performed. Nevertheless, blood glucose kinetics in the fasted situation did implicate re-
duced insulin sensitivity and prednisolone did alter hepatic glucose metabolism and lipid 
metabolism. In addition, the studies described in this thesis revealed that feeding status 
and hormonal regulation are important factors which have to be taken into account when 
studying GC’s induced insulin resistance. Taken together, these results showed that GCs 
both alter glucose and lipid metabolism, but GC-induced insulin resistance in mice is not 
as straightforward as reported in humans.  For future analysis of metabolic adverse effects 
of GC in mice, prior evaluation of the specific research question should lead the choice for 
an optimal animal model. The studies described in this thesis provide a first step in this 
direction. 










De term glucocorticoïden is een verzamelnaam voor hormonen en medicijnen die werken 
via de glucocorticoïd receptor (GR). Het belangrijkste glucocorticoïd in mensen is cortisol. 
cortisol wordt ook wel een stress hormoon genoemd, omdat het in verhoogde mate in 
het bloed wordt uitgescheiden tijdens stressvolle situaties. Cortisol wordt geproduceerd 
door de bijnier onder invloed van de hypothalamus-hypofyse-bijnier as. De hypothalamus 
is een gebied in de hersenen dat de stressvolle situatie registreert  en daarop de stof cor-
ticotropin releasing hormone (CRH) uitscheidt. CRH stimuleert de hypofyse die vervolgens 
adrenocorticotropic hormoon (ACTH) uitscheidt. In de bijnier activeert ACTH de omzet-
ting van cholesterol in cortisol. Dit proces heeft een negatieve terugkoppeling, wat bete-
kent dat de aanwezigheid van cortisol in de hersenen de uitscheiding van CRH verlaagt 
en daardoor de productie van cortisol door de bijnier afremt. In stressvolle situaties zorgt 
cortisol voor een verhoogde energiehuishouding door het glucose en lipide metabolisme 
te beïnvloeden. Dit verloopt via binding aan de cortisol receptor in meerdere organen en 
weefsels, waaronder de lever, spieren en vetweefsel. De energie die vrijkomt kan gebruikt 
worden voor bijvoorbeeld de ‘vecht-of-vlucht’ reactie. Cortisol beïvloedt ook het immuun 
systeem en de bloeddruk. Glucocorticoïden werken op bijna alle weefsels, want de GR 
komt vrijwel overal tot expressie.
Gebaseerd op de rol van glucocorticoïden in regulering van het immuun-systeem zijn 
meerdere medicijnen ontwikkeld die de immuunreactie kunnen onderdrukken. Dit 
worden  synthetische glucocorticoïden genoemd. Dexamethason en prednisolon worden 
het meest gebruikt. Deze medicijnen worden sinds de jaren 50 veelvuldig toegepast voor 
de behandeling van auto-immuun ziekten, zoals reuma, de ziekte van Crohn en astma. 
Helaas heeft het gebruik van glucocorticoïden vele vervelende bijwerkingen. De meest 
bekende zijn de zichtbare bijwerkingen, zoals gewichtstoename (met name rond de buik), 
een rond gezicht, acne en versnelde haargroei. Echter, de minder zichtbare bijwerkingen 
kunnen nog vervelender zijn, zoals osteoporose (botontkalking), hyperglycemie (ver-
hoogde bloedsuiker waarden), dyslipidemie (verstoorde vethuishouding in het bloed) en 
de ontwikkeling van insuline resistentie.  
Insuline is een belangrijk hormoon voor de glucose-huishouding. In een glucose-rijke situ-
atie (bijvoorbeeld na een maaltijd) stimuleert insuline de opname van glucose vanuit het 
bloed naar de weefsels waar glucose opgeslagen kan worden. In de lever kan glucose 
opgeslagen worden als glycogeen; spieren kunnen glucose direct benutten, maar ook 
opslaan als glycogeen. Het vetweefsel heeft echter de grootste opslagcapaciteit, maar 




daarvoor moet glucose eerst omgezet worden in vetten. Deze opslag vindt plaats onder 
invloed van insuline. In een glucose-arme situatie zijn de insuline spiegels laag. In samen-
werking met andere hormonen, stimuleert dit de lever tot de productie van glucose voor 
onder andere de hersenen, die glucose als belangrijkste energiebron gebruiken.
Insuline resistentie is een voorfase van diabetes mellitus type II. De cellen van de belan-
grijkste organen in het glucose metabolisme, zoals lever, spieren en vetweefsel, zijn in het 
geval van insuline resistentie minder gevoelig voor insuline. Hierdoor is er meer insuline 
nodig om de cellen even sterk te stimuleren om glucose op te nemen. Dit is echter een 
vicieuze cirkel, waardoor er steeds meer insuline nodig is. De alvleesklier produceert insu-
line en kan deze verhoogde vraag niet altijd aan  waardoor de glucose concentratie in het 
bloed toch oploopt. Dan is er sprake van diabetes type II. In een latere fase van diabetes 
type II raakt de alvleesklier zo overbelast dat de insuline secretie stopt. De type II gaat dan 
als het ware over in type I diabetes.
Doel van het onderzoek
Bij langdurige medicatie met glucocorticoïden zoals prednisolon, kunnen insuline re-
sistentie en dyslipidemie als bijwerkingen voorkomen. Het doel van het onderzoek be-
schreven in dit proefschrift was het achterhalen van de manier waarop deze bijwerkingen 
ontstaan. Met behulp van muismodellen werd het effect van prednisolon op het glucose 
metabolisme, insuline resistentie en dyslipidemie bestudeerd. Hiervoor werd onder an-
dere gebruik gemaakt van methoden waarbij gebruik gemaakt werd van stabiel gemerkte 
isotoop verbindingen. 
Samenvatting dit proefschrift
Na een inleiding en een overzicht van de inhoud van dit proefschrift in hoofdstuk 1, staat 
in hoofdstuk 2 staat een nieuwe methode beschreven om het glucose metabolisme te 
bestuderen in een gevaste situatie, als er dus relatief weinig glucose in het bloed aanwezig 
is. De methode maakt gebruik van een eenmalige injectie met stabiel gelabeld glucose. Dit 
houdt in dat tussen het reeds in het lichaam aanwezige glucose het geïnjecteerde glucose 
door middel van het label terug gevonden kan worden. Hierdoor kan de klaring van het 
glucose uit het bloed gereconstrueerd worden. Dit levert een mooie curve op. Aan de 
hand van deze curve kan de glucose productie (door de lever) en de glucose opname (met 
name door spieren en vet) worden berekend. Het vernieuwende van deze methode is 
dat het een vrij simpel uit te voeren techniek is, die voor de dieren veel minder belastend 
is vergeleken met bestaande methoden. In combinatie met gemeten insuline waarden, 
geven de berekende waarden een waardevolle indicatie over de mate van insuline resist-




entie. In hoofdstuk 2 werd een ‘normale’ groep muizen vergeleken met een groep muizen 
die een vorm van insuline resistentie kregen door middel van een hoog-vet dieet. 
De methode werd in hoofdstuk 3 gebruikt in muizen die 7 dagen met prednisolon be-
handeld waren. Deze muizen hadden verhoogde gevaste glucose en insuline waarden, 
wat insuline resistentie deed vermoeden. Ook was de glucose productie (gemeten met 
de methode beschreven in hoofdstuk 2) in deze muizen verhoogd. Echter, de gouden 
standaard voor het aantonen van insuline resistentie is de hyperinsulinemische euglyce-
mische clamp. Voor deze redelijk bewerkelijke en belastende methode kregen de muizen 
gedurende enkele uren een insuline infuus (hyperinsulinemie). Dit zorgt voor een dal-
ing van de bloed glucosewaarden. Om een hypoglycemie (te lage bloedsuikerwaarden) 
te voorkomen, werd gelijktijdig een aangepast glucose infuus gegeven en de glucose 
waarden gemeten om de glucose spiegel stabiel te houden (euglycemisch). De hoeveel-
heid glucose die geïnfundeerd moet worden om glucose spiegels stabiel te houden, is 
een maat voor de insuline gevoeligheid. Voor prednisolon behandelde muizen was een-
zelfde hoeveelheid glucose nodig als voor de controle dieren, wat aangeeft dat ze even 
insuline gevoelig waren. Hiermee werd ‘klassieke’ insuline resistentie uitgesloten. Er was 
echter opgemerkt dat de prednisolon behandelde muizen in de gevoede toestand een 
lagere glucosespiegel hadden. Hierop werden de muizen 24 uur gevast, waaruit bleek dat 
de prednisolon behandelde muizen een veranderde ‘gevoed-gevast’ overgang hadden. 
Daarnaast bleek dat FGF21, een recentelijk ontdekt hormoon dat sterk betrokken is bij de 
energiehuishouding gedurende een vasten-periode, sterk verhoogd was in prednisolon 
behandelde dieren. Deze resultaten samen geven aan dat de vermoede insuline resisten-
tie, klaarblijkelijk een effect was van de veranderde voeden-vasten regulatie.
Zoals ook beschreven in hoofdstuk 2 kan insuline resistentie opgewekt worden door een 
hoog-vet dieet, dat ook gebruikt werd in hoofdstuk 4. Er werd verwacht dat de combina-
tie van een hoog-vet dieet bovenop prednisolon therapie, de effecten van prednisolon 
zou versterken. Door de combinatie van een hoog-vet dieet met prednisolon therapie 
werden de glucose en insuline spiegels sterk verhoogd. Echter, ook nu bleek uit de hyper-
insulinemische euglycemische clamp dat de muizen op een hoog-vet dieet met predniso-
lon therapie even insuline resistent waren als de muizen met alleen een hoog-vet dieet. 
Dit was ook het geval gedurende een hyperglycemische clamp, waarin een glucose infuus 
gegeven werd om de bloedsuikerwaarden te verhogen tot 17 mM. Het lichaam reageert 
hierop door insuline aan te maken. Hier is de hoeveelheid glucose die toegediend moet 
worden een maat voor de insuline uitscheiding en gevoeligheid. Dit was onveranderd in 
muizen behandeld met prednisolon of alleen met het oplosmiddel. Het hoog-vet dieet 
daarentegen induceerde wel de verwachte verlaging in insuline gevoeligheid. Met behulp 
van de stabiele isotoop techniek MIDA (massa isotopomeer distributie analyse) werd de 




enzymatische omzetting van glucose en bijproducten (de glucose fluxen) in de lever gem-
eten. Hieruit bleek dat, ook al waren de prednisolon behandelde muizen niet insuline 
resistent, de glucose fluxen in de lever wel veranderd waren. Met name de omzetting van 
het glucose tussenproduct glucose-6-fosfaat in glycogeen (de opslag vorm van glucose) 
was verminderd. Daarnaast bleek dat niet alleen de insuline spiegels in het bloed ver-
hoogd waren, maar ook de spiegels van leptine en FGF21, beide hormonen die betrokken 
zijn bij de energiehuishouding. Op grond hiervan werd geconcludeerd dat veranderingen 
in het glucose metabolisme door prednisolon therapie met een hoog-vet dieet niet het di-
recte gevolg waren van insuline resistentie, maar een verandering in het regulatie systeem 
van de energiehuishouding op hormoon niveau.
Door de bijwerkingen van prednisolon is het van groot belang dat er nieuwe middelen 
ontwikkeld worden die net zo ontstekingsremmend werken, maar minder neveneffecten 
hebben. In hoofdstuk 5 staat een nieuw glucocorticoid beschreven, ORG 214007-0. Het 
idee van het achterliggende mechanisme van dit nieuwe middel is dat het wel bindt aan 
de GR en daarmee interacties met andere eiwitten in de cel uitvoert, maar dat het directe 
effect op de expressie van genen die betrokken zijn bij het ontstaan van de bijwerkingen 
verminderd is. Dit noemt men dissociërende effecten en dit type middelen worden se-
lectieve GR modulators (SGRM’s) genoemd. Allereerst werd in cellijnmodellen (in vitro) 
gekeken naar het effect op genexpressie van verschillende genen. Het effect op de genen 
die betrokken zijn bij bijwerkingen was minder met ORG 214007-0 dan met predniso-
lon. Het effect op de genen die betrokken zijn bij de ontstekingsremmende werking was 
echter bijna net zo goed als met prednisolon. In muisstudies (in vivo) werd gekeken naar 
de effectiviteit om ontstekingen te kunnen remmen in een muismodel voor reumatoïde 
artritis. Hieruit bleek dat ORG 214007-0 zelfs bij een lagere dosis effectiever was in het 
remmen van de ontsteking. Daarna werd gekeken naar het glucose metabolisme in een 
ander muismodel. Net als in de vorige hoofdstukken beschreven, verhoogde prednisolon 
ook in deze studie de gevaste glucose waarden; dit was met eenzelfde effectieve dosis van 
ORG 214007-0 niet het geval. Met behulp van de MIDA methode zagen we dat predniso-
lon wederom de glucose fluxen veranderde; ORG 214007-0 deed dit niet. Dit leidde tot de 
conclusie dat ORG 214007-0 een dissociërend glucocorticoïd is en dat dit middel zou kun-
nen bijdragen aan een verbeterde behandeling met gelijkwaardige ontstekingsremmende 
capaciteiten, maar met minder bijwerkingen.
In hoofdstuk 5 werden de metabole bijwerkingen en de ontstekingsremmende capac-
iteiten van glucocorticoïden bestudeerd in twee verschillende modellen. In hoofdstuk 6 
werd gestreefd naar optimalisatie van de analyse van bijwerkingen en effectiviteit in één 
diermodel. Hiervoor werd het collageen-geïnduceerde artritis model gebruikt. Deze mui-
zen worden echter erg ziek en belastende methoden, zoals de hyperinsulinemische eugly-




cemische clamp, kunnen niet in deze muizen uitgevoerd worden. Daarom hebben we de 
bloed glucose kinetiek methode uit hoofdstuk 2 in deze muizen met artritis uitgevoerd. 
Behandeling van artritis muizen met prednisolon verlaagde de artritis scores, waarmee 
de ontstekingsremmende werking van de gebruikte dosis prednisolon bevestigd werd. In 
deze muizen was de insuline uitscheiding, gemeten aan de hand van C-peptide, verhoogd, 
even als de hepatische glucose productie. Echter, dit leidde niet tot een hyperglycemie of 
tot insuline resistentie, wat aangeeft dat er een sterk compensatie mechanisme aanwezig 
is in deze muizen. 
Naast insuline resistentie heeft prednisolon ook minder bekende effecten op de vet-hu-
ishouding. Dyslipidemie, een verstoring van zowel cholesterol als triglyceride homeostase 
in het bloed, wordt ook als bijwerking van prednisolon gerapporteerd. Om meer inzicht 
te krijgen in het mechanisme werd het onderzoek in hoofdstuk 7 uitgevoerd in transgene 
muizen. Normaal gesproken werkt prednisolon via de GR. Na binding met de receptor 
in de cel gaat dit complex van ligand (prednisolon) en receptor naar de celkern. In de 
celkern zijn telkens 2 receptor-complexen (dimeer) nodig om aan het DNA te binden en 
als transcriptiefactor genen te activeren (of te onderdrukken). Dit noemt men dimerisa-
tie. Echter, wanneer een gebonden receptor alleen blijft (monomeer) kan het nog steeds 
verschillende effecten hebben, zoals binding aan andere transcriptiefactoren of eiwitten. 
Het idee is ontstaan dat de dimeren voornamelijk de bijwerkingen veroorzaken, terwijl de 
monomeren ontstekingsremmend werken. Hiervoor werd in hoofdstuk 7 gekeken naar 
het effect van prednisolon op dyslipidemie in muizen waarin geen dimerisatie plaatsvindt; 
zogenaamde GRdim muizen. Wildtype en transgene muizen werden met prednisolon of 
oplosmiddel behandeld gedurende 6 dagen. Zowel in prednisolon behandelde wildtype 
als transgene muizen was geen effect op glucosespiegels  in het bloed te zien. Prednisolon 
behandeling in wildtype muizen zorgde voor een lichte verhoging van plasma cholesterol 
en triglyceriden. Echter, in transgene muizen was dit effect van prednisolon enorm ver-
sterkt. Met name plasma triglyceriden en cholesterol spiegels waren 9 tot 12 keer ver-
hoogd. Verassend genoeg had dit geen effect op de triglyceride en cholesterol concentra-
ties in de lever en de muizen waren ook niet cholestatisch (vernauwing van de galwegen), 
want de concentratie van galzouten in plasma was normaal. Een interessante observatie 
was dat expressie van het lipoproteïne lipase gen in de lever 23  keer was verhoogd. Dit 
gen is betrokken bij de triglyceride afbraak. De zoektocht naar de precieze oorzaak van 
het ontstaan van deze extreme dyslipidemie in GRdim muizen moet nog verder uitgebreid 
worden, maar het is duidelijk dat monomeer GR hierbij een belangrijke rol speelt. 
Conclusie
Concluderend duiden de resultaten uit de hoofdstukken beschreven in dit proefschrift 




erop dat de effecten van prednisolon op de ontwikkeling van insuline resistentie en dys-
lipidemie in muizen niet zo eenduidig is als gerapporteerd in mensen. De verschillende 
factoren die hierop van invloed kunnen zijn, worden uitgebreid bediscussieerd in hoofd-
stuk 8. Deze factoren variëren van de behandelmethode en de duur van de behandeling, 
de verschillen tussen de verscheidene muizen stammen, tot de methode waarop insuline 
resistentie gemeten wordt en de effecten van overige organen en hormonen in het glu-
cose metabolisme.
Prednisolon therapie veroorzaakte hyperglycemie en hyperinsulinemie in C57BL/6J mui-
zen, maar de ‘klassieke’  insuline resistentie werd niet aangetoond met behulp van de 
‘gouden standaard’ de hyperinsulinemische euglycemische clamp methode. In de muizen-
stammen DBA/1J en BALB/c werd een hyperinsulinemie gevonden, zonder een hypergly-
cemie. In deze muizen is helaas geen hyperinsulinemische euglycemische clamp uitgevo-
erd. Echter, uit de gevaste bloed glucose kinetiek experimenten en de MIDA experimenten 
bleek dat het hepatische glucose metabolisme toch veranderd was door prednisolon be-
handeling. Daarnaast bleek uit meerdere studies beschreven in dit proefschrift dat de 
voedingsstatus en de hormonale regulatie belangrijke factoren zijn waar rekening mee 
gehouden moet worden wanneer de bijwerkingen van prednisolon op het metabolisme 
bestudeerd worden. Samenvattend bleek uit de resultaten dat glucocorticoïden zowel het 
glucose- als het lipide-metabolisme veranderen, maar dat prednisolon-geïnduceerde in-
suline resistentie in muizen niet zo eenvoudig ligt en niet zo duidelijk gezien wordt als in 
mensen. Voor toekomstig onderzoek van metabole bijwerkingen van prednisolon in mui-
zen, moet eerst het optimale diermodel gekozen worden. De resultaten beschreven in dit 
proefschrift voorzien in een eerste stap in deze richting.
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Een ongeluk zit in een klein hoekje…
Geluk zit hem in de rest!





En dan is het eindelijk zover. Wat begon als colloquium onderwerp, ligt hier nu in de vorm 
van een proefschrift. Van te voren wist ik dat het een roerig traject zou worden, want ik 
ken geen enkel promotieproject dat geen ups en downs kent, maar dat het zo’n heftige 
periode zou worden, had niemand denk ik kunnen vermoeden. Het overlijden van Har-
men en Anniek W. heeft mij ontzettend geraakt en deed me beseffen dat ‘genieten’ je 
belangrijkste taak in het leven is. Na mijn eigen ongeluk is dit alleen nog maar duidelijker 
geworden. Ik ben ontzettend blij dat ik na de ellende van 2009 toch in staat ben om dit 
dankwoord te kunnen schrijven, maar dat had ik niet kunnen doen zonder de steun, hulp 
en liefde van heel veel mensen. Met dit dankwoord kan ik waarschijnlijk mijn naasten 
nooit genoeg bedanken, maar ik ga toch een poging wagen.
Allereerst wil ik graag van deze gelegenheid gebruik maken om iedereen te bedanken die 
tijdens mijn ziekhuis- en herstelperiode kaartjes, berichtjes, bloemen en e-mails hebben 
gestuurd. Die steun, vaak vanuit onverwachte hoek, heeft mij heel erg goed gedaan.
Geachte Prof. dr. F. Kuipers, beste Folkert, ik ben erg dankbaar voor jouw vertrouwen om 
mij aan te stellen op een project bij een subsidiegever die nog niet eens bestond. Tijdens 
de eerste TiPharma meetings, waar ik de enige Aio was tussen alle professoren, leerde 
ik al gauw jouw sterke onderhandel kwaliteiten kennen. Bovendien ontdekte ik dat je 
als echte Groninger een man van weinig woorden bent, maar dat ieder woord raak is. Ik 
heb ontzettend veel van je geleerd, al moest ik in het begin wel een beetje wennen aan 
je manier van communiceren en je kritische vragen. Deze vragen stimuleerden me altijd 
weer om verder te zoeken, dieper te graven en langer na te denken. Nadat je decaan bent 
geworden, heb je Bert het vertrouwen over mijn project gegeven, maar ik ben blij dat je in 
de laatste maanden toch weer nauw betrokken was bij het afronden van dit proefschrift. 
Bedankt voor je begeleiding, de efficiënte besprekingen, goede discussies en je snelle en 
tekstueel briljante manier van redigeren. 
Geachte Prof. dr. A.K. Groen, beste Bert, nadat je Folkert zijn positie als hoofd van het lab 
kindergeneeskunde had overgenomen, hebben we elkaar volgens mij 2 á 3 keer gespro-
ken vóór mijn ongeluk. Tijdens mijn herstelperiode heb ik je leren kennen als een sociale, 
geïnteresseerde en spirituele man. Ik heb jouw interesse in mijn project zeer gewaar-
deerd. Je hebt me nog niet kunnen overtuigen dat cholesterol het aller leukste vakgebied 
is, maar ik heb veel van je geleerd en hoofdstuk 7 is toch in mijn boekje gekomen. Bedankt 
voor alle steun, begeleiding, je persoonlijke interesse en je vertrouwen dat ik een goede 
KCio zal worden.




Beste Dr. van Dijk,  Theo, ik had het geluk toen ik begon dat jij en Aldo al enig voorwerk 
hadden verricht. Hierdoor ben je vanaf het begin af aan bijzonder nauw betrokken gewe-
est bij mijn project. Door de vele tripjes naar TiPharma meetings in Oss en de vele uren op 
ADL8 waarbij we bestaande technieken nog verder optimaliseerden, hebben elkaar beter 
leren kennen en dat is uitgegroeid tot wat ik als een bijzondere samenwerking beschouw. 
Ik wil je graag bedanken dat ik je ’s ochtends vroeg voor een experiment nog even kon bel-
len met de laatste vraagjes en je geduld en stimulerende woorden om mij alle handelin-
gen tijdens dierexperimenten te leren. Ik denk dat jouw kennis en kunde door sommigen 
in ons lab wordt onderschat. En Theo, bedankt voor gezelligheid en goede gesprekken 
tijdens de vele bakjes koffie, de dure biertjes in Rome, de sushi in Amsterdam en de friet 
bij jou en Jenny en voor het puppy knuffelen. Kun je in de toekomst de weg wel vinden 
zonder AnkeAnke? Ik denk dat ik nu wel in je vergane glorie map kan.
Beste Dr. Grefhorst, Aldo, net zoals Theo was je al eerder met mijn project bezig dan ikzelf, 
met dit verschil dat jij in Texas zat toen ik begon. Maar toen je terugkwam was je direct 
weer bij mijn project betrokken. Ik heb je praktische hulp zeer gewaardeerd, vooral in 
de overgangsfase tussen Folkert en Bert en bij de begeleiding van Christine. Ik heb diep 
respect voor jouw manier van denken, bij ieder resultaat weet je gelijk wel weer een leuk 
experimentje te bedenken om dieper te graven; ik denk dat deze eigenschap jou tot een 
zeer goed onderzoeker maakt. Bedankt voor je interesse in mijn project en je snelle nakijk 
werk van mijn stukken.
Beste Dr. Reijngoud, Dirk-Jan, wie had ooit gedacht dat ik in je voetsporen zou treden. Nu 
die onuitputtelijke biochemische kennis nog. Ik wil je bedanken dat je deze kennis altijd 
hebt willen delen en voor je andere kijk op mijn stukken. Dankzij jouw vernieuwende in-
zichten is hoofdstuk 4 een mooi stuk geworden. Met jou wil ik ook graag Rebecca bedank-
en voor jullie hulp in mijn weg naar klinisch chemicus in opleiding. 
Bij deze zou ik ook graag de leden van de leescommissie, Prof. dr. Michaela Diamant, Prof. 
dr. Jan Tuckermann, Prof. dr. Gertjan van Dijk willen bedanken. Daarnaast wil ik de overige 
leden van kindergeneeskunde, Henk-Jan (voor wijs advies), Peter, Pieter, Edmond, Uwe, 
Barbera, Torsten (bedankt voor alle keren dat je me mee de grens over wilde nemen in ruil 
voor M&M’s), Hans, Robert, Klary en Frans S., bedanken voor hun kritische vragen en in-
put tijdens de dinsdagmorgen meetings. Dolf bedankt voor al je hulp met het papierwerk.
Mijn project was onderdeel van het TiPharma project ‘Glucocorticoid-induced insulin re-
sistance’ waardoor ik met veel verschillende afdelingen samen heb gewerkt. Beste Dr. 
Doktor, Wim, jouw leiding over dit project heb ik als zeer aangenaam ervaren en jouw 
efficiënte manier van vergaderen maakten de TiPharma bijeenkomsten zeer succesvol. 




Bedankt voor het opzetten en leiden van ons project en dat je ons altijd aan het belang 
van dosis-respons curves hebt herinnerd. Ook bedankt voor je hulp bij onze stukken. 
Dankzij dit project heb ik in vele samenwerkingen mogen participeren. De grootste van 
deze samenwerkingen was toch wel met Organon/Shering Plough/MSD, ook al waren het 
roerige tijden. Beste Marie-José, bedankt voor alle antwoorden op de praktische vragen 
vooral in het begin en je input in mijn stukken. Ik duim nog steeds voor ons PNAS-stuk. 
Monique, bedankt voor de overnachting in ‘Hotel van der Vleuten’ en de vele pakketjes 
prednisolone die je verstuurd hebt. Annelies, ik ken geen enkele bio-technicus die zo snel 
is als jíj. Erik, jij kwam als laatste als postdoc bij ons project en dit heeft de samenwerking 
nog meer versterkt. Ik heb onze telefoontjes als ik niet ‘somewhere in Germany’ was zeer 
gewaardeerd. Ik vind het knap van ons dat ‘even bellen?’ toch bijna altijd minstens een 
half uur werd. Ik heb goede hoop voor ons CIA-stuk!
Daarnaast wil ik de andere projectleden van TiPharma project T1-106 bedanken. Door de 
mix van in vitro in het LUMC via in vivo in het UMCG naar humane studies in het AMC, 
UMCU en VU waren de TiPharma meetings erg gevarieerd. Bedankt voor jullie input en 
discussies en de blik op de klinische relevantie. Daniël en Margot, ik vond het mooi om 
met jullie op de EASD in Rome te staan.
Ook wil ik de organisatie TiPharma, met in het bijzonder Prof. dr.  Crommelin, Karin en 
Patricia, bedanken voor een mooi PhD-project. Omdat ik een van jullie eerste promov-
endi was, kreeg ik de mogelijkheid mijn enthousiasme voor het onderzoek te delen met 
de buitenwereld, zowel in de promotie-film, het interview in intermediair, op het Ecopa 
congres in Alicante en in het gesprek met minister Ab Klink, al heeft dat laatste helaas niet 
geholpen. Daarnaast wil ik jullie bedanken voor jullie persoonlijke betrokkenheid na mijn 
ongeluk. 
Another great collaboration was with the Tuckermann-lab from the Leibniz Institute in 
Jena. Dear Prof. dr. Tuckermann, Jan, I’m glad I could work with you on the GRdim mice. I 
learned a lot from you on GR-dimerization and glucocorticoid function. I’ve really appreci-
ated your input in meetings and your structured supervision of the project. Thank you for 
a nice collaboration and for being in my reading committee. Alex, thank you for a good 
collaboration, sending data and mice. I hope chapter 7 will lead to a nice publication. De 
derde partij in deze samenwerking was met het lab van Prof. dr. Stunnenberg; beste Henk, 
Nagesha en Melysia, ik ben altijd erg onder de indruk geweest van de Chip-seq methode, 
al was de data niet altijd even makkelijk te begrijpen. Bedankt voor de interessante meet-
ings, waar ik veel over bio-informatica van jullie geleerd heb. 




De laatste samenwerking was niet zo ver van huis, maar op de andere gang. 
Beste Dr. de Vos, Paul, Maaike (Smelt) en Bart. Ondanks een prettige samenwerking, heeft 
het eilandjes isoleren helaas geen mooie resultaten opgeleverd, maar Maaike, gelukkig 
wel een vriendschap. Bedankt voor jullie hulp en het stug volhouden, helaas was 3x geen 
scheepsrecht. Leonie, bedankt voor je hulp bij de Luminex meting.
Zonder de vakkundige verzorging van ‘mijn’ muizen had geen enkel hoofdstuk dit proef-
schrift gehaald. Daarvoor wil ik alle medewerkers van het CDP enorm bedanken en in het 
bijzonder Diana (als ze vechten, moeten ze wel van Anke zijn), Ralph, Ar, Harm, Lucas (in 
herinnering), Maurice, Mark, Annemiek, Andrea, Angela, Flip (bedankt voor je persoon-
lijke interesse), Arie, Wiebe, Miriam, Cathrien, Hester, Marcia, Annet, en niet te missen 
(daar waar de muziek is) Ramon.
Ondanks de vele Aio’s en post-docs bij het lab kindergeneeskunde zijn het de analisten die 
het lab draaiende weten te houden. Daarvoor wil ik Rick, Vincent, Aycha, Renze (bedankt 
voor je hulp met de galzouten), Trijnie, Henk (bedankt voor je humor en muziek), Nicollete 
& Janny (ik heb jullie gemist bij het liedjes maken), Wytse, Juul & Angelika (bedankt voor 
alle histologie) en Marleen enorm bedanken. De specialistische kunde van een aantal 
mensen hebben een grote bijdrage aan dit proefschrift geleverd en deze vorm van tech-
nische assistentie beschouw ik als zeer waardevol. Daarnaast leveren sommige van jullie 
een belangrijke en gezellige bijdrage aan de half 12 lunch groep. Hilde & Gea, bedankt 
voor jullie secretariële ondersteuning en alle nieuwtjes.
Beste Rick, jouw specialistische kunde op het gebied van de microchirurgie is erg waarde-
vol geweest voor meerdere hoofdstukken. Ik heb jouw aanwezigheid altijd als zeer prettig 
ervaren en ik geloof niet dat er ooit een minuut stilte valt als wij samenwerken. Bedankt 
voor je hulp, de gezellige tripjes naar Heidelberg, Jena en Hannover en de mooie avondjes 
bij FC Groningen of bij jullie voor de houtkachel.
Beste Vincent, ik denk dat net zoals bij Theo jouw waarde voor het lab nogal eens onder-
schat wordt. Gelukkig heb ik veel van je mogen leren over statistiek, micro-arrays en an-
dere analytische details waar ik als bioloog soms geen oog voor had. Ook al worden jij en 
Theo soms als Waldorf en Statler neergezet, ik denk dat die beiden ook eigenlijk hele lieve 
mannen zijn. Bedankt voor al je hulp, je luisterend oor en dat je mijn ‘kleine’ leescommis-
sie wilde zijn. 
Beste Aycha en Marleen, naast dat ik jullie beide super leuke meiden vind, denk ik dat het 
lab kindergeneeskunde blij mag zijn zo’n enthousiaste jonge garde analisten erbij te heb-
ben. Aycha, bedankt voor al je hulp en de vele metingen die je hebt gedaan tijdens mijn 
laatste jaar. Die meiden etentjes houden we erin.




Naast werken op het lab kindergeneeskunde, heb ik ook vele uurtjes in het lab van me-
tabole ziekten zitten. Theo B, bedankt voor de vele GC-MS metingen en je hulp en geduld 
om mij wegwijs te maken in de wereld van de GC-MS. Ook Klaas wil ik hiervoor bedanken. 
Tineke, bedankt voor je hulp bij mijn metingen. Pim&Pim en Albert, bedankt dat jullie 
altijd een antwoord hadden op mijn praktische vragen. Ook alle andere mensen van het 
metabole lab wil ik bedanken voor het accepteren van mijn enorme hoeveelheid vieze 
buizen en het in bezet houden van het warmte blok. Fjodor, bedankt voor je regelmatige 
bezoekjes aan het chocoladelaatje.
Toen ik in 2006 op het lab kwam voelde ik me al snel thuis, dit was mede dankzij een grote 
groep slimme, hardwerkende maar ook erg gezellige collega Aio’s. Jelske, Esther, Leonie, 
Niels en Maaike (Oosterveer); ik was blij dat ik niet bij jullie in het kippenhok zat, maar wel 
voor de gezelligheid kon langskomen. Alle oud Aio’s bedankt voor de vele bieravondjes, 
waarna of flinke stapavondjes (Maaike: Folkert zou trots op ons zijn) of gezellige logeer-
partijtjes volgden (Leonie: alleen XX) en leuke uitjes met de meiden (wadlopen of sauna). 
Maxi, bedankt voor de vele feestjes, ze leverden mooie foto’s met pompoenen, snorren 
en pruiken op. Maxi en Leo, ik heb goede herinneringen aan de ’boat’ in happypants met 
een goede film, lekkere wijn en altijd wel iemand die in slaap viel. Hilde en Sabina, ik heb 
ook erg goede herinneringen aan de gezellige avondjes met z’n drieën met spelletjes (lek-
ker spanken die monkey), picknicken in het plantsoen en leuke dansavondjes. Sabina, ik 
ben blij dat we dat samen in Philly (I love the city!!!) nog een keer hebben overgedaan. 
Op de feestjes mis ik jou en Frans C. als Ray & Anita. Yan, thanks for sharing the stress 
hormone. Marijke en Maaike, de fameuze M&M, bedankt voor al jullie glucose hulp en 
gezelligheid. Maaike, waai je de volgende keer als een wervelwind weer eens langs? Lieve 
Marijke, enorme vraagbaak die alle antwoorden wel ergens netjes in een map heeft staan, 
ontzettend bedankt voor alle hulp, zowel de korte vragen als wel je praktische hulp in het 
lab. Door de vele uren die we samen in het lab hebben gestaan, heb ik veel van je geleerd. 
Keystone was mooi samen met jou!.. Ik wens je heel veel geluk met je 2e carrière als 
mama erbij. Annelies, (INTJ-tje) bedankt dat jij altijd het overzicht en de kalmte bewaart. 
Ik ben blij dat ik samen met jou de loopbaanoriëntatie cursus heb gedaan. De updates en 
etentjes met Marije houden we erin. En dan waren er nog de echte doktoren onder ons: 
Frans C. (superpresentator), Jaap, Hester, Anniek K, en Anniek W (in herinnering).  Anniek 
K. (supermama), ik heb grote bewondering voor jouw energie (haal je die uit koekjes?) en 
ontzettend bedankt voor je hulp in Haren. Jaap, jij bent voor mij de rust en precisie zelve, 
bedankt voor je hulp.
In bijna 6 jaar Y2.117 heb ik heel wat kamergenootjes versleten. Ondanks dat het miss-
chien een ‘ongeluks’ kamer was, was, is en blijft(?) Y2.117 voor mij de leukste kamer van 
KG dankzij Janine, Thierry, Antonella, Laura, Marijke, Hilde, Harmen (in herinnering), 




Gemma, Elise (stille kracht!), Jurre (moleculaire allesweter), Marije, Carolien, Jelena en 
Brenda. Meiden, ik hoop voor jullie dat er weer een vrouw in de chickies room komt! 
Bedankt voor de gezelligheid, goede gesprekken, adviezen, hulp bij experimenten, gezel-
lige etentjes, de vele koppen koffie, eerst dankzij de Senseo (bedankt Hilde) en nu lekker 
luxe beneden (Marije, Jelena, Gemma; do I owe you one?). Gemma and Marije, after 
more than 3 years in the same 6 m2 I think we build up something more than just being 
colleagues. Gemma I loved sharing cheasy movies, either watching them together or by 
sms. Marije, bedankt dat je me geïntroduceerd hebt in de bakvissen wereld van Twigh-
light en ik ben blij dat je met me mee wilde naar Snow Patrol (ik hoop dat ik niet tè luid 
meegezongen heb). I really enjoyed the positive vibes you both send. I hope and think we 
will stay close for many more years. Carolien, buuv, we komen elkaar vast nog tegen. Suc-
ces met de rest van je MD/PhD project. Jelena, bedankt voor alle inside-information voor 
promovendi. Brenda, ik zou zeggen ‘break a leg’ voor een voorspoedig aio-schap, maar 
een schouder is denk ik wel voldoende.
Daarnaast wil ik de andere aio’s en postdocs van het lab kindergeneeskunde bedanken 
voor een prettige werksfeer en succes wensen bij hun onderzoek: Jan-Freark (onze eigen 
oh oh Cherso was leuk)(heb je al een datum?), Gijs (nieuwe MIDA-man), Karen, Arne (Sin-
terklaas?), Wijtske (laat die mannen ook eens voor jou werken), Maurien, Jaana, Mark, 
Karin, Fiona, Agnes, Elodie, Jolita, Wei-lin (ik heb niks te klagen), Matthijs, Janine. En als 
laatste maar zeker niet de minste de meisjes van Verkade; Willemien, Marjan, Margot 
(nog even volhouden, NY is waiting for you), Nienke, Mariëtte (grote organisator van de 
Ladies night!) en Andrea (4:04!). Bedankt voor een mooie tijd!
Ook wil ik graag de buren op het lab, MDL, bedanken voor een prettige werksfeer en altijd 
de mogelijkheid om jullie pipetboy/plakband/stikstof hengelaar/etc. te lenen. Daarnaast 
wil ik de mensen van het Hofker-lab bedanken voor goede samenwerkingen en interes-
sante meetings.
Annemieke & Hilde, Marijke, Theo en Annelies, bedankt dat ik bij jullie mocht oefenen in 
het buigen. Ik vond het een grote eer om als paranimf naast een ieder van jullie te staan. 
De keuze voor het onderzoek is voor mij aangewakkerd door stimulerende voorbeelden 
tijdens mijn studie. Beste Prof. dr. Bos, Nico, ik heb een mooie en zeer leerzame periode 
bij jou op het lab gehad en bedankt dat je me hebt voorgedragen als student bij Mecky, 
dat was een levensveranderende ervaring voor mij. Dear Prof. dr. Pohlschröder, Mecky, 
I am very grateful for the opportunity you gave me to work in your lab as a student in 
Philadelphia. You’re a lighting example for me for successful women in science. Your mo-
tivating and stimulating supervision made me decide to get my PhD and last June I was 




happy to have such good and stimulating conversations again. Thank you for being you! 
Dear Maria, working with you in Mecky’s lab in Philly was a great pleasure for me, I hope 
I can visit Argentina again. Maaike (Stoel), ook jij was voor mij een voorbeeld om Aio te 
worden, maar ik heb vooral veel waardering voor de manier waarop jij een zwaar promo-
tie traject en een misschien nog wel zwaardere postdoc project hebt afgerond. Bedankt 
voor de mooie tijd in Philly.
Buiten het lab kon ik mijn energie en soms frustratie kwijt in sporten en voornamelijk 
het volleybal. Zowel bij Veracles week dames 2 als bij Oranje Nassau dames 8 heb ik een 
ontzettend leuke tijd gehad. Wd2, bedankt voor de leuke trainingen, de vele gezellige 
stapavondjes en bonenavondjes en een mooie vakantie in Portugal. ON d8, bedankt dat 
jullie me zo snel in jullie hechte club opnamen, ik vond het erg gezellig! Volgend jaar sin-
terklaas???
Daarnaast waren er een aantal lieve vriendinnetjes bij wie ik het ook eens ergens anders 
over kon hebben dan werk. Mijn sociale contacten lieten af en toe te wensen over, maar 
bij echte vriendinnen maakt het niet uit hoe vaak je elkaar ziet, het blijft altijd fijn als je 
elkaar ziet. Lieve Tanja, bij jou kan ik echt zeggen dat we ‘way-back’ gaan. Sinds de peu-
terschool ben jij een vaste waarde in mijn leven en daar ben ik heel dankbaar voor. Lieve 
Anniek, niet van de peuterschool, maar wel sinds de middelbare school. Ik denk dat we in 
vele dingen tegenpolen zijn, maar desalniettemin is het altijd gezellig, ook al moet je de 
zigeuners van je af slaan ;-). Christa, ik kom echt in 2012 naar Londen! Kim en Selena, ik 
zie jullie (en die kleine mannen) echt veel te weinig, maar bedankt voor alle gezelligheid 
en jullie steun toen ik in het ziekenhuis lag. Niet veel mensen komen vanuit Rotterdam (en 
Easterwierum) voor bezoek van een half uurtje, dat heb ik heel erg gewaardeerd.
Irma en Marc, bedankt voor jullie hulp en de vele etentjes tijdens de laatste fase.
Dan zijn er natuurlijk nog vriendinnetjes bij wie het wel vaak over de biologie gaat. Lisa, 
Saskia, Hilde, Marianne en Betty; zoals Hilde al beschreef zijn we super verschillende per-
soonlijkheden, maar wel een mooi stel biologen bij elkaar. Meiden, bedankt voor vele gez-
ellige avondjes, dinertjes & ontbijtjes, filmpjes kijken, het delen van mannen (en vrouwen) 
perikelen, uitjes, boottripjes en festivals. Lisa, we zijn de Groninger leftovers, maar ik ben 
blij dat ik nu het vaakst van jouw uitbundigheid en kookkunsten mag genieten. Saskia, ik 
heb grote bewondering voor het avontuur dat je met Huub, Jort en … (en natuurlijk Ingrid) 
aangaat in Australië. Ik mis je. Betty en Marianne, collega´s(!), dank jullie wel voor het 
delen van promotieperikelen en voor  jullie enthousiasme over de klinische chemie. Hilde, 
wat kan ik zeggen. Dat ik je mis weet je al.
Ik ben blij dat ik al vanaf het begin van mijn studie biologie zulke lieve vrienden heb 




gevonden, en onderdeel mag zijn van het JAAH-gezelschap. We hebben ontelbare keren 
samen gegeten (in het begin op vaste avonden na het BOMmen) en mooie weekendjes 
weg gehad. Met niemand kan ik zo lachen als met jullie (pwaap!). Lieve Hilde, niet alleen 
ben je een super goede vriendin, ik heb ook het voorrecht gehad om bijna 4 jaar je collega 
en kamergenootje te mogen zijn. Je hebt me geleerd dat ik bij pyruvaat rechtsaf moet. Ik 
heb grote bewondering voor jouw ambitie en passie voor de wetenschap en je vermogen 
om hier vol voor te gaan. Daarnaast heb ik je altijd als een wijze, lieve en attente vriendin 
gezien, bij wie ik altijd terecht kan, ook al was het midden in de nacht (omdat de politie 
mijn huis afgezet had). Ik hoop dat je heel succesvol zult zijn in Boston (voor mij ben je dat 
al!) en daarna weer snel terug komt. Niet alleen voor mij, maar ook voor mijn familie ben 
jij een bijzonder grote steun geweest na mijn ongeluk. Lieve Jan, ik ben met veel plezier je 
huisgenootje geweest en we hebben lief en leed gedeeld. Helaas kan email de trap toch 
niet helemaal vervangen, maar ik ben blij dat het altijd als vanouds is. Daar waar Hilde, 
Miek en ik net klaar zijn, begin jij net aan je promotietijd, maar in de tussentijd ben je al 
hard op weg om gynaecoloog te worden. Ik denk dat dit deze carrière switch heel goed bij 
jou past en ik wens je daarbij veel succes toe. Lieve Annemieke, je bent voor mij als super 
lieve, attente vriendin een vaste waarde in Groningen, waar ik altijd van op aan kan. Ik ben 
blij dat ik met jouw in dezelfde fase zit, zowel in de twijfelfase vooraf en nu tijdens de pro-
motiefase. Bedankt dat ik ook bij jou mocht oefenen met buigen en dat jij mijn paranimf 
wilt zijn en alle antwoorden op mijn vragen hebt. Ik hoop dat ik mijn zenuwen net zo goed 
in bedwang hou. Ik ben trots op je, dat jij de jeugd van tegenwoordig aan gaat pakken! 
Hilde en Miek, ik keek uit naar jullie dagelijkse bezoekjes aan mij in het ziekenhuis, toeval-
lig altijd net als ik liep, zodat ik vol trots aan jullie mijn vorderingen kon tonen.
Ze zeggen wel eens, je vrienden kun je kiezen maar je familie niet. Gelukkig niet, want ik 
zou niet weten waar ik zo’n fijne familie zou kunnen vinden. Met een klein clubje kan ik 
ze gelukkig allemaal bedanken voor hun steun en liefde. Lieve oma, Janny en Ina, bedankt 
voor jullie stimulerende woorden, steun toen ik in het ziekenhuis lag, interesse in mijn 
onderzoek en jullie bijdrage om mijn studie te halen. Oma, zonder jou zou Philadelphia 
niet mogelijk geweest zijn. Lieve John & Miriam, bedankt voor jullie interesse in mijn werk 
en de ontspannende bootvaarten. Rob & Willeke, bedankt voor jullie steun en de hulp 
met de jurken-issues. 
Liebe Judith und Lieber Stephan, gerne will ich Euch danken für die schönen Wochenenden 
in Eickhof und die Möglichkeit die Ihr mir gegeben habt dort in aller Ruhe an meiner Doc-
torarbeit zu arbeiten. Dear Anne und Tano, I would also like to thank you for all the nice 
times where I could relax from work, either in Eickhof, Genua, Frabosa, Bogliasco or at the 
Rennsteig. I hope we’ll visit your renewed place in Bogliasco soon! Anne, I also would like 
to thank you for the nice times in Philly and introducing me to your brother ;-). 




Lieve Sybren en Debora, ik vind het gezellig dat jullie nu ook in Groningen wonen (leuk 
huis!). Sybren, kleine zusjes worden groot, maar wie anders kon mijn hand vast houden 
toen ik het ziekenhuis weer uit liep dan mijn grote broer. Ik ben blij dat wij uit zo’n hecht 
gezin komen en bedankt dat je als puber je kleine zusje overal mee heen nam. Dankzij jou 
mocht ik veel. We moeten maar weer een broer-zus-zus tripje plannen.
Lieve Fardau en Bertus, bedankt dat jullie mij gedurende mijn promotietijd als jullie in-
boedel wilden hebben. Het was erg fijn altijd bij jullie aan te kunnen schuiven en op de 
bank te kunnen ploffen. Bertus, wat hebben we een boel leuke films gezien als Fardau 
sliep hè. Fardau, ik ben zo blij dat jíj mijn zusje bent, je staat altijd voor me klaar, kan mijn 
buien hebben (en ik de jouwe) en we hebben vaak aan een half woord genoeg (en anders 
zeggen we het tegelijk). Zoals ik al beschreef kan ik jou nooit genoeg bedanken voor alle 
steun toen ik in het ziekenhuis lag, je wilde alles wel voor me doen. Ik ben je briefje met 
100 redenen kwijt, maar dat is niet erg want ze zitten in mijn hoofd voor jou. Ook al ben je 
mijn kleine zusje, je bent mijn grote steun en toeverlaat. Wij zijn zusjes!
‘KVK Kelken’
Lieve papa en mama, ik voel me gezegend dat ik jullie dochter ben. Jullie manier van 
opvoeden, ongedwongen, open en vrij, maar stimulerend en warm, heeft me gemaakt 
tot wie ik ben. Zonder jullie was ik nergens. Jullie hebben me altijd gestimuleerd dat ik 
moest doen wat ik leuk vond en ik denk dat jullie daarin zeer geslaagd zijn. Jullie huis blijft 
altijd een thuis, niet alleen voor mij, maar voor een ieder die daar binnen stapt. Ik kan jul-
lie nooit genoeg bedanken voor jullie goede zorgen, iedere dag de hele dag bij me in het 
ziekenhuis en daarna 3 maanden thuis. Pap, wat was ik blij met jouw verplegende kunde. 
Ook al weet ik dat het voor jullie de normaalste zaak van de wereld is, dat is het niet. En 
ook nu ik in Leeuwarden werk, staan jullie vaak voor me klaar. Dankzij en voor jullie is dit 
proefschrift nu af.
‘want je kunt het niet alleen’
Lieve Christoph, er zijn niet genoeg woorden om te beschrijven wat ik voor je voel, maar 
ik weet wel dat jij mijn alles bent. Jouw rust en kalmte heb ik echt nodig en ik ben blij dat 
je af en toe op de stopknop drukt. In jouw armen voel ik me veilig en thuis. Van 600 km, 
via 450 km, nu op 100 km afstand, hoop ik dat het in 2012 0 km zal worden. Ik kijk er naar 
uit samen met jou de toekomst tegemoet te gaan. Ich liebe dich! 
‘Everything is better together’
Liefs Anke





Anke Jourika Laskewitz werd geboren op 9 februari 1982 te Leeuwarden. Aan het Piter 
Jelles Montessori (voormalig Slauerhoff college) in Leeuwarden behaalde zij in 2000 haar 
VWO-diploma, waarna ze aan de studie Biologie begon aan de Rijksuniversiteit Gronin-
gen. Na een specialisatie in de richting Medische Biologie  volgden twee afstudeer stages. 
De eerste werd uitgevoerd bij de afdeling Immunologie & Histologie van de afdeling cel-
biologie van het Universitair Medisch Centrum Groningen onder leiding van Prof. dr. Nico 
Bos. De bevindingen van deze stage werden geraporteerd in een verslag getiteld ‘Inductie 
van CD70-gemedieerde apoptose in multiple myeloma’. De tweede stage werd uitgevoerd 
bij het Department of Biology aan de University of Pennsylvania onder leiding van Prof. 
dr. Mecky Pohlschröder. Deze stage leide tot een auteurschap de publicatie in het Jour-
nal of Bacteriology (feb 2006; 188(4):1251-9), getiteld ‘Archaeal and bacterial SecD and 
SecF homologs exhibit striking structural and functional conservation’. Vervolgens werd 
de studie afgesloten met een scriptie bij de afdeling medische biologie onder leiding van 
Prof. dr. Ingrid Molema en een colloquium bij de afdeling kindergeneeskunde bij Prof. dr. 
Folkert Kuipers.
Na het behalen van het doctoraal Medische Biologie in januari 2006, begon zij aan een 
promotieonderzoek op TiPharma project  ‘glucocorticoïd-geïnduceerde insuline resisten-
tie’ in het laboratorium van de afdeling kindergeneeskunde met als promotores Prof. dr. 
Folkert Kuipers en Prof. dr. Bert Groen. De bevindingen van dit onderzoek staan beschre-
ven in dit proefschrift. Vanaf 1 december 2011 is Anke in opleiding tot klinisch chemicus 
bij stichting KCL Leeuwarden verbonden aan het Medisch Centrum Leeuwarden.





Anke Jourika Laskewitz was born on the 9th of february 1982 in Leeuwarden, the Nether-
lands. In 2000 she graduated from high school (Piter Jelles college Montessori) and started 
a Master degree in Medical Biology at the University of Groningen. As an undergrad stu-
dent she worked in the department of Immunology and Histology at the University Medi-
cal Center Groningen under supervision of Prof. dr. Nico Bos on CD70-induced apoptosis 
in Multiple Myeloma. A second internship was performed at the Department of Biology at 
the University of Pennsylvania in the lab of Prof. dr. Mecky Pohlschröder. This internship 
resulted in an authorship on the paper ‘Archaeal and bacterial SecD and SecF homologs 
exhibit striking structural and functional conservation’ in the Journal of Bacteriology (feb 
2006; 188(4):1251-9). This study was finished with a Master thesis at the department 
of medical biology under supervision of Prof. dr. Ingrid Molema and a colloquium at the 
Department of Pediatrics under supervision of Prof. dr. Folkert Kuipers at the University 
Medical Center Groningen.
After obtaining her masters degree in Medical Biology in 2005, she started a PhD in the 
Laboratory of Pediatrics at the University Medical Center Groningen under supervision of 
Prof. dr. Folkert Kuipers and Prof. dr. bert Groen. This project was financed by the TiPhar-
ma. The results obtained in this research project are described in this thesis. On the first 
of December 2011 Anke started as a clinical chemist in training at the clinical chemistry 
laboratory at the Medical Center Leeuwarden.
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